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ABSTRACT
Tumours are organised in a cellular hierarchy, originating in and maintained by a 
minority of cells with stem cell characteristics, so-called ‘cancer stem cells’. The 
Side Population (SP) phenotype, distinguished by its ability to efflux the nucleic 
acid dye Hoechst 33342, as well as surface markers CD44 and CD133 were 
evaluated as potential cancer stem cell markers in human colorectal cancer cell 
lines and primary adenocarcinomas by testing sorted cell fractions for 
phenotypical and behavioural stem cell-typical characteristics such as 
clonogenicity or sphere formation in vitro, tumorigenicity in vivo, and multilineage 
differentiation potential in vitro and in vivo. My results indicate that in human 
gastrointestinal cancer cell lines, the SP, albeit containing cells with stem cell 
characteristics, is not enriched in stem cells as compared to the non-SP and thus 
does not present a useful tool for the isolation and identification of stem cells. 
Similarly, no stem cell characteristics were detected in the CD44+, CD133+, or 
double positive cell fractions of primary human colorectal carcinomas.
Next, tumour-initiating capacities of transplanted cells and the reciprocal effects 
between transplanted cells, engrafted in the skin, and the local microenvironment 
were investigated in human kidney transplant patients and a BM-transplanted 
mouse model. We were able to show that donor-derived cells engraft as epithelial 
cells in normal and tumour epithelium, and contribute to stromal and endothelial 
tumour components without any events of cell fusion in both, human and mouse 
skin tumours. Observations of cell clusters and proliferation activity suggested that 
cells from BMTs may be able to engraft at earlier differentiation stages than cells 
from solid organ transplants. The sporadic distribution of engrafted cells and the 
absence of donor-derived tumours in our large scale human study indicated that 
cells from kidney transplants do not engraft as stem cells or cancer stem cells in 
the skin, even upon HPV-infection. Rather than playing an active role in 
carcinogenesis or tissue remodelling, donor-derived cells appear to imitate their 
surrounding cells in morphology and function. Following the patterns of 
engraftment and tumour development strongly suggests that the local cellular host 
microenvironment exerts more influence on the outcome phenotype than the effect 
of genetic pre-disposition of engrafted transplanted cells.
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Finally, on a histochemical and molecular level I show that squamous cell 
carcinomas (SCCs) and basal cell carcinomas (BCCs) show distinct 
developmental dynamics, presumably reflecting their origin in different stem cell 
pools. Moreover, evidence is provided for a common developmental origin of outer 
root sheath and BCC, presumably in the stem cells of the hair follicle bulge. 
Histochemical analysis demonstrates that the companion layer is genetically 
continuous with the inner root sheath lineages and can be viewed as its outermost 
layer. We also suggest that BCCs and their stroma may share a common origin.
Together, these results provide insight into the characterisation of cancer stem 
cells and the role of cancer-originating cells in tumour development.
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LIST OF ABBREVIATIONS
AML acute myeloid leukemia
BCC basal cell carcinoma
AK actinic keratosis
BK bowenoid keratosis
BADJ bronchioalveolar duct junction
BM bone marrow
BrDU bromodeoxyuridine
CC cholangiocarcinoma
CFU colony forming unit
CIS carcinoma in situ
CML chronic myeloid leukemia
CSC cancer stem cell
DM BA 7,12-dimethylbenz(a)anthracene
EPU epidermal proliferative unit
FACS fluorescence-activated cell sorting
5-FU 5-fluorouracil
GvHD graft versus host disease
HCC hepatocellular carcinoma
IFE interfollicular epidermis
IRS inner root sheath
LRC label retaining cell
ORS outer root sheath
SC stem cell
s e e squamous cell carcinoma
SP side population
TAC transit amplifying cell
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CHAPTER I 
GENERAL INTRODUCTION
1.1 ADULT STEM CELLS
Stem cells are primitive cells that are capable of self-renewal, proliferation 
and differentiation into mature cells. First identified in the inner mass of the 
blastocyst in embryos, stem cells have also been and continue to be found 
in adult tissues. Whereas embryonal stem cells display pluripotentiality and 
can constitute any organ in the body, adult stem cells are regarded as 
multipotential and thus limited to differentiate into cell types of the tissue in 
which they reside. However, there is accumulating evidence that adult stem 
cells may show plasticity and are able to engraft fully functionally into 
tissues outside their lineage. The ability of a single cell to give rise to a 
large family of descendants, containing all the lineages normally found in 
that cell’s tissue of origin is considered a reasonably robust proof of 
‘sternness’. If cell migration occurs in a tissue, stem cells are at the 
beginning of the flux. Particularly where cell flux is unidirectional, such as in 
the epidermis, stem cells are at the beginning of the cell flux in the basal 
layer, with cells being shed at the surface. Adult stem cells with capacities 
for self-renewal and multilineage potential were first recognised in the bone 
marrow (BM) by Till and McCulloch who described cells that gave rise to 
multilineage haematopoietic colonies in the spleen (colony forming units -  
spleen [CFU-S]) (Till etal. 1961).
Stem cells, though highly clonogenic, are considered by most to be 
proliferatively quiescent. They cycle infrequently, giving rise to highly 
proliferative transit-amplifying cells (TAC) which are capable of limited self­
renewal. After at the most, three to four cell divisions, their progeny 
differentiate into one of the mature cell types. Due to these proliferative 
habits, stem cells in animals that incorporate DNA synthesis labels such as
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tritiated thymidine or bromodeoxyuridine (BrdU) tend to remain ‘labelled’ for 
longer than TACs whose more rapid cycling soon dilutes the label below 
detection levels. Thus, the identification of label-retaining cells (LRCs) is 
often used as a stem cell marker (Braun et a/. 2004).
1.1.1 The stem cell niche
Stem cells are located in restrictive environments called ‘niches’ that play 
an integral part in stem cell survival and function. According to the “stem 
cell niche” hypothesis, interactions with the niche cells are crucial to the 
self-renewal process of stem cells (Schofield 1978), suggesting that stem 
cells may be regulated by their environment, rather than by intrinsic 
programming.
Characterisation of the components comprising the stem cell niche is 
difficult, partly due to the indistinct phenotype of stem cells, which prevents 
them from being identifiable in many adult tissues. Essentially, the stem cell 
niche consists of a sheath of mesenchymal cells and extra-cellular 
substances which surrounds the epithelial stem cells and provides an 
optimal microenvironment by paracrine secretion of growth factors and 
cytokines. The extracellular matrix is thought to play a special role in 
maintaining homeostasis by regulating adhesion to stem cells, thereby 
regulating retention and loss of stem cells from the niche. Due to the 
hierarchical and migratory nature of cells in the differentiation process, the 
niche is most likely situated at the origin of the cellular flux. When stem cell 
progeny leave the niche they differentiate to become transit-amplifying cells 
(Figure 1.1, pg.21).
Given the immense influence the niche exerts on the development and 
behaviour of stem cells, it is clearly equally, if not more important, to 
understand and unravel the cells involved and the regulatory processes in 
the niche than it is to understand the nature of stem cells themselves. 
Indeed, controlling factors for setting up the niche microenvironment are 
rapidly becoming elucidated: in the gut for example, Wnt signalling is
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crucial to stem cell homeostasis (Sancho et al. 2004), and Wnt inhibitors 
such as Dikkopf-1 could become important anti-cancer agents (Kuhnert et 
al. 2004).
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Figure 1.1. The stem cell niche. Stem cell behaviour is 
governed by niche cells which provide an optimal microenvi­
ronment by the secretion of extracellular matrix, signalling 
molecules, and cell-to-cell contact. Stem cell progeny can 
leave the niche as transit amplifying cells (yellow) and un­
dergo the pathway to terminal differentiation (bulk of yellow 
cells). Diagram taken from (Spradling et al. 2001).
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1.1.2 Stem cell division
Three different mechanisms for division of adult stem cells have been 
proposed: (1) asymmetric division is thought to be the major mechanism for 
stem cell renewal, producing one stem cell and one TAC per division; (2) 
symmetric division with self replication where two stem cells are produced 
that continue to operate as stem cells; (3) symmetric division with stem cell 
loss, where both stem cells move on to differentiate (Loeffler et al. 1993). 
These division types may coexist and be triggered according to need 
(Figure 1.2, pg.23).
Potten et al. proposed a theory that there are two different stem cell types: 
actual (functional) stem cells which maintain tissue homeostasis, and 
potential stem cells which are mobilised in case of stem cell depletion and 
restore stem cell number by symmetrical division (Marshman et al. 2002, 
Potten et al. 1990, Potten et al. 1997). To achieve self-renewal, on 
average, each stem cell division gives rise to one replacement stem cell 
and one TAC by asymmetric cell division. Thus, the probability (P) of self­
renewal is 0.5, and any upward shift in p will lead to a rapid escalation in 
stem cell numbers -  a likely event in many cancers (Clevers 2005). Indeed, 
disruption of asymmetric neuroblast cell division in Drosophila 
melanogaster leads to lethal, expansive, tumour-like lesions when such 
cells are transplanted to adult hosts (Caussinus et al. 2005).
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Figure 1.2. Possible outcomes of stem cell division, (a) in asymmetric divi­
sion, one stem cell progeny leaves the niche to undergo terminal differentia­
tion and one cell remains in the niche, (b) When stem cells undergo sym­
metrical division, they either produce two identical stem cell progeny or two 
transit amplifying cells. (Diagram courtesy of Matthew Lovell).
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DNA synthesis is error prone and thus, teleologically, it would seem 
prudent to limit stem cell replication. Additionally, some stem cells appear 
to have devised a strategy for maintaining genome integrity; another cause 
for label retention’. Termed the ‘immortal strand’ hypothesis by John Cairns 
(Cairns 1975), newly forming stem cells designate one of the two strands of 
DNA in each chromosome as a template strand, such that in each round of 
DNA synthesis, while both strands of DNA are copied, only the template 
strand (and its copy) are allocated to the daughter cell that remains a stem 
cell. Thus, any errors in replication are readily transferred (within one 
generation) to TACs that are soon lost from the population (Figure 1.3, pg. 
25). Such a mechanism will produce LRCs after injection of DNA labels 
when stem cells are being formed, but validation of the hypothesis requires 
the observation that LRCs go through further rounds of DNA synthesis, yet 
still segregating the immortal DNA strands from sister chromatids into the 
daughter cells that remain as stem cells; this has been demonstrated in the 
small intestine and breast (Potten et al. 2002, Smith 2005), but recent 
evidence from the bone marrow has found no evidence of this phenomenon 
(Kiel etal. 2007).
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Figure 1.3. The immortal strand hypothesis, proposing how the 
genomic integrity of stem cells can be preserved. Newly synthesized 
strands of DNA are always allocated to TACs, and stem cells retain 
the immortal (template) strand. The template strand of each chro­
mosome is established when stem cells are created. (Diagram 
taken from Burkert et al. 2006).
25
1.2 CANCER STEM CELLS
For many years it has been clear that stem cells feature in processes as 
diverse as wound healing, metaplasia and cancer. Cancer cells harbour 
significant similarities to stem cells -  they are capable of self-renewal, give 
rise to highly proliferative cells, and they display organogenic capacity, 
since tumours often consist of heterogeneous cell populations resembling 
the cell lineages that would be generated from the normal stem cells within 
the organ from which they originate.
1.2.1 The cellular hierarchy within tumours
Not all cells within a tumour are equally able to form tumours. Rather, the 
tumorigenic capability seems to be exclusive to a small minority of tumour 
cells, so-called ‘cancer stem cells (CSC)’, that exhibit stem cell 
characteristics, particularly the ability to self-renew and to give rise to a 
hierarchy of progenitor and differentiated cells, albeit in a disorganised 
manner (Figure 1.4, pg.28). The existence of tissue specific stem cells was 
first demonstrated in the haematopoietic system (Till et al. 1961). In an 
ethically controversial experiment, where only a few tumour cells from 
patients with disseminated malignancies showed tumour initiating capacity 
when injected back into the same patients, Brunschwig et at. demonstrated 
for the first time that tumour cells seem to be hierarchically-organised 
(Brunschwig et al. 1965). Other evidence for a hierarchical organization 
within a tumour came from the observation that only 1-4% of lymphoma 
cells were able to form colonies in vitro or generate spleen colonies when 
transplanted in vivo (Bruce et al. 1963). Likewise, studies of human 
tumours revealed clonogenic potentials in the range of 0.0001-1% in vitro 
(Hamburger et al. 1977, Park et al. 1971). These observations led to the 
hypothesis that leukaemia and other malignancies must be maintained by a 
small population of CSCs with the potential for self-renewal and extensive 
proliferation (Griffin e ta i 1986, Hamburger et al. 1977, McCulloch 1983).
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With the development of non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) mice for the xenografting of human tumours, 
came the first good in vivo evidence for the existence of CSCs (Bonnet et 
al. 1997). Bonnet and Dick showed that only a small subset of AML cells 
was capable of producing leukaemic progenitors and leukaemic blasts 
upon transplantation into immunodeficient mice, resulting in a disease 
phenotype identical to the donor (Bonnet 2005). Since the first account of 
CSCs in leukaemia, they have also been demonstrated in various solid 
tumours. In the breast, the existence of stem cells was inferred by the 
clonogenicity (ability to form mammospheres) and by the multipotentiality of 
a subpopulation of murine mammary cells (Al-Hajj et al. 2003, Dontu et al. 
2003). The existence of CSCs has been confirmed in tumours of the brain, 
breast (Al-Hajj et al. 2003), colon (O'Brien et al. 2007, Ricci-Vitiani et al. 
2007), liver, skin (reviewed in (Perez-Losada et al. 2003)) and others.
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Figure 1.4. The generation of cellular heterogeneity in a tumour. Dysregu- 
lation of asymmetrical cell division in a malignant stem cell (mSC) leads to 
increasing numbers of mSC, and haphazard combinations of symmetric 
and asymmetric divisions will produce malignant transit amplifying cells 
with limited proliferative potential and malignant terminally-differentiated 
cells with no proliferative potential. (Figure taken from Burkert et al. 2006).
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1.2.2 The cellular origin of cancer stem cells
A connection between tissue development and tumour formation was first 
proposed in 1855 by Rudolph Virchow. Based on histological similarities 
between the developing foetus and tumours such as teratocarcinomas, he 
suggested his ‘embryonal-rest hypothesis’ of cancer, believing that tumours 
resulted from the activation of dormant residual embryonic tissue (Virchow 
1855). This hypothesis is supported by the fact that in certain cancers, 
clusters of abnormal retained embryonic cells and cancer-associated 
mutations can be detected prenatally or at birth (Beckwith et al. 1990, 
Wiemels 1999).
Cancer could arise from the dedifferentiation of mature cells that have 
retained the ability to divide, or it could result from the ‘maturation arrest’ of 
immature stem cells (Sell et al. 1994). Over the years, the idea of ‘blocked 
ontogeny’ has gained acceptance, and observers accept that the arrested 
differentiation of tissue-based stem cells or their immediate progenitors is 
closely linked to the development of not only teratocarcinomas and 
haematological malignancies, but also carcinomas. Some of the most 
frequent tumours occur in tissues with a high cell turnover such as the skin 
and the epithelial lining of the gastrointestinal tract. It is argued that in these 
tissues the stem cells are the only cells with sufficient lifespan to acquire 
the requisite number of genetic abnormalities for malignant transformation. 
Additionally, with a self-renewal mechanism already in place, seemingly 
fewer alterations are required to change normal stem cells into CSCs. In 
the now classical two-stage model of mouse skin carcinogenesis, severely 
delaying the interval between 7,12-dimethylbenz(a)anthracene (DMBA) 
initiation and the application of the phorbol ester promoter had no bearing 
on subsequent tumour yield -  strongly suggestive of an origin in a long- 
lived cell, an epidermal stem cell (Berenblum et al. 1949). This has again 
been experimentally demonstrated in mouse skin with an experiment where 
the interval between chemical cancer initiation and promotion proved that 
the only cells with a sufficient lifespan to have been present at the time of 
initiation are SCs (Van Duuren et al. 1975).
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A stem cell origin of cancer is often inferred from the location of the tumour 
or its dysplastic antecedents, which does not preclude an origin from a 
more committed progenitor cell in the same location. For example, gliomas 
in the human brain are frequently found in a periventricular location, and 
experimental brain tumours induced by ethyl nitrosourea (ENU) are usually 
found in the subventricular zone -  both major CNS stem cell areas 
(reviewed in (Sanai et at. 2005)). In the mouse lung, the bronchioalveolar 
duct junction (BADJ) is a major stem cell zone for the airway, and ras- 
induced adenocarcinomas arise in this area containing clusters of cells with 
the same stem cell characteristics (Kim et al. 2005). In the liver, the 
consensus view is that a variety of intrahepatic stem cells can give rise to 
hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) (Alison et 
at. 2005). Many liver tumours arise in a cirrhotic setting at a time when 
hepatocyte senescence triggers a reserve stem cell compartment to give 
rise to bipotential hepatic progenitor cells (HPCs); the fact that many liver 
tumours have features of both HCC and CC, combined with the presence 
of numerous HPCs, is consistent with an origin from HPCs or their 
antecedents. Indeed, gene expression profiling has identified a subset of 
HCCs with a very poor prognosis that had a profile consistent with an origin 
from HPCs (Lee et at. 2006). In the cornea, tumours appear to arise in the 
peripheral zone, which is the limbal stem cell zone, again suggestive of a 
stem cell origin (Waring etat. 1984). In the colon too, inspection of the very 
earliest dysplastic lesions suggests an origin from a mutated basally- 
situated stem cell that ‘hitchhikes’ its way to clonal dominance in a crypt of 
multiple stem cells through a process known as ‘niche succession’ to form 
a moncryptal adenoma (Calabrese et al. 2004, reviewed in (Leedham et al. 
2005)). Though it is a widely held view that tumours are clonal populations, 
studies of early familial adenomas both in patients with familial 
adenomatous polyposis (FAP) and those in the mouse model (Apc^in/*) 
suggest that the majority of nascent tumours are in fact polyclonal, 
requiring short-range interactions between adjacent initiated crypts: 
‘collision’ tumours as a cause of this apparent polyclonality were ruled out
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by genetically manipulating the ApcMin/+ mouse to have far fewer tumours 
than normal (Thliveris et al. 2005).
In many haematological malignancies an origin from normal HSCs is 
indicated by the fact that one of the oncogenic alterations (presumably the 
earliest), can also be found in a variety of haematopoietic progenitor and 
differentiated cell types in patients in remission -  again suggestive of an 
origin in a multipotential stem cell that subsequently accrues further 
mutations that lead to malignancy. This can be observed in acute myeloid 
leukaemia (AML) where the balanced translocation t(8;21) leads to the 
fusion transcript AML-ETO being found in many non-leukaemic cells 
(Miyamoto et al. 2000). Likewise, in chronic myeloid leukaemia (CML) 
where 95% of affected individuals have the Philadelphia chromosome, the 
BCR-ABL fusion transcript can also be found in otherwise normal mature 
blood cells (Cobaleda etal. 2000).
SCs seem to be not only involved in but even necessary for cancer 
development. In the skin for example, the stem cells of the hair bulge have 
been shown as a target for UV-induced mutagenesis and the source of 
SCCs as mice that had their interfollicular epidermis (IFE) removed, still 
developed SCC in response to UVB radiation (Faurschou et al. 2007). 
CD34 is expressed in the hair bulge of mice and considered as a potential 
epidermal stem cell marker. Knockout mice lacking the CD34-gene locus 
also fail to develop papillomas in initiation-promotion experiments (Trempus 
etal. 2007).
While it seems likely that most CSCs originate from transformed normal 
stem cells, they could also have their origins in more committed cells 
caused through, for example, reactivation of self-renewal mechanisms. 
Induction of stem cell-like features in more mature cells may permit a CSC 
to emerge from a cell not originally a tissue stem cell (Passegue et al. 
2003). For example, when HSCs and myeloid progenitor cells were 
transduced with a leukemogenic MLL-ENL fusion gene and the cells 
transplanted in vivo, AML arose from both populations with the same
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latency (Cozzio et al. 2003). Moreover, their immunophenotype and gene 
expression profiles suggested maturation arrest at identical stages of the 
differentiation pathway. Likewise, the MOZ-TIF2 oncogene can confer 
leukaemic stem cell properties (which could be continuously propagated in 
liquid culture and result in AML after transplantation) upon granulocyte- 
monocyte progenitors (Huntly et al. 2004). Interestingly, the BCR-ABL 
oncogene was not able to do this, indicating a hierarchy of leukaemia- 
associated protooncogenes. The stem cell profile may also change during 
the course of a disease: in patients with CML in blast crisis, granulocyte- 
monocyte progenitors can become self-renewing CSCs, a change 
associated with Wnt pathway activation (Jamieson et al. 2004).
1.3 CONTROL OF STEM CELL FUNCTION
1.3.1 Wnt/p-eatenin pathway
The Wnt/p-catenin pathway is involved in all of the stem cell-defining 
characteristics: self-renewal, proliferation and differentiation, and has been 
identified most frequently among cancers of the colon (reviewed (Reya et 
al. 2005)). The signalling cascade is initiated when extracellular Wnt 
molecules bind to frizzled, their receptor on the cell membrane. This causes 
an inhibition of the p-catenin destruction complex and consequently an 
accumulation of p-catenin, which then translocates to the nucleus where it 
activates the transcription of proliferation-promoting genes via binding to 
LEF/TCF transcription factors (Figure 1.5, pg.34). In vitro cultures of HSCs 
overexpressing stabilized p-catenin proliferate with a 100-fold increase 
(Reya et al. 2003) and addition of purified Wnt3a protein renders in vitro 
cultures of HSCs 6-fold more likely to proliferate and reconstitute the 
haematopoietic system of irradiated mice, but less likely to differentiate and 
express differentiation markers (Willert etal. 2003).
Wnt also controls differentiation. It has been shown to exhibit control over 
the migration of stem cell progenitors from intestinal crypts by regulating 
the EPH-family of adhesion molecules (Steinle et al. 2002). Its role in
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proliferation and migration of epithelial stem cells in the normal gut has also 
been documented by the absence of intestinal stem cells in transgenic mice 
that lack the TCF4 transcription factor (Korinek et al. 1998). The essential 
nature of Wnt signalling in vivo is confirmed by the fact that mice lacking 
Wnt3a or p-catenin are not viable.
Ectopic expression of axin, an inhibitor of Wnt signalling leads to inhibition 
of proliferation and increased death of HSCs in vitro and reduced 
reconstitution in vivo (Reya et al. 2003). Wnt signalling can be kept in check 
by bone morphogenetic proteins (BMPs), which in the gut are produced by 
pericryptal mesenchymal cells (He et al. 2004): disruption of BMP signalling 
results in an expansion of the stem and progenitor cell compartment 
leading to a juvenile-polyposis-like state. BMP may be mediated by PTEN; 
another protein that is often mentioned as a key factor in colorectal 
carcinogenesis. This lipid and protein phosphatase activates BMP 
signalling through inhibition of the phosphatidylinositol-3 kinase (P13K)-Akt 
pathway, thereby preventing the nuclear localisation of p-catenin. Thus, a 
deficiency in PTEN in intestinal stem cells may be responsible for colorectal 
carcinogenesis (He et al. 2007).
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Figure 1.5. Wnt signalling pathway. (A) In the absence of Wnt signal 
Dishevelled (Dsh) is inactive and the destruction complex of GSK3, APC 
andaxin is active causing phosphorylation of p-catenin and subsequent 
degradation. Meanwhile, Tcf is bound to its binding site in the nucleus and 
represses target gene expression. (B) When a Wnt signal is present 
Dsh inactivates the destruction complex, allowing cytosolic accumulation of 
P -catenin which interacts with Tcf to allow transcription of the 
downstream genes. (Diagram courtesy of M.J. Lovell).
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1.3.2 The Polycomb protein family
Key regulators of stem cell renewal appear to be members of the Polycomb 
group protein family of transcriptional repressors (Bmi-1, Rae28, Mel-18). 
Bmi-1 targets genes such as P16 and P14, preventing stem cell 
senescence by respectively maintaining cyclinD/Cdk4 signalling and 
MDM2-destruction of P53 (Park et al. 2004). Bmi-1 is in fact a downstream 
target of the morphogen Sonic hedgehog (Shh). Shh acts on the receptor 
complex of Patched (PTCH) and Smoothened (SMO), blocking the 
restraining influence of PTCH on SMO, resulting in the activation of the Gli- 
family of transcription factors through SMO signalling, thereby activating 
target genes like BMI-1. Inhibiting the action of SMO with the anatagonist 
cyclopamine is a highly effective strategy against a wide range of foregut 
cancers in mouse models (Berman et al. 2003).
1.3.3 The Notch family
The Notch family of receptors plays a key role in intestinal stem cell 
physiology as well as colorectal cancer development. Triggered by binding 
of ligands of the Delta and Jagged families, Notch is cleaved and 
translocated to the nucleus where it activates the transcription factor Csl. 
Doing so, it controls cell self-renewal (Dontu et al. 2004, Karanu et al. 
2000) and directs the differentiation of progenitor cells (Fre et al. 2005), 
thereby maintaining the balance between stem cells and differentiated cells 
in the intestinal epithelium. It has been shown that blocking the stem cell- 
maintaining activity through Notch-cleavage with y-secretase inhibitors can 
reduce intestinal neoplastic development by forcing cellular differentiation 
(van Es et al. 2005).
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1.4 MARKERS OF STEM CELLS
Considerable effort is being expended in the search for ‘markers’ of stem 
cells, with the expectation that many of the molecules expressed by normal 
stem cells will also be found in their malignant counterparts. Some 
proposed markers of normal human stem cells and their malignant 
counterparts are listed in Table 1.1 (pg.47). Collectively these molecules 
appear to be involved in maintaining ‘sternness’, such as transcription 
factors like Oct-4.
Many tumours appear to be caused by mutations which dysregulate normal 
self-renewal pathways, causing uncontrolled proliferation and resulting in 
neoplastic proliferation (Reya et al. 2001, Taipale et al. 2001, Reya et al.
2003). Thus, many of the potential stem cell/cancer stem cell markers are 
members of the pathways controlling stem cell self-renewal, such as 
proteins involved in the Wnt pathway including p-catenin, PTEN and 
members of the Polycomb family such as Bmi-1, PTCH. Recently, the Wnt 
target Lgr5 has been suggested as a new promising stem cell marker. It 
was shown to be expressed in mouse cycling columnar cells at the crypt 
base and moreover, Lgr5-expressing cells were able to generate all 
intestinal cell lineages, as revealed by lineage tracing experiments (Barker 
etal. 2007).
Other proteins that are commonly dysregulated in tumours are responsible 
for ensuring adhesion to the niche. For example, in the human epidermis, Li 
and Kaur have noted superior colony forming ability from cells selected on 
the basis of expression of the hemidesmosomal integrin a6, which partners 
P4 to attach cells to the basement membrane component, laminin V (Webb 
et al. 2004), while Jones and Watt noted that high expression of p1-integrin 
enriched for cells with colony-forming ability in basal keratinocytes (Jones 
etal. 1993).
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Potential stem cell markers also include proteins that ensure their 
cytoprotection. CSCs undoubtedly contribute to relapsed and drug-resistant 
tumours because of their drug-effluxing properties. For example, 
haematopoietic stem cells (HSCs) have high levels of aldehyde 
dehydrogenase (ALDH), a detoxifying enzyme that confers resistance to 
alkylating agents such as cyclophosphamide (Storms et al. 1999). In the 
bronchiolar epithelium, stem cell function appears to be the property of rare 
pollutant-resistant cells linked to a deficiency in the phase I drug 
metabolising enzyme CYP450 2F2 (Giangreco et al. 2002, Giangreco et al.
2004). In the liver, progenitor cells can expand despite exposure to 
pyrrolizidine alkaloids because of a similar deficiency in cytochrome P450 
(Vig et al. 2006).
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1.4.1 Side Populations
Perhaps the best-known cytoprotective mechanism claimed to distinguish 
stem cells is conferred through the expression of members of the ABC 
membrane transporter superfamily. Expression of an ATP-binding cassette 
region enables cells to hydrolyse ATP to support energy-dependent 
substrate exportation against steep concentration gradients across 
membranes. In this manner, actively effluxing lipophilic drugs such as the 
fluorescent dye Hoechst 33342 causes the cells to appear as a distinct tail­
shaped ‘side population (SP)’ on the side of the profile when subjected to 
fluorescence activated cell (FAC) analysis (Goodell et al. 1996). Like the 
activity of the p-glycoprotein (encoded by the MDR-1 gene), this activity is 
verapamil-sensitive, and is also sensitive to reserpine (Zhou et al. 2001, 
Zhou et al. 2002). Many studies suggest that the SP phenotype in rodent 
and human tissues is largely determined by the expression of a protein 
known as the ABCG2 transporter (ATP-binding cassette [ABC] subfamily G 
member 2, also known as breast cancer resistance protein (BCRP1), and 
that the SP fraction more or less equates with the stem cell population in 
both normal tissues (Alison 2003) and tumours (Hirschmann-Jax et al. 
2004, Hirschmann-Jax et al. 2005). Moreover, not only do tumour SPs 
appear to have characteristics of CSCs, but additionally they may 
contribute to relapsed and drug-resistant cancers because of their drug- 
effluxing properties.
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In common with many tumours, CNS tumours may have an SP fraction 
likely to be enriched for CSCs. They have been found in the rat C6 glioma 
cell line (Kondo et al. 2004), and in a great variety of human primary 
tumours (Hirschmann-Jax et al. 2005, Hirschmann-Jax et al. 2004). In two 
human liver tumour cell lines, a small (<1%) SP fraction has been found 
and transplantation of as few as 1000 of these cells was able to generate 
xenograft tumours in NOD/SCID mice (Chiba et al. 2006). Most 
gastrointestinal cell lines also appear to contain a small SP fraction that can 
self-renew, possibly being the CSCs (Haraguchi etal. 2006).
However, Burkert et al. have recently found in gastrointestinal cancer cell 
lines, that the SP phenotype does not enrich for cells with stem cell 
characteristics and thus does not represent a useful stem cell marker in 
these malignancies (Burkert etal. In Press, Chapter III).
1.4.2 Musashi, Hairy and Enhancer-of-split 1
Musashi-1 (Msi-1) is the mammalian homologue of a Drosophila protein 
required for asymmetric division of sensory neural precursor cells (Okabe 
et al. 2001). It is an RNA binding protein first found to be expressed in 
neural stem cells (Good et al. 1998, Sakakibara etal. 1996). Its expression 
has been confirmed in putative stem cells in intestinal crypts in neonatal 
and adult mice (Potten et al. 2003) and has been demonstrated in epithelial 
crypt cells of the human colon in predicted stem cell positions (Martin et al. 
1998, Nishimura etal. 2003).
Hairy and Enhancer-of-split (HES)-1 is a major transcriptional repressor 
downstream of Notch-signalling involved in neural stem cell self-renewal 
and suppression of neural stem cell differentiation (Akazawa et al. 1992, 
Nakamura et al. 2000, Sasai et al. 1992). It is positively regulated by and 
appears to be in close association with Msi-1. It is expressed in intestinal 
crypt stem cell regions in the mouse small intestine, but its expression also 
extends to the cells migrating up the crypt (Kanemura et al. 2001, Kayahara 
et al. 2003). It is suggested that in the small intestine, co-expression of Msi-
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1 and Hes-1 just superior to the Paneth ceils is indicative of the stem cell 
population, whereas Hes-1 expression alone represents proliferating cells 
committed to differentiation (Kayahara et al. 2003). The significance of Msi- 
1 and Hes-1 as putative stem cell markers in other tissues has yet to be 
elucidated.
1.4.3 Surface markers
For the purpose of isolation, identification and as a potential therapeutic 
target, the most convenient and useful features distinguishing stem cells 
from somatic cells would be unique surface markers. Bonnet and Dick 
provided the first surface marker characterisation of CSCs. They showed 
that a small subset of AML cells with the same phenotype as described for 
primitive HSCs; CD34+CD38* was capable of producing leukaemic 
progenitors and leukaemic blasts upon transplantation into immunodeficient 
mice, resulting in a disease phenotype identical to the donor (Bonnet et al. 
1997, Bonnet 2005). Then in breast cancer, a subpopulation of cells with 
the surface antigen expression pattern ESA+CD44+CD24'/l0W was shown to 
be capable of tumour formation when implanted in limiting dilution into 
immunodeficient mice and of self-renewal as shown by serial 
transplantation (Al-Hajj et al. 2003). More recently, these same tumour- 
initiating cells have been shown capable of mammosphere generation in 
vitro (Ponti etal. 2005).
1.4.3.1 CD133
The most promising cell surface protein to date, implicated as stem cell 
marker in various tissues and cancers is CD133, also known as prominin-1 
or AC133 (Shmelkov et al. 2005). It belongs to a family of 5- 
transmembrane glycoproteins, which specifically localizes to cellular 
protrusions. It was first shown in brain cancer that clonogenicity 
(neurosphere forming) and self-renewal was exclusive to the nestin and 
CD 133-expressing subpopulation of tumour cells. In several pieces of 
research, the CD 133-positive cell fraction isolated from different types of
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brain tumours displayed stem cell properties in vitro and in vivo. In vitro, 
CD133+ cells were capable of neurosphere generation and multipotential 
differentiation into cells with neural and glial phenotypes, in proportions 
resembling the original tumour with a proliferative capacity that was 
proportional to the aggressiveness of the original tumour (Singh et al. 
2003).
In vivo, intracranial injection of CD133+ cells derived from various brain 
tumours, including the most malignant adult human CNS tumour 
‘glioblastoma multiforme’, but also paediatric brain tumours, into NOD/SCID 
or nude mice at limiting dilution produced serially-transplantable tumours 
identical to the patient’s original phenotypes. As few as 5000 cells formed 
tumours in nude mice, whereas injections of up to 105 CD 133-negative cells 
failed to produce tumours (Hemmati et al. 2003, Singh et at. 2004, Galli et 
al. 2004, Yuan et al. 2004). Additionally, the CD133+ cell fraction was able 
to generate both CD 133+ and CD 133- cells, since islands of cells with both 
phenotypes were present within the resulting xenograft tumours. However, 
it is worth noting that up to 33% of cells in glioblastomas was CD133- 
positive, indicating that not all CD 133-positive cells can be stem cells.
Recently, several reports have emerged that the CD133+ cells may also 
represent a stem cell-enriched population in colon cancer. CD133-positivity 
was found in 2.5-9% of primary human colorectal cancer cells, representing 
a population 200-fold enriched in serially-transplantable tumorigenic cells 
upon renal capsule or on subcutaneous (s.c.) injection into immunodeficient 
mice (O’Brien et al. 2007, Ricci-Vitiani etal. 2007).
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1.4.3.2 0044
CD44 is a widely expressed transmembrane receptor protein, and acts as 
an adhesion molecule in cell-cell and cell-substrate interactions. It is a 
proteoglycan with an NH2-terminal region, structurally related to 
hyaluronate binding proteins (Underhill 1992), binding to collagen and 
hyaluronate (Carter et al. 1988, Miyake et al. 1990). CD44 is encoded by a 
single gene, but exists in 10 different isoforms, generated by alternative 
splicing and differential glycosylation. At least in part it is involved in the 
Wnt signalling cascade, as its expression is activated by p-catenin 
(Wielenga et al. 1999). In normal tissues, it is involved in cell adhesion, 
lymphocyte homing and haematopoiesis, but it also seems to play a role in 
tumour progression and in the metastatic cascade, where it is thought to 
confer metastatic potential by changes in adhesion to extracellular ligands. 
Treatment of cells with an anti-CD44 variant 9 (CD44v9) and variant 6 
(CD44v6) antibody has been shown to inhibit metastases in mice (Matzku 
etal. 1989, Yamaguchi etal. 1998).
CD44-expression differs between normal and neoplastic colonic tissue. 
Particularly CD44v6 and CD44v9 are differentially expressed in invasive 
carcinomas and carcinoma metastases, as well as in adenomatous polyps, 
compared to very weak expression in normal colonic epithelium (Heider et 
al. 1993). During the course of disease progression, the expression of 
CD44v9, normally restricted to the basal membrane, loses its polarity and 
increases in extent (Kawahara et al. 1996). CD44v6 has also been 
suggested to confer metastatic potential to rat tumours (Matzku et al. 
1989).
In breast cancer, a subpopulation of cells with the surface antigen 
expression pattern of ESA+CD44+CD24*/low is tumorigenic and self- 
renewing when serially implanted into immunodeficient mice and capable of 
mammosphere generation in vitro (Al-Hajj et al. 2003, Ponti et al. 2005). 
Recently, the CD44-expressing population from pancreatic 
adenocarcinomas proved to be 4-fold enriched in tumorigenic cells, and
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when CD44-expression was combined with ESA and CD24-expression, a 
100-fold enrichment in tumorigenic cells was observed (Li et al. 2007), In 
various prostatic carcinoma cell lines, the CD44+ population showed a 
higher tumorigenicity, proliferation ability and clonogenicity than the 
negative counterpart. They also showed other characteristics of stem or 
progenitor cells, such as co-localisation with BrdU label-retaining cells, and 
expression of ‘sternness genes' OCT-3/4, BMI-1, p-catenin and SMO. 
Morever, CD44+ cells generated CD44- and CD44+ cells in vitro and in 
vivo (Patrawala et al. 2006). Another recent study has shown that CD44+ 
cells from head and neck squamous cell carcinomas (SCC) have the ability 
to self-renew and differentiate in vivo, have a primitive morphology, and co­
stain with the basal stem cell marker cytokeratin 5/14 and Bmi-1 (Prince et 
al. 2007). During the course of our experiments (chapter IV), a report 
emerged identifying the CD44+/EpCAMhigh population as a tumorigenic cell 
population in colorectal cancers when s.c injected into NOD/SCID mice 
(Dalerba et al. 2007).
1.4.3.3 CD117
CD117 is a 145 kD tyrosine kinase receptor encoded by the proto­
oncogene c-KIT, acting as a receptor for the cytokine stem cell factor 
(SCF). Dimer formation with its ligand causes indirect activation of several 
signalling cascades that are involved in cell survival, adhesion, proliferation, 
and differentiation (Kitamura et al. 1998, Alexander et al. 1998, Ashman et 
al. 1999). The fact that animals deficient in CD117 fail to develop highlights 
its importance for cell survival and differentiation (Alexander et al. 1991). 
CD117 was first demonstrated differentially expressed on the surface of 
haematopoietic stem cells (HSCs), multipotent progenitors and myeloid 
progenitors. Since then, its expression has also been observed on 
thymocyte progenitors (Massa et al. 2006), mast cells, melanocytes in the 
skin, and interstitial cells of Cajal (Bernex et al. 1996) in the digestive tract. 
Another target of CD117-expression appears to be hair matrix 
keratinocytes of melanocyte-deficient hair follicles in mice treated with an 
anti-Kit antibody, and was found to be hair-cycle-dependent. Involvement in
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hair growth control was also indicated by the observation that anagen 
development in c-KIT-deficient mice is significantly retardxed (Peters et al. 
2003).
Differential overexpression of CD117 in many malignant tissues suggests 
roles in growth, survival, migration, and invasive potential of malignant 
cells. Acting as a proto-oncogene, activation mutations in the c-KIT 
sequence can cause its overexpression, contributing to tumour 
development by its effect on signalling cascades involved in cell cycle- 
regulation (Turner et al. 1992).
Overexpression of c-KIT has mainly been associated with 
lymphoproliferative disease, but it has also been demonstrated in various 
non-haematopoietic malignancies including gastrointestinal stromal 
tumours (Druker 2001, Kitamura et al. 1998), mast cell disease (Heinrich et 
al. 2002), neuroblastoma (Timeus et al. 1997), malignant cells from breast 
(Hines et at 1999), lung (Turner et al. 1992) and prostate (Simak et al. 
2000). Immunohistochemical studies have also suggested an involvement 
of CD 117-expression in endometrial carcinogenesis (Elmore et al. 2001). 
The effect of CD117 was in many instances achieved through inhibition of 
apoptosis, which has been shown in melanocyte precursors (Ito et al.
1999), soft tissue sarcomas (Ricotti et al. 1998), neuroblastomas (Turner et 
al. 1992), and normal and malignant haematopoietic cells (Hassan et al.
1996).
The extent and involvement of CD 117-expression in colorectal carcinomas 
is unclear. In human carcinoma cell lines, such as HT-29, overactivation of 
c-KIT was responsible for anchorage-independent growth (Bellone et al. 
2001, Lahm et al. 1995). However, other studies on primary tissues 
observed CD117 expression as a rare event, only seen in 1.6% of 126 
colorectal carcinoma specimens and altogether absent from normal colon 
(Reed et al. 2002). Together, the expression of CD117 on several types of 
stem cells and differential expression in tumours renders it a possible 
candidate as a potential cancer stem cell marker.
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However, contrasting evidence argues that c-KIT activation does not play a 
universal role in stem cell function and cell survival. CD117 is not 
ubiquitously expressed on malignant or metastatic cells. In advanced 
melanoma cells for example, its expression appears to be very low 
(Montone et al. 1997). Forced c-KIT expression inhibits the metastatic 
potential of melanoma cells through SCF-induced apoptosis; a mechanism 
to be explored as a novel therapeutic approach (Huang et al. 1996).
1.4.3.4 CD34
CD34 is a siaiomucin-like adhesion molecule that is specifically expressed 
on the cell surface of human haematopoietic stem cells (HSC) (Lubbert et 
al. 1991) and has been implied as a potential stem cell marker in several 
non-haematopoietic tissues. Encoded on gene locus 1q32, its gene product 
is a 100 kD transmembrane protein, the function of which has not been 
elucidated to date (Satterthwaite et al. 1992). First demonstrated in 
baboons, it was shown that the CD34-positive population of primate BM 
shows a high efficiency in clone formation and is capable of repopulating 
lethally-irradiated BM in vivo (Berenson et al. 1988, Civin et al. 1984). This 
fact is the basis for the widely used clinical application of CD34 in selecting 
haematopoietic stem cell progenitors for BM transplantation (Sutherland et 
al. 1993). Its expression has also often been implicated in haematopoietic 
malignancies. However, CD34-expression in tumours seems variable, 
possibly having a prognostic significance (Stagno et al. 1996).
On the other hand, SP cells from human BM, known to restore BM function 
in lethally irradiated mice, are in many tissues CD34-negative (CD34-), 
suggesting that a CD34- HSC population exists (Goodell et al. 1997). This 
was also confirmed by other researchers who demonstrated that CD34- 
cells show stem cell-typical behaviour such as multilineage 
haematopoiesis, as well as the ability to generate CD34-positive (CD34+) 
cells in vitro and in vivo (Zanjani et al. 1998). Based on the bulk of 
conflicting evidence, a mechanism has been suggested whereby human 
HSCs possess reversible CD34-expression ability with the CD34- HSC
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population representing a more primitive SC population and the CD34+ cell 
population being enriched in more rapidly-proliferating progenitor cells.
A similar scenario has been proposed in mice. HSCs are found in both the 
CD34+ and CD34- cell fractions. CD34-deficient mice show a delay in 
haematopoietic development. However, in the blood of adult mice, the 
haematopoietic profile is normal, suggesting, that CD34-expressing cells, 
although not essential for survival, are involved in mouse haematopoiesis 
(Cheng et al. 1996). On the other hand, transplantation of CD34- cells can 
result in haematopoietic reconstitution and multilineage differentiation, 
implying their stem cell potential (Osawa et a l 1996). A mechanism has 
been suggested whereby CD34 expression on murine HSCs is reversible: 
CD34- cells start expressing CD34 when stimulated by early-acting 
cytokines, but still retaining their HSC function. When cell activation is 
terminated, they presumably revert back and stop CD34-expression (Sato 
etal. 1999, Ito et al. 2000, Matsuoka etal. 2001).
CD34 has also been associated with stem cells from other tissues. In the 
portal vein endothelium of the liver, it is co-expressed with the liver stem 
cell marker Thy-1 (Terrace etal. 2007). In the hair follicle, CD34-expression 
is specifically targeted to a known stem cell area, the hair follicle bulge, in 
several species, including humans, mice and rabbits (Pascucci et al. 2006, 
Poblet et al. 2006, Raposio etal. 2007). Within the bulge, CD34-expression 
was co-localised with expression of the stem cell marker keratin 15 in 
mouse hair follicles (Poblet et al. 2006) and with the proliferation marker Ki- 
67 in humans (Raposio et al. 2007). Additionally, its expression is 
implicated in the progression (Affara et al. 2006) and may even be essential 
for the formation of skin tumours (Trempus etal. 2007).
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Table 1.1
Some proposed markers of normal human stem cells and their malignant
counterparts
Brain/medulloblastoma CD133+nestin+GFAP+ 
A2B5+
Musashil
SSEA-1
CD133+
Breast a6+C K19+ES A+M U C1 ' 
CALLA-
ESA+C D44+C D24'/low
Haematopoietic/C ML CD34+CD38"
CD133+
ALDH*
SP
CD34+CD38"
Gastrointestinal Musashil
Hes-1
Nuclear p-catenin
SP -  found in cell lines
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1.5 CLONALITY
A major difficulty in finding methods to isolate and identify stem cells, which 
prevents them from being identifiable and examined directly in many 
tissues is their immature phenotype. To circumvent this obstacle, 
researchers rely on the fact that stem cells give rise to clonal populations of 
differentiated and identifiable progeny. Investigating the progeny can 
indirectly reveal information about normal and pathological developments 
within their ancestors. Additionally, the difficulty in studying developmental 
dynamics in vivo renders following clonality and the spread of mutations the 
method of choice to provide insight into tissue development. Patterns of 
mutations that do not confer a selective advantage or disadvantage allow 
for the study of tissue and tumour development.
1.5.1 Genomic variations as markers of clonality
Mosaic animals and mouse aggregation chimeras with somatic mutations in 
the Dlb-1 locus on chromosome 1, affecting the lectin-binding ability for 
Dolichos biflorus agglutinin (DBA), have been used to follow clonality and 
tissue development in the intestinal tract. The lectin-binding ability can be 
lost by spontaneous mutation of the Dlb-1 locus, or by treatment with the 
chemical mutagen ethylnitrosourea (ENU). In heterozygous mouse 
aggregation chimeras derived from a cross between a C57BI/6J wild type 
strain and the SWR strain containing a carbohydrate polymorphism of Dlb- 
1, DBA can only bind to clones of C57BI/6J-derived, but not to SWR- 
derived cells (Schmidt et al. 1988). Similarly, ENU treatment results in loss 
of DBA binding in mutated cells, and if the mutation of the Dlb-1 locus 
happens in a stem cell, it then expands stochastically to produce a clone of 
cells that cannot bind DBA (Winton etal. 1988).
Mutations and known polymorphisms of the X-linked gene glucose-6- 
phosphate dehydrogenase (G6PD) have also been exploited for clonality 
studies revealing the mosaic patterns of G6PD staining in heterozygous
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animals. Use of this model to investigate clonality excludes the possibility 
that cells derived from distinct strains in chimeric mice segregate 
differentially during organogenesis (Thomas et al, 1988). In humans, a 
convenient method for studying clonality is to follow X-inactivation patterns 
or X-linked heterozygous polymorphisms, since it is well known that X- 
inactivation is inherited to daughter cells in a clone (Novelli et al. 2003). 
One study that provided important information regarding the clonal origin of 
human intestinal crypts came from the examination of the colon of a rare 
XO/XY patient who had received a prophylactic colectomy for familial 
adenomatous polyposis (FAP) (Novelli et al. 1996). However, studies 
involving X-linked mutations and inactivation patterns, although convenient 
and easily carried out, can only be carried out on females and exclude male 
development and potential sex-specific developmental differences from the 
research.
As a solution, examining methylation patterns can make it possible to map 
stem cell division histories and cell fate by following the methylation pattern 
of non-expressed genes (Yatabe et al. 2001, Kim et al. 2002).
1.5.2 Mitochondrial mutations as markers of clonality
Mitochondria (mt) are cellular power generators, creating cellular ATP 
through oxidative phosphorylation. They contain a circular 16.6 kb DNA 
molecule encoding 37 genes, of which 22 encode tRNA, 2 rRNA, and 13 
proteins involved in oxidative phosphorylation. Each mitochondrion 
contains several hundred molecules of its circular genome and in most cells 
several thousand of these organelles exist. Mt contain their own replication 
machinery and genetic code and lack protective histones and DNA repair 
mechanisms which renders the rate of mutation random; higher than in 
genomic DNA and increasing with age. These properties, in addition to their 
abundance, make them important tools in forensic science, specifically 
useful in heavily-degraded, aged and small samples. Mt DNA mutations 
can produce a biochemical deficiency dependent on the site and severity of 
the mutation and have been implicated in the progression of many
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diseases, including carcinogenesis (Brierley et al. 1998, Michikawa et al. 
1999, Coller et al. 2001, Taylor et al. 2003). Mt mutations can spread 
throughout the cells through mt replication and render the cells 
heteroplasmic with a mixed population of mutated and wt mitochondria, or 
homoplastic with all mitochondria in a cell mutated or wt. For a cell to show 
an overall mutated mt phenotype, homoplasmy or low levels of 
heteroplasmy must be present.
Non-oncogenic mitochondrial DNA (mtDNA) mutations, which result in the 
deficiency of cytochrome c oxidase, have been used as a marker of 
clonality in the intestinal tract, and provided information regarding SC 
numbers and maintenance dynamics in the normal and dysplastic colon 
and stomach (Greaves et al. 2006, McDonald et al. 2006). Cells that 
demonstrate a deficiency in cytochrome c oxidase function and normal 
succinate dehydrogenase (SDH) activity generally have increased numbers 
of overall mtDNA mutations (Johnson etal. 1993). Cytochrome c oxidase is 
a large lipoprotein composed of 13 subunits. In mammals, 10 subunits are 
encoded by the nuclear genome and 3 are synthesized mitochondrially. It is 
the last protein in the electron transport chain and catalyses the reduction 
of dioxygen to water, thereby generating an electro-chemical gradient that 
provides cellular energy. In a histochemical method to detect the activity of 
cytochrome c oxidase, cells with mutations affecting cytochrome oxidase 
activity stain blue, whereas normal cells stain brown.
1.6 THE INTESTINAL EPITHELIUM
1.6.1 Cell lineages of the intestinal epithelium
The intestine consists of the small and large intestine, both of which are 
composed of three cell layers: the lamina propria and the submucosa are 
the two outermost layers and serve as structural and regulatory support. 
The vascular lamina propria is composed of numerous cell types such as 
fibroblasts, fibrocytes, vascular endothelial and smooth muscle cells, blood 
cell lineages and intestinal subepithelial myofibroblasts (ISEMF). ISEMFs
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secrete growth factors, such as transforming growth factor beta 2 (TGFp2) 
and Wnt, which is known to play a role in stem cell differentiation and 
proliferation (Powell et al. 1999). The innermost layer consists of columnar 
epithelial mucosa with glandular invaginations, the crypts of Lieberkuhn. As 
concave indentations, the crypts extend through the lamina propria down to 
the muscularis mucosae. In the small intestine, crypts give rise to fingerlike 
projections known as villi, whereas the colon is devoid of villi. Cells are 
organised in a hierarchical migratory fashion within the crypts and villi, with 
fully-differentiated cells towards the luminal surface, which are continually 
shed into the lumen and replaced by a constant stream of proliferating 
progenitor cells located in the bottom two-thirds of the crypt.
There are four common cell lineages contributing to the epithelial layer in 
the small intestine, all of which are reconstituted by the same stem cell 
population. Absorptive and columnar cells are the predominant cell type, 
known as ‘enterocytes’ in the small intestine and ‘colonocytes’ in the colon. 
Columnar cells are polarised cells with a basal nucleus and an apical brush 
border composed of microvilli, which increase the surface area. The 
gastrointestinal tract is the largest endocrine organ in the body, a function, 
which is provided by an abundance of ‘endocrine’, ‘neuroendocrine’ or 
‘enteroendocrine’ cells that secrete peptide hormones. Approximately 10 
different endocrine cells, defined by their hormonal content are known to 
date in the mammalian small intestine (Solcia et al. 1998). Goblet cells are 
dispersed throughout the epithelium and secrete mucin granules to 
lubricate the mucosa and expel microorganisms. Paneth cells are the only 
exception to the polarized hierarchical structure of the epithelial ceil layer. 
They are the only cells in the small intestine that escape the upwards- 
migratory flow of differentiating cells. All other cell types migrate upwards 
along the crypt-to-villus axis as they become more differentiated and 
undergo apoptosis, with subsequent shedding when they reach the 
intestinal lumen, but Paneth cells migrate downwards during maturation 
(Bjerknes et al. 1981). They secrete proteins that keep the crypt sterile, 
such as lysozyme, tumor necrosis factor a and antibacterial defensins or
51
cryptdins, from large apical secretory granules (Darmoul et al. 1997, 
Ouellette etal. 1994, Ouellette etal. 2000, Ouellette 2004).
Other less common cell lineages are also present, such as caveolated cells 
(Nabeyama et al. 1974), and M- (membranous- or microfold-) cells that are 
involved in antigen transport and reside in the small intestine near 
specialised lymphoid follicles, known as ‘Peyer’s patches’ (Gebert et al. 
1997) (reviewed in (Kerneis etal. 1999)).
1.6.2 Developmental dynamics in the intestinal epithelium
It is believed that crypts are polyclonal at birth, but subsequently convert to 
pure monoclonal crypt populations. This has been shown in aggregation 
chimeric mice with Dlb-1 mutations (Schmidt et al. 1988). When treated 
with mutagens, monoclonal conversion in mouse small intestinal crypts 
takes 8-12 weeks, whereas in the colon, it only takes 4 weeks. The 
temporal differences in the appearance of monophenotypical crypts may be 
due to differential rates of crypt fission at the time of mutagen 
administration (Park et at. 1995), but it could also reflect different stem cell 
numbers. After irradiation, human homozygotes for mutations in the O- 
acetyl transferase gene suggested a monoclonal conversion time of one 
year in human colonic crypts (Campbell etal. 1996).
Crypts divide and expand in number by crypt fission, whereby crypts divide 
longitudinally after basal bifurcation resulting in two daughter crypts (Park 
etal. 1995, Greaves etal. 2006). Clonal patches of crypts and observations 
of bifurcating crypts in steady state provide evidence for this mechanism. In 
humans, the crypt cycle takes approximately 9-18 years, and in mice 108 
days (Bjerknes 1986).
The mechanisms that stimulate a crypt to divide are unknown. It has been 
suggested that high crypt fission rates are linked with increased stem cell 
numbers (Totafurno et al. 1987). This theory however, is challenged by 
observations of increased numbers of bifurcating crypts upon chemical
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mutagenesis (Loeffier et al. 1993). Another model suggests that crypt 
fission is initiated upon crypts reaching a certain threshold size (Park et al. 
1995).
No matter what the mechanisms of fission initiation are, fission itself results 
in the formation of patches of related crypts. Novelli et al. utilised the 
heterozygosity for a mutation in the X-linked G6PD gene (563 C>T) present 
in 17% of Sardinian females to analyse patch size by histochemical staining 
for G6PD. They have shown that crypts exist in large families of either 
G6PD-positive or negative crypts. Of 10,538 colonic crypts analysed from 9 
patients, patch size in the colon was found to comprise up to 450 crypts 
(Novelli et al. 2003). Crypt fission is increased in pre-neoplastic lesions 
such as aberrant crypt foci (ACF). On this view, crypt fission is a vital 
component of the ACF-adenoma-carcinoma pathway and seems to be the 
main mechanism of the extra-cryptal spread of clones containing mutations 
in the adenomatous polyposis coli (APC) gene, frequently mutated in 
colorectal cancer (Kinzler et al. 1996).
1.6.3 Intestinal stem cells
The intestinal mucosa undergoes constant and rapid cell turnover with a 
frequency of every 2-3 days in rodents and other mammals (Goodlad et al. 
1984). The high regenerative pressure is managed by careful homeostasis 
between cell proliferation, differentiation, senescence and apoptosis, 
governed by the stem cells. In spite of their immense importance for 
intestinal function, limited and controversial evidence exists regarding the 
location, quantity, regulatory pathways or function of intestinal stem cells. 
This is exacerbated by the fact that to date there is no culture method 
robust enough to allow primary culture of the intestinal epithelium to test 
proliferative and differentiation potential of intestinal cellular subtypes.
Ablation studies of specific epithelial cell lineages have failed to identify 
candidate stem cells. Targeted ablation of Paneth cells (Garabedian et al.
1997), and three different endocrine cell lineages in the mouse small
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intestine (Rindi et al. 1999), did not affect epithelial cell proliferation. It is 
thus conceivable that the stromal/mesenchymal cells comprising the stem 
cell niche set up an optimal microenvironment through their secretion of 
specific growth factors and inflammatory cytokines, and play an important 
role in stem cell function, perhaps more so than the genetic programming 
within the stem cells themselves (Dignass et al. 1994, Riegler et al. 1996, 
Podolsky 1997, Polk 1998, reviewed in (Powell etal. 1999), Dignass 2001).
1.6.3.1 Stem cell location
In the small intestine, the stem cell niche is believed to reside in position 4- 
5 counted from the bottom of the crypt with positions 1-3 occupied by 
Paneth cells (Figure 1.6, pg.55). In the colon, where Paneth cells are 
absent, the niche is believed to lie directly at the crypt base (Alison et al.
2000). In the mouse small intestine, these stem cell positions were 
proposed in the ‘stem cell zone’ hypothesis. Following a series of 
microscopic morphometry and autoradiography-labelling studies, it was 
suggested that multiple stem cells occupy the crypt base at cell positions 1- 
4, and can undergo proliferation but do not differentiate until they have 
migrated to cell position 5 (Bjerknes etal. 1981, l-V). This is consistent with 
radiation experiments, which gave rise to a hierarchical crypt model 
whereby cells move through three tiers upon leaving the stem cell 
compartment, continuing to divide, but gradually losing their clonogenic 
ability. Some cells within the three tiers may be capable of reconstituting a 
crypt in the case of damage (Marshman et al. 2002). This view however, is 
disputed by some researchers following recent observations (Barker and 
Clevers, 2007).
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Figure 1.6. The human small intestinal crypt. Stem cells are believed to be 
located at position 4-5 from the bottom, just above the Paneth cells. Differ­
entiating cells migrate upwards out of the stem cell zone towards the lumi­
nal surface, first as transit amplifying cells (TAC), which then proceed to ter­
minal differentiation. Paneth cells are an exemption and migrate down­
wards from the stem cell zone. (Figure taken from Spradling etal., 2001)
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1.6.3.2 Stem celt number
Much controversy exists regarding the stem cell numbers in the intestine 
and in various parts of the intestine. A widely-believed model is the 
‘Unitarian hypothesis’, which was proposed following observations of clonal 
expansion and the migratory pattern of differentiating cells within crypts 
(Cheng et a/. 1974). It suggests that all epithelial cells in a crypt originate 
from one multi potential stem cell sited towards the bottom of the crypt. 
Stem cell progeny follow a hierarchical migratory pattern along the crypt-to- 
villus axis with a more advanced stage of cell maturation with increasing 
proximity to the luminal surface, and eventually populate the entire crypt, 
which is therefore clonal. Villi notably can be polyclonal since they receive 
input from several crypts, which is supported by the fact that crypts are 7- 
fold more numerous in the mouse duodenum, and 4-fold in the ileum. The 
Unitarian hypothesis appears to apply to both mice and humans.
Intestinal crypts in neonatal B6/SWR mice are polyclonal for the first two 
weeks after birth, suggesting that multiple stem cells exist during 
development (Schmidt et al. 1988). After the initial neonatal polyclonality, 
the epithelial cells in the crypts become monoclonal in the adult mouse 
intestine, possibly due to positive selection of a single dominant clone or by 
segregation of lineages due to the division of crypts by ‘crypt fission’, which 
occurs frequently during this developmental period. These observations 
infer the existence of one sustaining stem cell (Ponder et al. 1985, Winton 
etal. 1990, Park etal. 1995, Bjerknes etal. 1999). Radiation studies, where 
eradication of all but single clonogenic cells resulted in the repopulation of 
all cell types within the mouse crypt, also support this view (Withers et al. 
1970). Similarly, ENU-triggered mutation of the Dlb-1 locus in a stem cell 
subsequently led to stochastic cell expansion to produce a clone of cells 
which contained all epithelial lineages within the small intestinal crypt 
(Winton et al. 1988). Temporal differences in the time taken for mutant 
stem cells to expand stochastically and create monoclonal crypts led to the 
suggestion that larger numbers of stem cells are present in the colon than 
in the small intestine (Williams et al. 1992).
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In humans, a fortuitous discovery by Novelli and colleagues in 1996 
revealed that crypts were clonal. In a patient with familial adenomatous 
polyposis (FAP), who had undergone prophylactic colectomy and was also 
chimeric for the Y chromosome (each cell either XO or XY), crypts were 
either positive or negative for the Y chromosome, but rarely mixed (Novelli 
et al. 1996). Only 4 of 12,614 crypts examined showed a mixture of XO and 
XY cells, which was explained by non-disjunction with loss of the Y 
chromosome in a crypt stem cell. However, the small intestinal villi were 
generally mixtures of XO and XY cells, consistent with the notion that villi 
are fed from more than one crypt. Clonality must be determined at the 
patch edge, since cells within the centre of a patch could be truly clonal or 
simply monophenotypic, formed from several stem cells of the same 
genotype. Examination of 2,260 crypts located at the patch periphery of 
females with heterozygosity for the G6PD Mediterranean mutation also 
showed no evidence of any crypts with a mixed phenotype, indicating that 
colonic crypts must be monoclonally-derived (Novelli et al. 2003).
Further to this, other studies have shown that single cell cloned HRA-19 
cell lines can induce tumours in mice that contain all the major 
differentiated intestinal epithelial cell lineages (Kirkland et al. 1994) -  strong 
evidence supporting the Unitarian hypothesis, although this cell line was 
derived from a colonic adenocarcinoma which should not automatically be 
assumed exemplary for the same mechanisms in the normal epithelium.
However, recent important research has proposed that crypts contain 
multiple stem cells, revealed by ribbons of cells reaching from the crypt 
bottom to the top that showed the same mutation in the mitochondrially- 
encoded cytochrome c oxidase gene in amongst cells that are otherwise 
cytochrome c oxidase-positive (Taylor etal. 2003).
Additionally, phylogenetic analyses of methylation patterns of three neutral 
loci show variations in cells in separate, unrelated crypts, whereas cells 
within one crypt display closely related or identical methylation patterns 
(Yatabe et al. 2001). This suggests that human colonic crypts contain
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multiple stem cells, which are constantly lost and replaced, eventually 
leaving all cells monoclonally-derived, related to the closest ancestor; a 
process called ‘monoclonal conversion’
Attempts to determine the exact number of stem cells within each crypt 
have yielded variable results. Estimates based on radiaton experiments 
range from 0.4-60% of all crypt cells, with species-specific differences 
(Marshman et al. 2002). Cell kinetic and mathematical simulation data 
suggest that by clonal expansion, 4-6 stem cells per crypt could easily 
maintain the mammalian intestinal epithelium. This number emerged when 
epithelial cells were randomly marked by DBA or G6PD mutations and 
followed with regards to position, morphology and longevity (Bjerknes et al. 
1999, Griffiths et al. 1988). Other reports have also determined that 
between 4-6 stem cells located at cell position 4-5 from the base of the 
crypt, just superior to the Paneth cells, comprise the small intestinal stem 
cell population (Cai etal. 1997, Potten etal. 1997, Potten 1998,)
However, others claim that up to 16 or more stem cells can exist in a single 
intestinal crypt (Roberts et al. 1995). It has also been suggested that stem 
cell number fluctuates throughout the crypt cycle until a threshold number 
of cells is reached, thereby signalling for crypt fission to occur (Loeffler et 
al. 1997).
1.6.4 Intestinal cancer
Cancer of the intestinal tract has an estimated lifetime risk of 5% (Horne- 
Badovinac et al. 2003). This high frequency is attributable to the constant 
cell turnover and necessary stem cell proliferation within the intestinal 
epithelium and the comparatively high exposure to carcinogens throughout 
the intestinal tract. Although intestinal cancer is among the best-understood 
solid malignancies on a molecular and genetic level, little is still known 
regarding the cellular origins of gastrointestinal malignancies.
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There are two conflicting models of intestinal neoplastic development in 
humans, both regarding stem cells as their origin. According to the ‘bottom- 
up’ theory, stem cells acquire the carcinogenic mutation within their niche at 
the crypt base and subsequently expand to colonise the entire crypt with 
their neoplastic progeny (Preston et al. 2003). This is followed by increased 
crypt fission giving rise to an oligocryptal adenoma and further leading 
down the adenoma-carcinoma path. This model is in accordance with the 
notion that intestinal stem cells are located near the crypt base. By 
contrast, the ‘top-down’ hypothesis is based on empirical evidence of 
dysplastic cells exclusively located at the orifices and luminal surface of 
colonic crypts (Shih et al. 2001). Since there is no evidence for a stem cell 
population in the intracryptal zone, the original top-down hypothesis, 
whereby transformed intracryptal stem cells migrate laterally and 
downwards into the crypt has been modified. It is now proposed that after 
stem cells acquire a second hit at the crypt base, the daughter cells 
undergo neoplastic expansion upon reaching the intracryptal zone. There is 
evidence for both mechanisms of adenoma morphogenesis and thus, both 
of these mechanisms may hold true. Whereas top-down spread seems to 
occur more in advanced adenomas, in early adenomas, only bottom-up 
development can be observed.
Defects in the adenomatous polyposis coli (APC) gene, which plays an 
important role in regulating the Wnt pathway through p-catenin degradation, 
are the most commonly found genetic abnormalities in colorectal tumours. 
Additionally, it regulates stem cell division by establishing correct cell 
polarity through indirect interactions with microtubules (Mogensen et al. 
2002, Yamashita et al. 2003). Misalignment of the mitotic spindle following 
loss of APC function may lead to dysregulated stem cell division and 
increased cell proliferation. Hundreds of mutations have been identified 
within this gene, many of which with specific prognostic implications. APC 
has the first genetic alterations in the development of gastrointestinal 
neoplasia according to the adenoma-carcinoma sequence of events 
(Morson 1974) as most patients with hereditary Familial Adenomatous 
Polyposis (FAP) carry a germline mutation of the APC gene (Bodmer et al.
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1987). A second mutation in the other allele and thus loss of function of the 
APC tumour suppressor results in development of a monocryptal adenoma 
which may further progress into microadenoma, macroscopic adenoma and 
finally colorectal carcinoma (Knudson 1993, Miyaki etal. 1994).
1.7 Skin
The skin is the largest organ in the human body, providing a protective 
barrier to environment. Its outer layer, the epidermis, is composed of a 
multilayered stratified squamous keratinised epithelium, the interfollicular 
epidermis (IFE), interspersed with hair follicles, sebaceous and sweat 
glands (Figure 1.7, pg.61). Cells are continuously shed from the epidermal 
surface and homeostasis is maintained by basally situated self-renewing 
stem cells (SC), which generate daughter cells capable of terminal 
differentiation into the various epidermal cell lineages.
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Figure 1.7. The epidermal structures with putative associ­
ated stem cell zones. The stem cells of the interfollicular epi­
dermis are believed to be at the top of the rete ridges (basal 
invaginations). The bulge region is a postulated stem cell 
zone in the hair follicle. The outer root sheath (ORS) togeth­
er with the inner root sheath (IRS) line the hair shaft. (Figure 
courtesy of M.J. Lovell).
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1.7.1 The interfollicular epidermis
1.7.1.1 Architecture of the interfollicular epidermis
The epidermis is a multilayered epithelium composed of basal layer, 
spinous layer, granular layer and the stratum comeum, which is in contact 
with the outer environment. The basal layer rests on a basement 
membrane, overlying the dermis, a dense fibroelastic connective tissue 
composed of collagen and elastic fibres containing the vasculature and 
nervous system of the skin. The basal layer of the epidermis contains the 
epidermal stem cells and their transit amplifying cell progeny, which follow 
a single terminal differentiation pathway to form keratinocytes, the principal 
epithelial cell lineage in the epidermis, which migrate to the corneal layer of 
the epidermis. In humans, the spinous layer, or stratum spinosum, is 4-8 
cells wide, whereby the upper spinous cells have a more flattened 
appearance. The granular layer, or stratum granulosum, is in humans 
comprised of 2-3 cell layers. Exemptions are the skin of the palms and 
soles, the granular layer of which contains significantly more cell layers. 
The outermost stratum comeum consists of 15-20 layers of terminally 
differentiated, non-viable, anucleate, flat, hexagonal keratinocytes, also 
known as squames.
1.7.1.2 Cell lineages of the interfollicular epidermis
Keratinocytes are the principal epithelial cell type in the epidermis. Their 
cytoskeleton is mostly composed of keratins, a family of filamentous 
proteins and differs slightly in structure depending on differentiation stage 
and layer position. The differentiation cycle of keratinocytes is 
approximately 8-9.5 days in mice (Potten et al. 1987), and between 28-60 
days in humans (Hunter et al. 1995). The intracellular cytoskeleton of basal 
cells is composed of a dispersed, extensive network of keratin filaments. 
The spinous layer contains post-mitotic keratinocytes with large, dense 
bundles of keratin intermediate filaments extending to the cell periphery to 
form desmosomal cell junctions, which equip the tissue with mechanical 
strength. Spinous keratinocytes also express lamellar keratohyalin
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granules, which secrete lipids and enzymes that fill the intercellular spaces 
of the stratum comeum, thereby contributing to the barrier function of the 
epidermis. The keratinocytes in the stratum corneum are fully terminally 
differentiated, devoid of a nucleus, not viable and are eventually shed from 
the epidermal surface. The cornified cell envelope of the stratum corneum 
consists of crosslinked structural proteins synthesised by granular 
keratinocytes.
Non-keratinocyte cell lineages in the epidermis comprise melanocytes, 
Langerhans and Merkel cells, which together account for less than 20% of 
all epidermal cells. Langerhans cells are found suprabasally in the spinous 
layer. They provide immunological protection through uptake, processing 
and presentation of specific antigens. Distinguished by a dendritic 
appearance, Langerhans cells lack keratin filaments, but possess ‘Birbeck 
granules', which enclose bound antigen through the formation of 
invaginations in the plasma membrane (Takahashi etal. 1985).
The basally-situated melanocytes function in their absorption of ultraviolet 
light. They are also of a dendritic phenotype, lack keratin filaments and are 
distinguished by the presence of small, membrane-bound melanin pigment- 
containing melanosomes. Via the dendritic processes, melanin is 
transferred to keratinocytes. Melanocytes and keratinocytes occur in a 
precise 1:36 ratio, forming a regular structural element known as the 
‘epidermal melanin unit' (Fitzpatrick etal. 1963, Jimbow etal. 1976).
Merkel cells are hormone-secreting cells which function as slow-adapting 
mechanoreceptors of the epidermis (Halata et al. 2003). In contrast to the 
non-keratinocyte cell types, Merkel cells can synthesise keratin 
intermediate filaments in their small, membrane-bound dense core 
granules. However, the keratin filaments are loosely distributed within the 
cytoplasm and do not occur in structurally organised bundles as it is the 
case in keratinocytes. Merkel cells are the least common non-keratinocyte 
lineage in the epidermis, with elevated numbers in regions of high touch
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sensitivity such as palms, buccal mucosa, lips and soles (Lacour et al. 
1991).
1.7.2 The sebaceous gland
The sebaceous glands are attached to the upper permanent portion of the 
hair follicle where they operate independently of the hair cycle. With the 
exemption of hairless body areas such as palms and soles, sebaceous 
glands are always associated with hair follicles. The greatest density of 
glands is found on the face and scalp. The glands vary in size and can be 
composed of one or multiple lobules, independent of their location.
Cells of the sebaceous glands follow a unidirectional differentiation pathway 
featuring a single cell lineage, the sebocytes. As they differentiate, the cells 
migrate from the basal layer toward the centre of the gland, gradually 
accumulating a lipid-rich fluid, or sebum. At the sebaceous duct their 
sebum content becomes so high that nuclei and other intracellular 
structures disappear. The cells eventually rupture and release their 
contents via the duct by holocrine secretion (reviewed in (Thiboutot 2004)).
1.7.3 The hair follicle
Hair follicles are more complex and comprise eight different cell lineages 
that form an epithelial core surrounded by a mesenchymal sheath. The hair 
shaft is composed of the medullary cells in the centre, surrounded by 
cortical and hair cuticle cells. The lower portion of the hair follicle protrudes 
into the dermis and is dilated into a bulb of epithelium enclosing the dermal 
papilla, a specialised pocket of mesenchymal cells. Surrounding the dermal 
papilla is a matrix region, which contains progenitor cells that give rise to 
the hair shaft (reviewed in (Goldsmith 1991)).
The hair shaft is enclosed within the inner root sheath (IRS), composed of 
three cell lineages, namely from centre to periphery: cuticle, Henle layer 
and Huxley’s layer. The outermost layer of the hair follicle is the outer root
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sheath (ORS), continuous with the overlying interfollicular epidermis (IFE). 
The ORS is believed to harbour a stem cell population and play a special 
role in the maintenance of the multiple hair lineages (reviewed in (Watt 
2002, Watt et al. 2006). The IRS and ORS are separated by the companion 
layer, the evolutionary origin of which and its attribution to either the IRS or 
the ORS is subject to debate. Analysis of keratin expression patterns 
ascribed it to the IRS as its outermost layer (Gu et al. 2007).
Hair follicles undergo a constant cycle of alternating growth (anagen), 
regression (catagen) and rest (telogen). In the mouse, anagen lasts 
approximately three weeks. In humans, anagen varies depending on body 
region. In the scalp, the anagen phase of hair follicles can last several 
years, whereas in hair follicles of eyelashes and eyebrows it lasts around 
1-4 months. Each follicle maintains an independent rhythm of growth and 
rest (reviewed in (Alonso et al. 2003)).
1.7.4 Stem cells in the skin
Maintenance of the epidermal layer is achieved through a highly complex 
and orchestrated process. It is clear that epidermal SCs are closely 
associated with and appropriately activated through close communication 
with the cells comprising their SC niche. However, only limited knowledge 
exists about stem cell niches in the skin and the mechanisms that regulate 
epidermal stem cell behaviour. Lineage tracing suggests that the epidermal 
components are replenished from distinct SC compartments in the hair, IFE 
and sebaceous glands (Ghazizadeh et al. 2001), whereby it is not entirely 
clear whether the sebaceous gland contains its own SC population or 
whether it is maintained by hair SCs. It is generally accepted that a 
population of stem cells exists in the bulge region of the hair follicle and in 
clusters in the IFE. SCs from both, the hair and the IFE can show 
multipotential characteristics when exposed to the appropriate stimuli, and 
which differentiation pathway the SCs undergo seems to be dictated by the 
local microenvironment rather than by genetic pre-programming (Watt 
1998, Panteleyev et al. 2001). For example, SCs in the hair follicle can be
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induced to give rise to IFE and sebaceous cells (Taylor et al. 2000, Oshima 
et al. 2001) and wee versa, IFE SCs have been shown to differentiate into 
hair lineages and sebocytes (Reynolds et al. 1992, Ferraris et al. 1997). 
Similarly, sweat gland SCs can generate a stratified epithelium (Miller et al. 
1998). This interconversion seems to be triggered upon exposure to the 
right microenvironmental cues, for example contact with the dermal papilla 
for hair follicle generation, or shifts in the balance of p-catenin (Silva-Vargas 
et al. 2005). An increase in p-catenin triggers hair follicle formation, 
whereas its deficiency triggers IFE formation (Huelsken et al. 2001). It 
appears that under normal conditions, SCs follow their normal pattern of 
differentiation, retaining multilineage potential for emergency situations, 
such as injury or stress.
Much research has focused on identifying markers of skin stem cells. As 
with other epithelial stem cells, some of the suggested stem cell markers 
include genes that confer SC characteristics such as self-renewal, 
quiescence, and maintaining cells in an undifferentiated state such as Wnt- 
inhibiting factor WIF1 and Dickkopf DKK3 (reviewed in (Watt et al. 2006)). 
Other putative molecular markers of epidermal SCs include CD34, which in 
humans is a well-described marker of haematopoietic SC, but is also 
expressed just below the bulge and in the ORS of anagen follicles (Poblet 
etal. 1994). Other potential stem ceil markers are the bulge-specific keratin 
15, as well as a6 and p1 integrins, and as recently suggested, CD200 
(Terunuma etal. 2007).
1.7.4.1 Hair follicle stem cells
Controversy exists over the number of SC populations in the hair follicle. 
One suggested hair SC niche is located in the hair bulge, a specialised 
region in the ORS (Fuchs et al. 2001). Another SC pool has been 
suggested within the dermal papilla in the hair matrix at the base of the hair 
root, supposedly giving rise to the lineages of hair shaft and IRS (Kamimura 
et al. 1997). However, it is unclear whether these proposed stem cell niche 
locations actually represent separate SC pools, thus separating the
66
developmental origins of IRS and ORS, or whether one of them is a 
progenitor cell pool, derived from a common SC niche for ORS and IRS. 
Lineage tracing studies support the view of separate stem cell niches; 
matrix SCs responsible for generating the IRS lineages, bulge SCs 
generating the ORS (Blanpain et al, 2004, Legue et al. 2005). In contrast, 
the ‘unitarian hypothesis’ suggests that bulge SCs form the ORS and 
additionally move along the ORS to the matrix of the hair bulb, where they 
function as SCs to replenish IRS and hair shaft at the end of each hair 
growth cycle (Kopan et al. 2002).
1.7.4.2 The epidermal proliferative unit
Based on irradiation and kinetic studies, the existence of SCs in the IFE 
seems unquestionable. The exact stem cell number is still subject to 
debate. In the mouse epidermis, the proposed stem cell fraction ranges 
from 2% (Morris et al. 1985) and 4% (Bickenbach et al. 1998) to 10% 
(Withers 1967, Potten etal. 1988, Clausen et al. 1990, Kolodka etal. 1998, 
Mackenzie 1997) of the cells of the basal layer. The IFE SCs are believed 
to be organised in small clusters of basal quiescent cells, surrounded by 
proliferative transit amplifying cells (TAC), which after a few cell divisions 
undergo terminal differentiation (Jones et al. 1995, Jensen et al. 1999). It is 
not clear whether TACs are committed to differentiation into a certain cell 
lineage. They may be multi potential at the beginning of their division cycle 
or exist in gradients of commitment along the differentiation pathway.
In the mouse, it was shown that the stratum spinosum is organised into 
distinct cell columns of approximately 10 overlying cells, extending from the 
basal layer. It is believed that basally-located SC together with surrounding 
TACs form the so-called ‘epidermal proliferative unit’ (EPU) which gives 
rise to progenitors that divide and migrate upwards, thereby forming the 
column and providing a steady flow of differentiated keratinocytes to 
compensate for the constant shedding of cells from the epidermal surface 
(Mackenzie 1969, Christophers 1971, Potten 1974).
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It is conceivable that humans too have a basal SC niche similar to the EPU, 
since the human and mouse epidermis are structurally organised in a 
similar fashion. However, cellular columns such as the ones observed in 
the mouse have not been identified to date (reviewed in (Potten 2002, 
Potten et a/. 2004)). Nevertheless, expression of putative stem cell markers 
suggests that human epidermal stem cells reside in projections of the IFE 
into the dermis, known as rete ridges, above the mesenchymal dermal 
papilla. Keratin-19 (Michel et al. 1996) and fa integrin (Mackenzie 1970, 
Jones et al. 1995) have both been identified as potential markers of slow- 
cycling epidermal stem cells. Co-expression of both proteins has been 
observed in basally-located evenly spaced clusters within the rete ridges, 
making these locations likely candidates to home to the stem cell niche 
(Michel etal. 1996)
1.7.4.3 The bulge activation hypothesis
It has been' argued that there is only one epidermal SC pool, located in the 
hair bulge, which gives rise to all epidermal cell lineages and all associated 
structures, and that what appears as IFE stem cells are in fact progenitor 
cells derived from this unique stem cell pool (Park et al. 2004). When 
cultured in vitro, bulge keratinocytes yield larger colonies than those from 
other skin sites. Other pieces of evidence show that the IFE stem cells are 
less numerous, less potent, display shorter longevity and are not capable of 
multi potential differentiation like bulge stem cells (Cotsarelis et al. 1990, 
Taylor et al. 2000, Alvarez-Do lad o et al. 2003). A possible activation 
mechanism for this unique SC pool generating all structures of the human 
skin is explained by the ‘bulge activation hypothesis’. Accordingly, cells in 
the dermal papilla of the hair bulb are capable of multi potential 
differentiation and generate both the hair shaft and the keratinocytes of the 
IFE. During catagen, the lower part of the hair follicle regresses, positioning 
the dermal papilla at the level of the bulge, where it remains throughout 
telogen. With the onset of anagen and the start of a new hair cycle, some 
cells from the bulge proliferate and move downward to form a new hair 
shaft, and other bulge-derived cells move upward to generate the
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sebaceous gland and the keratinocytes of the IFE. Therefore, interactions 
between the mesenchymal cells from the dermal papilla and the epithelial 
cells of the hair bulge are responsible for stem cell activation. Several 
studies have confirmed that proliferation and differentiation of epidermal 
cells is dependent on direct contact between the bulge and the dermal 
papilla. If the dermal papilla is mechanically separated from the growing 
hair follicle, follicle growth ceases (Link et al. 1990). Moreover, mice that do 
not express bone morphogenetic protein-4 (BMP-4), which is normally 
produced in the dermal papilla cells, show complete loss of all hair due to 
reduced or absent keratinocyte differentiation and dysregulated cell 
proliferation (Kulessa et al. 2000).
1.7.5 Non-melanoma skin tumours
The skin is one of the most common sites of carcinogenesis, mostly due 
the constant exposure of the epidermal surface to environmental assaults, 
such as UV-exposure, chemicals and pollution. Amongst the wide variety of 
different types of skin cancer, basal cell carcinoma (BCC) and squamous 
cell carcinoma (SCC) are the most common.
It is hypothesised that tumours originate in the normal SCs of the tissue in 
question. As a logical conclusion one would expect that the different SC 
pools in the skin give rise to different typers of tumours. Indeed, epidermal 
tumours show variances in cell lineage differentiation, which may reflect the 
SC pool from which they originated. For example, SCCs have elements of 
IFE differentiation and hence are thought to originate from the IFE SC pool. 
Trichofolliculomas and pilomatrichomas show differentiation towards the 
hair shaft and are thus believed to originate from the SC pool that gives rise 
to these lineages.
Basal cell carcinomas (BCC) are the most common cutaneous malignancy 
in humans, accounting for up 75% of all skin cancers. Typically, BCCs 
appear on sun-exposed skin, are slow growing, and rarely metastasize. 
BCCs display a relatively homogeneous cellular appearance, resembling
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keratinocytes. Although the exact etiology of BCC is unknown, a well- 
established relationship exists between BCC and the pilosebaceous unit, 
as tumours are most often discovered on hair-bearing areas. It has been 
suggested that they may originate in the ORS of the hair follicle, which is 
supported by the fact that sonic hedgehog (SHH) signalling, the malfunction 
of which results in BCC development, only occurs in hair follicles.
1.7.5.1 Clonality of skin tumours
The study of clonality has become a useful tool for studying cancer 
development by circumventing the technical difficulty of studying 
developmental dynamics in vivo. Mutation tracing studies have shown 
differences in clonality patterns between different types of skin tumours and 
revealed a clear link between actinic keratoses and SCCs, but attributed a 
different developmental origin to BCCs.
Despite a morphologically multifocal appearance, genetic analysis and 
three-dimensional reconstructions of BCCs have favoured a unicellular 
origin. This has been suggested by following non-random patterns of X 
chromosome inactivation, as well as by tracing the BCC-typical loss of 
heterozygosity (LOH) of chromosome 9 (9q22.3) (Walsh et al. 1996). These 
techniques showed that even anatomically-distinct BCCs may represent 
expansion of the same clone (Shulman et al. 2006). However, in some 
BCCs, the tracing of molecular markers showed genetic heterogeneity, 
which could indicate genuine polyclonality within the same tumour and 
reflect the independent origin of two or more tumours, or might show 
subclonality and represent the difference between following an early or late 
mutation in carcinogenesis (Asplund et al. 2005).
Controversy exists regarding the stromal origin of BCCs. Xenograft studies 
suggested that BCC generate their own ‘specialised stroma’, interspersed 
with cells derived from the host (Hales et al. 1989, Stamp et al. 1988), 
whereas other researchers believe that BCCs are embedded in a
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connective tissue stroma at least in part of polyclonal origin (Asplund et al. 
2005).
SCCs are believed to harbour more genetic heterogeneity. Comparison of 
the LOH patterns in oesophageal SCCs revealed that they are clonal 
neoplasms with considerable degree of divergence and genetic progression 
(Shima et al. 2006).
1.8 STEM CELL PLASTICITY
The capability of BM-derived cells to engraft into multiple organs is well 
documented and has in recent years attracted substantial attention from the 
research community. The plasticity of adult stem cells has challenged the 
widely-accepted belief that tissue stem cells are restricted to the production 
of adult lineages within their tissue of residence and simultaneously opened 
up new paths in the field of regenerative medicine, with the hope of finding 
treatments' for a number of diseases such as cancer, cardiovascular 
disease, neurodegenerative disease and diabetes.
Transplanted adult BM cells have been shown to form adult cell types in 
many different tissues both, in mice and in humans (reviewed in (Poulsom 
et al. 2001)) (Figure 1.8, pg.74). In normal murine tissues, BM have been 
shown to engraft in the liver (Petersen et al. 1999, Lagasse et al. 2000), 
brain (Eglitis et al. 1997, Brazelton et al. 2000, Mezey et al. 2000), heart 
(Jackson et al. 2001, Orlic et al. 2001, Orlic 2002), kidney (Poulsom et al. 
2001), intestine (Krause et al. 2001, Brittan et al. 2005) and skin (Krause et 
al. 2001, Badiavas et al. 2003, Kataoka et al. 2003, Harris et al. 2004, 
Brittan et al. 2005). Krause and colleagues confirmed the plasticity of a 
single purified BM cell by demonstrating donor-derived male cells eleven 
months post-transplant in the lung, the skin and throughout the 
gastrointestinal tract, including the oesophagus, stomach, small intestine 
and colon (Krause et al. 2001). In humans, plasticity of BM cells has been 
shown by engraftment into muscle (Ferrari et al. 1998), liver (Alison et al. 
2000, Theise et al. 2000), vascular system of the skin and gut (Jiang et al.
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2004), neurons (Cogle et al. 2004), Purkinje cells (Weimann et al. 2003), 
and the epithelium of the gastrointestinal tract (Spyridonidis et al. 2004). 
The extent of engraftment varies between different studies, tissues and 
detection techniques used. It ranges between 0.5-15% and is enhanced by 
injury. In general, it appears to reflect the turnover-rate of the tissue of 
destination.
BM cells can contribute to epithelial, mesenchymal, as well as vascular 
lineages. In the mouse lung, stomach, oesophagus, skin, kidney and 
adrenal glands they can contribute to large proportions of myofibroblasts 
and fibroblasts. Up to 65% of myofibroblasts in the mouse stomach were 
found to be BM-derived 6 weeks post-transplant (Direkze et al. 2003). 
Analysis of fibrotic livers from patients that had received a BM 
transplantation showed a significant BM-derived proportion of 
myofibroblasts and that the engraftment was not a transient, but a 
permanent event. Approximately 23% of myofibroblasts in one fibrotic liver 
were BM-derived 2 years post-transplant (Forbes et al. 2004). BM contains 
progenitor cells that can differentiate to form both endothelial cells and 
smooth muscle cells of blood vessels, particularly in areas of neo- 
vascularisation. BM-derived endothelial cells have been found in the human 
skin, stomach and small intestine up to 7 years post transplant. However, 
engraftment levels are low, ranging between 2.3% and 1.7% of endothelial 
cells in blood vessels of the skin and gut, respectively (Jiang et al. 2004). 
Plasticity is not restricted to BM cells, and even seems to underly bi­
directional mechanisms, since BM cells have also been generated from 
muscle (Jackson et al. 1999) and neuronal cells (Bjornson et al. 1999), 
although the latter observation is disputed by some (Morshead etal. 2002).
The functionality of engrafted BM cells has been demonstrated in several 
pieces of research. Injection of BM cells from wt mice into transgenic mice 
with a deficiency in the liver enzyme fumarylaceto-acetate hydrolase as a 
model for the human metabolic liver disease Type 1 tyrosinaemia, resulted 
in normal liver enzyme expression conveyed by the engrafted cells into the 
mouse liver (Lagasse et al. 2000). Cu/Zn superoxide dismutase null
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(S0D1) mice develop a lethal neurodegenerative disease similar to 
amyotrophic lateral sclerosis (ALS) in humans. When transplanted with wt 
BM, transdifferentiation of donor cells was shown into neurons, skeletal 
muscle fibres and cardiomyocytes, resulting in a delay in the onset of ALS 
and an increased lifespan (Corti et at. 2004). Another study has 
demonstrated a few BM-derived competent endocrine p-cells in the 
pancreatic islets of mice, inferring a potential cell-based therapy for 
diabetes mellitus (lanus et al. 2003). In our laboratory, BM cells have been 
shown to alleviate symptoms of disease in a mouse model of chronic 
inflammatory bowel disease, suggesting the full functionality of normal BM- 
derived epithelial cells in the intestine (Bamba et al. 2006).
What triggers BM cells to transdifferentiate and home to the new 
microenvironment is unknown. Nevertheless, the fact that stem cell 
plasticity is also observed in adult tissues challenges the notion that stem 
cell pluripotentiality is a feature exclusive to embryonic stem cells. This 
presents a new outlook on regenerative medicine as adult stem cells, 
devoid of the ethical difficulties associated with the use of their embryonic 
counterparts.
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Figure 1.8. The plasticity of BM cells. BM cells have been shown to 
engraft into multiple organs, including the muscle, brain, heart, liver, 
kidney and gut.
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1.8.1 Chimerism
It is well known that BM transplants result in permanent cellular chimerism 
in the haematopoietic system of recipients. But the fate of chimeric cells is 
not restricted to the haematopoietic system. Donor-derived keratinocytes 
have been demonstrated in the normal skin of female recipients of male 
peripheral blood HSC (Korbling et al. 2002). Moreover the pathway of 
transdifferentiation of cells in a chimeric individual appears not to be limited 
to the donor cells. Transplanted hearts showed cells of host origin in up to 
10% of myocytes, arterioles and capillaries (Quaini et al. 2002). Similarly, 
within grafted kidneys, 23%-38% of mesenchymal cells were of host origin 
(Grimm et al. 2001). Chimerism can also be a result of pregnancies and 
blood transfusions. Women that had a male pregnancy years to decades 
earlier displayed mesenchymal SCs, liver cells and other differentiated cell 
types in several peripheral organs of male origin (Johnson et al. 2002, 
Khosrotehrani etal. 2004, O'Donoghue et al. 2004).
1.8.2 Mechanisms of stem cell plasticity
It appears that two mechanisms of stem cell plasticity exist: 1) de novo cell 
generation through BM transdifferentiation and; 2) heterokaryon formation, 
whereby BM cells fuse with pre-existing cells in the tissue to form a cell with 
multiple, genetically-variant nuclei. In cell fusion, it seems that the original 
stem cell markers become repressed and the transplanted cells transform 
the resident tissue cell they fuse with to a sustainable, functional cell. 
Heterokaryons appear to increase with tissue age (Weimann etal. 2003).
Co-cultures of embryonic stem (ES) cells with either adult neural stem cells 
(Jiang et al. 2002), or BM stem cells (Terada et al. 2002) displayed some 
fusion, albeit at very low frequency. Only 2-11 clones of 106 BM cells were 
heterokaryons (Terada et al. 2002). However, these studies involved 
genetically modified cells in culture and extracted from their niche 
environment, and may not reflect the mechanisms that apply in vivo.
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Cell fusion has been proposed as the mechanism of BM cell incorporation 
in the generation of hepatocytes (Vassilopoulos et al, 2003, Wang et al. 
2003, Willenbring et al. 2004). However, hepatocytes by nature are 
frequently polyploid, and it is thereby possible that the liver presents a 
unique environment for heterokaryon formation (reviewed in (Alison et al.
2004)). In the brains of mice and humans, transplanted BM stem cells have 
been shown to fuse with Purkinje cells (Weimann et al. 2003). Fusion has 
also been reported with skeletal (Camargo et al. 2003) and cardiac 
(Alvarez-Dolado etal. 2003, Nygren etal. 2004) muscle cells, and epithelial 
cells (Spees et al. 2003).
However, other reports could not confirm the occurrence of cell fusion in 
the human brain. Brain specimens from 3 female sex-mismatched BM 
transplant recipients showed that only one X chromosome was present in 
all male-derived neurons, indicating that transplanted BM cells are capable 
of neurogenesis, contributing to approximately 1% of all neurons for up to 6 
years post-transplant (Cogle et al. 2004). In epithelia, fusion has not been 
reported in the gastrointestinal tract, based on a normal ratio of sex 
chromosomes (Korbling et al. 2002). Keratinocytes of BM origin are 
frequently observed in the mouse epidermis with no evidence of cell fusion 
(Borue etal. 2004).
1.8.3 Engraftment into the intestinal epithelium
Microinjection of 1-12 highly purified MSCs extracted from whole BM into 
3.5-day-old mouse blastocysts resulted in chimeric mice with BM-derived 
epithelial cells in many somatic tissues, including the small intestine (Jiang 
et al. 2002). In humans, a combination of Y-FISH and cytokeratin 
immunohistochemistry, on specimens from female patients that had 
undergone sex-mismatched BM transplantation demonstrated epithelial 
cells of donor origin in the gastric cardia (Korbling et al. 2002). Similarly, 
donor-derived epithelial cells were detected in the oesophagus, stomach, 
small intestine and colon in four long-term BM transplant survivors who had 
developed GvHD or intestinal ulceration up to 8 years post-transplant,
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demonstrating the long-term engraftment of transdifferentiated BM cells 
(Okamoto et al. 2002). Similarly, BM-derived cells have also been 
described in the colonic epithelium of 8 sex-mismatched BM recipients. 
Immunohistochemical staining for epithelial and lymphocyte markers 
combined with Y-FISH confirmed that the engrafted cells are not merely 
intraepithelial lymphocytes (Spyridonidis et al. 2004). Donor-derived cells 
occured as sporadic, randomly dispersed epithelial cells throughout the 
crypts and villi, and ranged from 0.04% (Spyridonidis et al. 2004) to 
approximately 10% (Jiang et al. 2002) of epithelial cells. These low levels of 
engraftment suggest that the BM-derived cells do not engraft as stem cells.
1.8.4 Engraftment into the epidermis
BM-derived cells have also been found in the mouse and human epidermis. 
In the normal murine skin, the engraftment of donor-derived cells ranges 
between 1-7% (Krause et al. 2001, Korbling et al. 2002, Badiavas et al. 
2003, Kataoka et al. 2003, Harris et al. 2004, Brittan et al. 2005). The donor 
cells mostly occur as sporadically distributed single cells, which has lead to 
the suggestion that epithelial engraftment into the normal epithelium occurs 
merely as a form of cell mimicry by the donor-derived cells (Cogle et al. 
2007). In the mouse epidermis, cytokeratin-positive donor-derived cells 
have also been demonstrated in postulated stem cell zones (Brittan et al.
2005), but the lack of observed clonal expansion suggested that they did 
not behave as stem cells (Hematti et al. 2002).
The contribution of transplanted BM cells to differentiated keratinocyte 
lineages is significantly increased in the regenerating mouse epidermis 
(Badiavas et al. 2003, Borue et al. 2004). Kataoka and colleagues reported 
of a ‘skin reconstitution assay’, where adult BM cells were transplanted 
directly onto the wounded mouse epidermis. Within three weeks, epidermal 
keratinocytes, follicular epithelial cells, sebaceous gland cells, dendritic 
cells and endothelial cells of BM origin were observed (Kataoka et al. 
2003). In humans, little research has been carried out to determine the 
engraftment of BM-derived cells in the normal skin. A recent study could
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not confirm any engraftment of BM cells into the normal skin of humans, but 
only in patients with graft-versus-host disease, particularly in areas of 
heightened tissue damage (Murata et al. 2007). In another study, 
researchers were able to detect BM-derived epidermal cells in human 
female recipients of male HSC transplants as late as 354 days post­
transplantation (Korbling et al. 2002).
1.8.5 BM engraftment in stem cell niches
Research in our lab has demonstrated that BM-derived cells can home to 
known stem cell niches, such as the CD34-positive bulge region of the hair 
follicle and the epidermal proliferative unit in the interfollicular epidermis 
(Brittan et al. 2005), and thus can presumably contribute to epithelial 
homeostasis. Cells that are engrafted and act as stem cells then have a 
sufficient lifespan to acquire the mutations required for neoplastic 
transformation and in this manner may give rise to donor-derived tumours. 
This notion.is challenged by a study carried out by Hematti et al., who could 
not detect cells capable of growing under conditions favourable for 
keratinocyte stem cells after haematopoietic stem cell transplantation 
(Hematti et al. 2002).
1.9 BONE MARROW CONTRIBUTION TO INJURY AND 
TUMOURS
The engraftment of BM cells is markedly increased by injury such as 
epidermal wounding or inflammation. In the mouse epidermis for example, 
wounding increased the extent of BM cell engraftment to 13% of epithelial 
cells. In a mouse model of experimental colitis, BM cells showed increased 
engraftment in the inflamed intestinal epithelium, and they contributed to 
the repair of the injured tissue (Brittan et al. 2005). Similarly increased BM 
cell engraftment was observed in murine models of cerebral infarction 
(Hess et al. 2002), and myocardial infarction (Jackson et al. 2001, Orlic 
2001, Orlic et al. 2002). In humans, BM contribution to intestinal epithelium 
showed a 5-50-fold elevation in tissue damaged by GvHD or intestinal
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ulceration, compared to intact epithelium (Okamoto et al. 2002, 
Spyridonidis et al. 2004). It is proposed that BM stem cells respond to 
specific signals from damaged tissues, causing them to migrate to, engraft 
in and differentiate into cells within the tissue, thereby contributing to 
regeneration.
In disease scenarios, BM engraftment appears to underlie different 
principles than in normal tissues. In areas of chronic inflammation, 
engraftment is not only profoundly enhanced in quantity, but donor-derived 
cells are seen in patterns that are typical for cells derived from a common 
ancestor (Houghton et al. 2004). It appears that in most cases, an 
environment of continuous damage, such as chronic inflammation, is 
required for BM-derived cells to engraft and act as stem cells in epithelia. A 
possible explanation for this scenario is that permanent tissue damage 
eventually results in failure of the resident tissue stem cells, whereupon BM 
cells are recruited to fill the free stem cell niche. Acting as the new tissue 
stem cells, the BM-derived cells have the longevity to acquire the changes 
required to transform into cancer stem cells that then may give rise to entire 
donor-derived, post-transplant tumours (Figure 1.9, pg.80). In accordance 
with this theory, Houghton et al. showed donor-derived gastric cancer in a 
mouse model of chronic inflammation and progression to gastric cancer 
(Houghton et al. 2004).
BM cells can also contribute to the tumour stroma and to 
neovascularisation of tumours (Duda et al. 2006, Nolan et al. 2007). In our 
laboratory, it has been demonstrated in a mouse model of pancreatic 
insulinoma that transplanted BM cells can contribute to the supporting 
stromal myofibroblasts (Direkze etal. 2004).
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Figure 1.9. A new paradigm of epithelial tumour development using the 
small intestine as an example. Continued tissue damage leads to loss of 
the indigenous stem cell compartment and its replacement by cells from 
the BM. As acting stem cells, the engrafted BM cells have now sufficient 
lifespan to undergo neoplastic transformation and give rise to entire BM- 
derived cancers. (BM-derived cells are red, mutated BM-derived cells are 
blue). (Figure taken from Burkert et al. 2006).
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1.10 DONOR-DERIVED CELLS IN POST-TRANSPLANT 
CANCERS
The development of malignancies is a well-known side effect of tissue and 
cell transplantations, attributable to immunosuppression, UV-irradiation and 
human papillomavirus (HPV) infection. Compared to the general 
population, transplant recipients have a 3-5-fold increased cancer risk, with 
a particular prevalence of skin cancers and lymphoproliferative 
malignancies (Dantal et al. 2007). Post-transplant tumours are generally 
more aggressive than their counterparts in the general population and 
present with poorer prognoses, which makes the investigation of these 
malignancies an important issue in transplant medicine and an important 
step in the improvement of post-transplant treatment regimes.
Cells of donor-origin have been observed in post-transplant tumours to a 
variable extent. In most cases, the engraftment of BM cells in tumours 
appears td occur in a sporadic fashion, similar to the engraftment of 
transplanted cells in norma! tissues. However, it has also been shown that 
post-transplant lesions can be completely composed of BM-derived cells. 
Papadopoulos and colleagues (1994) reported on a BM transplant patient 
who developed leukaemia post-transplant with the entire leukaemic clone 
derived from donor-derived cells. A pioneering study by Houghton et al. 
(2004) proved the BM origin of entire solid tumours in a mouse model of 
gastric cancer. Since then, adherent cells from whole BM have been shown 
to be capable of transformation in vitro into malignant cells expressing 
multiple tissue markers when treated with 3-methylcholanthrene, and when 
the transformed cells were injected subcutaneously into nude mice, they 
were capable of generating tumours with multiple phenotypes including 
epithelial, neural, muscular tumours, tumours of fibroblasts and tumours of 
endothelial origin (Liu et al. 2006).
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In humans, engraftment of donor-derived cells after solid organ 
transplantations has also been reported. In kidney transplant recipients, 
leukaemic clones completely derived from the donor have been found 
(Bodo et al. 1999). Moreover, cells stemming from the transplanted organ 
were shown in Kaposi sarcomas in recipients of liver allografts (Barozzi et 
al. 2003). Notably, these are tumours of a haematopoietic origin that could 
be derived from haematopoietic progenitors carried over with the 
transplanted organ. However, Aractingi and colleagues described one 
basal cell carcinoma (BCC), which appeared to be composed mostly of 
male cells indicating that transplanted cells may be able to undergo 
neoplastic transformation in the host. However, a possible origin of this 
tumour in haematopoietic cells from an earlier blood transfusion could not 
be excluded.
Donor-derived cells could be haematopoietic stem cells carried over with 
the transplanted organ, or a population of cells residing within the organ, 
which is capable of plasticity. Whatever the case, these results 
demonstrate that neoplastic progenitors can be transmitted with the 
transplanted organ, or that cells from the donated organ are capable to 
transform into cancer-generating cells in the host.
1.11 THE CONNECTION BETWEEN MICROENVIRONMENT
AND ENGRAFTED CELLS
Our knowledge of the stem cell niche in the skin indicates that the 
microenvironment may be an extremely important factor in cellular 
development. The transdifferentiation and incorporation of transplanted BM 
cells as functional members of their new environment also highlights the 
effect of local cellular and biochemical cues on cell behaviour. However, it 
is not clear to what extent cellular behaviour and environment is governed 
by the cells' intrinsic genetic programming, or by their immediate 
microenvironment, respectively. More insight into this matter would yield 
important information for the field of transplant medicine. It may be possible
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that transplanted cells with an adverse genetic predisposition, upon 
engraftment into their new tissue of destination, act according to their 
genetic program and for example, transform to cancer stem cells, 
generating a tumour in the new host. Similarly, do transplanted cells 
incorporated into a diseased microenvironment merely develop as part of 
the tissue and adopt the disease phenotype or can they exert an influence 
according to their genetic predisposition?
Evidence for at least a certain degree of impact exerted by genetic 
programming is provided by the proven functionality of engrafted BM cells 
and the reversal or delay of disease phenotypes in mouse models of liver 
disease Type 1 tyrosinaemia (Lagasse et al. 2000), neurodegenerative 
disease amyotrophic lateral sclerosis (ALS) (Corti et al. 2004), and diabetes 
(lanus et al. 2003). In a mouse model of colitis, transplanted BM-derived 
cells were able to alleviate the symptoms and contribute to epithelial 
healing (Bamba et al. 2006). Recently, a study has shown that in a rat 
model of Ml associated with hypertension, administration of BM cells 
significantly improved cardiac function (de Macedo Braga et al. 2007). This 
evidence indicated that transplanted cells are able to affect their immediate 
surroundings.
On the other hand, the impact of the immediate cellular environment is 
highlighted in the event of chronic inflammation, where it has been shown 
that intercellular factors such as adhesion molecules or cytokines are 
ultimately responsible for influencing cells to transform. A murine model of 
gastric cancer, where BM-derived cells engrafted into the gastric mucosa 
upon exposure to H.Pylori infection eventually transform to give rise to 
gastric cancer, is a prime example for the effect of the surroundings on 
newly-incorporated cells (Houghton etal. 2004).
Together, this suggests that the effects between incorporated cells and 
their local microenvironment are reciprocal, and similarly challenges the 
notion of incorporated cells merely contributing to their destination tissue as 
by cell mimicry as suggested by Cogle and colleagues (Cogle et al. 2007).
83
If the genetic predisposition of a transplanted cell has an impact on the 
host, this implies a new risk factor for transplant patients. On the other 
hand, an immediate influence of incorporated cells might also present new 
exciting therapeutic potential.
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AIMS AND OBJECTIVES
The search for markers of stem cells and cancer stem cells is a prominent 
objective of the research community. In this project, we aimed to test the 
Side Population phenotype, as well as surface markers CD44 and CD133 
for their applicability as stem cell markers in colorectal cancer cell lines and 
primary colorectal adenocarcinoma cells, respectively. Studies involving 
cells lines were outlined as a comprehensive assessment of phenotypic 
and behavioural stem cell-typical characteristics of FAC-sorted SP and 
non-SP cells, examining the expression of other putative stem cell markers, 
clonogenicity, multipotentiality in vitro and in vivo, tumorigenic ability in vivo, 
drug effluxing capacity and proliferation efficacy of both populations. Next, 
we seeked to test the differential expression characteristics of CD133 and 
CD44 and their combination on colonic normal tissue and 
adenocarcinomas, and their ability to act as stem cells by a sphere-assay in 
vitro and upon injection in nude mice. A stem cell enriched population 
would be expected to result in formation of normal crypts and xenograft 
tumours.
The next main objective of this thesis was to look into the origin of epithelial 
tumours in a transplant setting. Following several recent reports of donor- 
derived post-transplant tumours, we set out to perform the first large-scale 
study investigating this phenomenon in order to determine whether the 
seeding of cancer-originating cells from the host is a realistic and, so far, 
unknown risk for transplant patients. For this study, skin tumours from 176 
female recipients of male renal allografts were selected for molecular 
procedures such as qPCR to quantify the amount of male DNA within the 
tumours, as well as immunohistochemical techniques like X and XY-FISH 
and combined Y-FISH and immunohistochemistry for various cell type - 
specific antigens to locate the Y-positive cells and identify their cell type.
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To investigate the possibility that the genetic predisposition of transplanted 
cells could have a detrimental effect on the host and the reciprocal effects 
of transplanted and immediate host cellular environment in more detail and 
in an experimental setting, we decided to employ a mouse model of 
spontaneous skin carcinogenesis. Reciprocal injections of BM into lethally 
irradiated mice and follow-up assessment of tumour formation, tumour 
latency and the incorporation of donor-derived cells into the formed skin 
tumours using the techniques described above was to elucidate the 
phenotypic effects of donor and host cells on each other.
Finally, we aimed to gain more understanding about skin tumour 
development and lineage relationships in the skin. The method of choice for 
this study was tracing a clonality marker; the phenotypic manifestation of 
mitochondrial mutations in the genes coding for cytochrome c oxidase, the 
deficiency of which results in a blue staining upon an enzyme histochemical 
assay. Mutation analysis and sequencing the mitochondrial genome of 
microdissected cells from cytoochrome oxidase deficient and competent 
areas can then reveal molecular relationships between skin tumours and 
the normal tissue, between different cell lineages and potentially reveal 
information regarding field cancerisation in the human skin.
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CHAPTER II 
MATERIALS AND METHODS
2.1 OUTLINES OF INDIVIDUAL EXPERIMENTAL STUDIES
2.1.1 Side Populations of human gastrointestinal cancer cell lines are 
not enriched in stem cells
Following observations from several tissues, cancers, and cell lines, it was 
suggested that the SP phenotype may represent a universal stem cell 
marker. We tested whether this hypothesis holds true in cell lines derived 
from various gastrointestinal cancer cell lines.
2.1.1.1 Phenotypic characteristics
SP and non-SP cells were tested for expression of putative stem cell 
surface markers by multicolour FAC analysis using antibodies directly 
labelled with a fluorescent protein. Expression of CD34, CD44, CD117, 
CD133 and BCRP1 was tested in vitro before and after culturing of SP and 
non-SP fractions before and after xenograft formation in vivo. Additionally, 
we examined expression of putative stem cell markers on colonies 
generated from single cell-sorted SP and non-SP cells by 
immmunohistochemistry, including p-catenin, HES-1, OCT-3/4, MSI-1, 
MDR-1, CD34, CD117 and CD133.
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2.1.1.2 Behavioural characteristics
Stem-cell typical behaviour, such as self-renewal and multilineage 
differentiation potential of SP and non-SP fractions was experimentally 
tested by clonogenic assays, sodium butyrate-triggered differentiation 
assays in vitro, as well as by injection of sorted cells into nude mice at 
limiting dilution for xenograft formation. Immunohistochemistry on xenograft 
tumours was performed to reveal cell type composition of xenograft 
tumours.
2.1.2 Characterisation of cells expressing the putative stem cell 
markers CD44 and CD133 from human adenocarcinoma and 
normal epithelium of the colon
The surface proteins CD44 and CD133 have both been suggested to 
identify cell populations that are enriched in stem cells. We examined, 
whether the combination of both markers results in a further purified stem 
cell population. Stem cell characteristics were experimentally tested by a 
sphere-formation assay in vitro and xenograft formation in vivo. Freshly 
resected specimens of colonic adenocarcinomas and adjacent normal 
epithelium were processed into single cell suspensions for multicolour FAC 
sorting. Isolated were the CD45-negative populations that expressed either 
CD44 or CD133 or both markers together, as well as their negative 
counterparts. The sorted cell fractions were incubated in serum-free 
medium to foster sphere formation, as well as injected s.c. into nude mice 
in a mixture of PBS:matrigel (1:2) for xenograft formation. Additionally, 
double fluorescent immunohistochemistry was performed for both surface 
markers on paraffin-embedded tissue sections to visualise the locations of 
double-positive cells.
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2.1.3 Donor-derived skin tumours after kidney transplantation
It is well known that transplanted BM cells can show considerable plasticity, 
including their incorporation into cancers. However, little is known about the 
contribution of cells derived from solid organ transplants to post-transplant 
cancers. 176 skin cancers from 35 sex-mismatched female kidney 
transplant recipients were examined for the presence of Y-chromsomal 
DNA by qPCR. Positive samples were further analysed by XY-FISH to 
reveal location and distribution of the donor-derived cells. Preferential cell- 
type specific engraftment of Y-positive cells was tested by a technique 
combining Y-FISH and immunohistochemistry for the cell type-specific 
antigens a-SMA (stromal myofibroblasts), pan-cytokeratin (epithelial cells), 
CD34 (endothelial progenitors, potential stem cells), and CD45 
(leukocytes). The same technique was used to elucidate whether the 
donor-derived cells are prone to HPV infection.
2.1.4 Effect of local microenvironment and genetic predisposition on 
cancer development in a mouse model of skin carcinogenesis
In this study, we evaluated the impact of genetic pre-disposition of 
transplanted cells in the host organism, and vice versa, the impact that the 
local microenvironment exhibits on the development of transplanted cells. 
Reciprocal BM transplants were carried out with lethally irradiated hosts 
and an injection dose of 2 million whole BM cells, involving C57/Black 6 
wild type (wt) mice and transgenic HPV8 mice that develop spontaneous 
skin tumours. Control transplant groups were included. Resulting skin 
tumours were examined by Y-FISH and immunohistochemistry for the 
presence of donor-derived cells, the extent of engraftment, and cell type- 
specificity of donor cell-engraftment.
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2.1.5 Clonality in skin tumours and implications for lineage
relationships in the skin and the cell origins of BCCs
To test lineage relationships and genetic origins of various types of skin 
tumours, a well-established method was employed, which is used in our 
laboratory to study clonality in the gastrointestinal system. We tested frozen 
sections from skin cancers of squamous and basal origin for cytochrome c 
oxidase activity by enzyme histochemistry and immunohistochemistry. 
Cells were extracted from cytochrome c oxidase-deficient and competent 
areas by laser-assisted microdissection, and their mt genome was 
sequenced following a nested PCR method. Individual mutations were 
directly compared to evaluate clonality and trace developmental origins 
within skin tumours.
2.2 ANIMAL STUDIES
All animal procedures were carried out under UK Home Office procedural 
regulations after approval of an ethical committee. All mice were 
maintained in the Biological Resource Unit, Cancer Research UK, London 
Research Institute.
2.2.1 Xenograft experiments with cell populations from human 
gastrointestinal cell lines
Xenograft experiments were performed using 4 selected cell lines (HT29, 
HGT101, Caco2, HRA19a1.1). FAC-sorted SP or non-SP population cells 
in 200 pi medium/matrigel (1:1) were injected s.c. into 4-8 week-old nude 
mice at limiting dilution (Table 2.1, pg.107). Before injection, sorted cells 
were stored on ice for no more than 1 hour. Tumour development was 
monitored starting from the second week, and then measured weekly. All 
animals were culled by CO2 inhalation and cervical dislocation 16 weeks 
after injection or when tumour size passed the limit of 15 mm in diameter. 
Harvested tumours were cut in half. One half of each tumour was fixed in 
4% neutral buffered formalin (NBF) and embedded in paraffin for H&E
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staining and immunohistochemistry; the other half was minced, digested in 
a mixture of 3% collagenase/5% dispase at 37°C for 1 hr, passed through 
70-micron cell strainers and incubated in the culture conditions previously 
described, to establish cell cultures for future experiments.
2.2.2 Xenograft experiments with primary human cells
FAC-sorted cells from freshly resected adenocarcinomas and normal 
colonic epithelium were injected s.c. into nude mice in 200 \i\ PBS/matrigel 
(1:2) in cell doses of 100 and 1000 cells per injection (Table 2.2, pg.108). 
Before injection, sorted cells were stored on ice for no more than 2 hours 
and viability was tested immediately before injection on a Vi-Celll XR™ cell 
viability analyser (Beckman Coulter). Cells and control cells were injected 
s.c. ventrally into opposite flanks. Mice were earmarked individually. 
Tumour development was monitored weekly. All mice were culled 20 weeks 
after injection as described above. Subcutaneous tissue was dissected 
where accumulation of matrigel marked the site of injection, fixed in 4% 
NBF, and embedded in paraffin for H&E staining and mouse-human pan- 
centromeric in situ hybridisation.
2.2.3 Bone marrow transplants
2.2.3.1 Mouse strains
The mice strains used for BM transplantations were either C57/Black 6 wild 
type (wt) mice or transgenic mice with genomic incorporation of the 
complete early region with its early oncoproteins E2, E6, and E7 of the 
cutaneous Human papillomavirus 8 (HPV8) on a FVB/N background. The 
HPV8 transgenes are integrated downstream of the cytokeratin-14 
promoter, which is known to target expression to the epidermis and 
developing hair follicles of mouse embryos, as well as the basal and 
spinous layers of mouse adult skin. Transgenic heterozygote mice develop 
single or multifocal epidermal lesions with a median age of tumour 
development of 8.4 weeks. Benign tumours identified by papillomatosis,
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hyperkeratosis, and acanthosis develop in 91% of transgenic mice, 25% of 
which proceed to moderate or severe epidermal dysplasia. SCCs develop 
in 6% of these mice (Schaper et al. 2005).
2.2.3.2 Transplants
Six week old female recipient mice had their BM ablated by 12 Gray whole 
body irradiation in a divided dose, 4 hours apart, using an IBL 637 gamma 
irradiator equipped with a caesium 137 source (Cis-Bio International). This 
was immediately followed by tail vein injection of approximately 1 x 106 
whole BM cells from male mice. BM was flushed from both tibias and 
femurs of donor mice with sterile PBS using a 5 ml syringe, and cells were 
centrifuged at 200xgr for 2 x 5 minutes, the supernatant was discarded, and 
cells resuspended in 0.2 ml sterile PBS. The number of cells was 
calculated using a haemocytometer. Cells were stored on ice for no more 
than 2 hours before transplant. Following transplants, the mice were 
housed in sterile conditions. All mice were killed by C02-inhalation and 
cervical dislocation 20 weeks post-transplant or when tumour burden was 
unbearable (exceeding the threshold diameter of 20 mm or multiple tumour 
foci). Epidermal lesions, as well as samples of unwounded and wounded 
skin were fixed in NBF for 24 hours at room temperature, transferred to 
70% ethanol and embedded in paraffin.
2.2.4 Cutaneous wounds
Four weeks post-transplantation, two full-thickness circular wounds, each 3 
mm in diameter, were made to the dorsal skin of the mice in the groups 
indicated in Table 2.3 (pg.109). Mice were killed 20 weeks post-transplant 
or when tumour burden was unbearable (exceeding the threshold diameter 
of 20 mm or multiple tumour foci).
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2.3 HUMAN STUDIES
2.3.1 Kidney transplant patients
42 female recipients of male kidney allografts that had developed skin 
lesions following the transplant were identified. Archival paraffin-embedded 
biopsies from 176 skin lesions with varying histopathological diagnoses 
were used for this study (Table 2.4, pg.110). Ethical approval was sought 
and obtained as per the requirements of the United Kingdom Human 
Tissue Act (2006).
2.3.2 Skin cancer patients
For the study described in chapter VII, patients that underwent surgical 
resection of skin tumours were selected. Specimens were snap-frozen in 
liquid nitrogen-cooled isopentane or fixed in 4% PFA and embedded in 
paraffin. Ethical approval was sought and obtained as per the requirements 
of the United Kingdom Human Tissue Act (2006).
2.4 TISSUE CULTURE
2.4.1 Cell Culture
2.4.1.1 Cell lines and maintenance
The human gastrointestinal cancer cell lines used for our experiments were 
of colorectal (HT29, HRA19a1.1 [doubly cloned from HRA19 (Kirkland etal. 
1994)], Co!1, Col29 [sublines of HCA7 (Marsh et al. 1993)], SW480, 
SW1222) and gastric (HGT101 (Laboisse et al. 1982)) origin. HRA19a1.1 
cells were cultured in high glucose Dulbecco’s modified Eagle's medium 
(DMEM, PAA) supplemented with 2mM glutamine, 0.06 g/L penicillin, 0.1 
g/L streptomycin and 10% Foetal Bovine Serum (FBS) (Sera Laboratories 
International). The remaining cell lines were maintained in DMEM, 
supplemented with penicillin, streptomycin, and 10% FBS. All cell lines 
were incubated at 37°C in humidified atmosphere containing 8% CO2.
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2.4.1.2 Clonogenic assays
To analyse clonogenic and morphological properties of SP and non-SP 
cells of HGT101, HT29 and Caco2 cell lines, single cells of both fractions 
were sorted into 96-well plates and cultured as described above. The 
medium was changed every 2-3 days. After 3 weeks, cells were fixed in 4% 
PFA in PBS for 15 min at room temperature. Cloning efficiency was 
measured to indicate the percentage of cells that initiated a clone. Size and 
morphology of the clones was assessed, whereby the different 
morphological behaviour displayed by Caco2 clones was taken into 
account by a classification system separate from HT29 and HGT101 cells. 
HGT101 and HT29 colonies were grouped into 4 different categories as: (i) 
very small (<50 cells), (ii) Holoclones: tight colonies displaying a clearly 
defined border, (iii) Paraclones: dispersed colony morphology (iv) 
Meroclones: intermediate colonies - containing areas of tightly-packed as
well as dispersed cells with no clear border. Caco2 colonies were
categorised by size as small (<50 cells), intermediate (spanning up to half 
of the field of view on a phase-contrast microscope with an overall 
magnification of x40, and large (spanning more than half of the field of 
view). Experiments were performed in triplicate, and repeated twice.
2.4.1.3 Re-analysis of cultured cell fractions
To examine long-term behaviour of sorted SP and non-SP cells, cells were 
seeded at clonal density in T25 culture flasks (Becton Dickinson) (1500 
cells/flask) and maintained in the culture conditions described above. Media 
were changed every 2-3 days. After 3 weeks, cells were prepared for flow- 
cytometric analyses as described above.
94
2.4.1.4 Differentiation assays
Purified SP and non-SP cells were plated at 1x103 cells/chamber in plastic 
8-chamber slides (LabTek™) and maintained as described above. When 
ceils reached confluency, medium supplemented with 2 mM sodium 
butyrate (NaB) was added to trigger differentiation (Stokrova et al. 1999, 
Cai et al. 2004, Hossain et al. 2005) and after 72 hrs, cells were fixed in 4% 
PFA in PBS.
2.4.2 Fresh tissue
Freshly resected human colonic adenocarcinoma and normal colon 
samples were washed 5x thoroughly in PBS supplemented with 1 mM 
dithiolthreitol (DTT) (invitrogen) to remove mucous. Normal colon was then 
incubated in E4 medium lacking Mg2+ and Ca2+, supplemented with 
30mM EDTA at 37°C for 15 min to dislodge crypts, followed by vigorous 
shaking by hand. The supernatant was transferred to a Falcon flask and 
spun at 200g for 5 min. The pellet was re-suspended in 5 ml 0.2% 
collagenase/0.5% dispase solution in PBS and incubated in a shaking 
waterbath at 37°C for 1 hr. Tumour and xenograft samples were covered 
with 0.2% collagenase/0.5% dispase and minced with two scalpels, 
followed by incubation in a shaking waterbath at 37°C for 2-3 hrs. Both, 
tumour and normal digested materials were passed through 70pt nylon 
meshs and spun at 200g for 5 min. The pellets were re-suspended in 
ammonium chloride and left on ice for 10 min to lyse red blood cells. The 
cells were spun at 200g for 5 min, re-suspended in PBS and counted using 
a haemocytometer. The cells were spun again and re-suspended at 
appropriate dilutions in PBS. If cells were to be used for the sphere 
formation assay in vitro (chapter IV), they were re-suspended in DMEM 
without the addition of FCS.
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2.5 FLUORESCENCE-ACTIVATED CELL ANALYSIS AND 
SORTING
2.5.1 Side population analysis
To identify the presence of SPs, the protocol developed by Goodell et al., 
(Goodell et al. 1997) was largely followed. In brief, near-confluent cells 
were trypsinised, washed with phosphate-buffered saline (PBS), 
resuspended in DMEM/3% FCS at 1x106 cells/ml and passed through 40- 
micron cell strainers (BD Falcon) to achieve single-cell suspensions. To 
verify the SP phenotype, we used the ABC-transporter blocking ability of 
reserpine (100 ^mol/L) as described by Zhou et al. (Zhou et al. 2001). 
Optimal staining conditions, defined as the Hoechst concentration and 
incubation time where the SP phenotype could be maximally inhibited by 
reserpine, were determined in time-course experiments with Hoechst 
concentrations ranging between 5-10 ng/ml and incubation times of 30-90 
min (Table 2.5, pg.111). Cells were then transferred to ice and labelled with 
1 ng/ml propidium iodide (PI) to discriminate dead cells. The stained cells 
were analysed using a LSR II Flow cytometer (BD Biosciences). The 
Hoechst dye was excited by UV laser at 355 nm and its fluorescence 
measured with 440/40 nm (Hoechst blue) and 620 LP (long-pass, Hoechst 
red) optical filters.
Three cell lines (HT29, Caco2, HGT101) were selected for further 
experiments based on their origin and growth characteristics. In vivo 
experiments were carried out with 4 cell lines, using HRA19a1.1 cells in 
addition to the three above mentioned cell lines.
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2.5.2 Fluorescence-activated cell sorting
For sorting of SPs, non-SPs and whole Populations, cells were stained 
according to the optimal conditions determined above for each of the 
selected cell lines. Cells were sorted using a MoFlo™ High Performance 
Cell Sorter (Dakocytomation). The Hoechst dye was excited at 350-356.4 
nm and fluorescence was measured at 424/44 nm (Hoechst blue) and 620 
nm (Hoechst red). Doublets and Pl-stained dead cells were electronically 
gated out. Inhibition of the SP phenotype by reserpine was used as 
guidance for drawing of appropriate sorting gates.
2.5.3 Multicolour immunofluorescence flow cytometric analysis
2.5.3.1 Staining of live cells for putative stem cell surface
markers
To determine whether SP cells differ from non-SP cells in surface marker 
expression; we analysed the selected cell lines (HGT101, HT29 and 
Caco2) for expression of the putative stem cell surface markers CD34, 
CD44, CD117 (c-Kit), CD133 (promininl) and BCRP1 (ABCG2). Cells were 
first stained with Hoechst 33342 under previously determined optimal 
conditions. Excess Hoechst dye was removed by pelleting cells at 4°C and 
re-suspending them at 1x107 cells/ml in DMEM/10% FBS. One million cells 
were incubated on ice for 20 min with fluorescently conjugated antibodies, 
details of which are outlined in Table 2.5 (pg.111). In control experiments, 
cells were also stained with each antibody individually, and all antibodies 
less one to draw and confirm correct gates marking antibody negativity at 
analysis. All antibodies were used undiluted. The stained cells were 
analysed using the LSR II Flow cytometer. Fluorescence signals of the 
conjugated antibodies were measured at wavelengths outlined in Table 2.6 
(pg.112). Data were analyzed using FloJo computer software (Treestar).
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2.5.2.2 Staining of fixed celis for Ki-67
Cells were fixed by adding in ice cold 70% ethanol dropwise to the cell 
pellet and stored overnight at -20°C. Two washes were performed in 20ml 
staining buffer (PBS with 1%FCS, 0.09% NaN3) with interim centrifugation 
at 200xg for 5min, whereupon cells were resuspended to 1x107 cells/ml. A 
FITC-labelled anti-Ki-67 antibody (20p,l at appropriate dilution) was added 
to 100^1 of the cell suspension and incubated at RT in the dark for 1 hr. The 
cells were then washed twice in 5ml staining buffer, again with 
centrifugations at 200xg for 5min. Finally, the stained cells were 
resuspended in 500p,l staining buffer. After addition of 3 drops of propidium 
iodide (PI) solution, flow cytometric analysis was performed.
2.6 IMMUNOHISTOCHEMISTRY AND IN SITU
HYBRIDISATION
Immunohistochemistry for various antigens was used to establish cell 
phenotype. In tissues of female mice that received a BM transplant from a 
male mouse donor and sex-mismatched female transplant recipients, in situ 
hybridisation for the XY chromosomes or the Y chromosome was used to 
distinguish the transplanted cells. The combination of 
immunohistochemistry and in situ hybridisation permitted both tracing of 
cell origin and phenotypical analyses.
Information regarding primary and secondary antibodies is presented in 
Tables 2.7 and 2.8. For all immunohistochemical and in situ hybridisation 
protocols, appropriate positive and negative controls were used. Prior to 
routine use of any newly acquired antibody, the optimal dilution and 
conditions were determined by testing serial dilutions and various antigen 
retrieval techniques on positive control sections of fixed tissue. Normal sera 
and secondary antibodies were used at the highest concentration (i.e., 
lowest dilution factor) recommended by the manufacturer.
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2.6.1 Tissue embedding and sectioning
Fixed tissue was transferred to 70% ethanol and embedded in paraffin wax 
by the CRUK Histopathology Unit. Embedded tissue blocks were sectioned 
at 4 pm or 10pm using a Leica RM2235 microtome, depending on whether 
sections were used for immunohistochemistry or laser capture 
microdissection, respectively. Tissue sections were placed on frosted glass 
microscope slides (Thermo Shandon c o l o r f r o s t® ) and dried overnight at 
37°C. Sections were stored at room temperature in sealed slide boxes.
2.6.2 Dewaxing and blocking of endogenous peroxidases
Tissue sections were dewaxed by immersion in sulphur-free xylene (VWR) 
for 5 min, followed by rehydration in decreasing concentrations of ethanol 
(100%, 95%, 80%, 70% and 50%) for 3 min each. Sections were then 
transferred to distilled water. Where immunohistochemistry was performed 
using the horseradish-peroxidase (HRP) detection system, endogenous 
peroxidases were blocked by treating sections with 30% hydrogen peroxide 
(VWR) in methanol, rinsed in tap water, and washed in PBS.
2.6.3 Immunohistochemistry protocol
Antigen retrieval was performed either by microwave treatment in boiling 
sodium citrate buffer, pH 6.0 at 700 W for the time indicated in Table 2.8 
(pg.114), by incubation in bovine trypsin (VWR) for 15 minutes at 37°C, or 
by pressure cooking in boiling sodium citrate buffer, pH 6.0. Sections were 
then rinsed in tap water, washed in PBS, and pre-incubated in normal 
serum (DAKO) from the species the secondary antibody was raised in for 
15 minutes, diluted at 1:25 in PBS. Sections were then incubated in the 
appropriate dilution of primary antibody, followed by incubation in a 
species-specific secondary antibody. All secondary antibodies were 
biotinylated, except in the case of anti-CD44 and anti-CD133 staining of 
human adenocarcinoma and normal colonic tissue (Chapter IV), where 
directly labelled fluorescent secondary antibodies were used. A tertiary 
layer of either streptavidin-horseradish peroxidase (strep-HRP)(DAKO)
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diluted to 1:500, or streptavidin-alkaline phosphatase (strep-AP)(DAKO) 
diluted to 1:50, was finally applied. Primary, secondary and tertiary layers 
were all diluted in PBS and incubations were carried out for 35 minutes at 
room temperature unless otherwise indicated in Table 2.8 (pg.114). Tissue 
sections were washed for 3 x 5 minutes in PBS between each antibody 
layer, and following the tertiary layer.
Strep-HRP was detected by 3,3-diaminobenzidine (DAB) (Sigma), and 
Strep-AP was detected using the Vector Red Alkaline Phosphatase 
Substrate Kit 1 (Vector Laboratories) for 2-15 min until the brown colour of 
the DAB or the red colour of the Vector Red kit could be detected 
macroscopically. Sections were then washed in PBS for 2 x 5 minutes, 
rinsed in tap water and counterstained with haematoxylin and eosin, unless 
immunohistochemistry was followed by in situ hybridisation, where the 
sections were immediately subjected to the first step of the procedure.
2.6.3.1 Double fluorescent immunohistochemistry
For double immunohistochemical detection of CD44 and CD 133, sections 
were dewaxed and subjected to antigen retrieval by pressure-cooking in 
boiling sodium citrate buffer, pH 6.0, for 3 min. This was followed by 
incubation in goat serum (DAKO) for 25 min at a dilution of 1:25 in PBS. 
Anti-CD44 was applied (1:100) for 40 min at room temperature, followed by 
a FITC-labelled anti-mouse IgG secondary antibody (1:200) (Invitrogen). 
Subsequently, anti-CD133 (1:500) was applied for an overnight incubation 
at 4°C, followed by a secondary Cy-3 labelled anti-rabbit IgG 
(1:1000)(lnvitrogen) at room temperature for 35 min. Sections were then 
mounted in VECTASHIELD® Hard Set™ mounting medium containing 
DAPI (Vector Laboratories) for nuclear visualisation. Between each step of 
the protocol, sections were washed twice in PBS for 5 min.
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2.6.4 in situ hybridisation
After dewaxing, sections were incubated in 1 M sodium thiocyanate 
(Sigma) in distilled water for 10 minutes at 80° C. The sections were 
digested in 0.4% w/v pepsin (Sigma) in 0.1M HCI at 37° C. Digestion times 
were determined in optimisation time trials and varied between 20-25 min 
for human skin, 15-20 min for mouse skin, 10-15 min for mouse spleen 
controls, and 2-4 min when in situ hybridisation was preceded by 
immunohistochemistry requiring antigen retrieval. Pepsin digestion was 
followed by incubation in 0.2% glycine (Merck) in double concentration PBS 
for 5 min to stop digestion. The sections were then fixed in 4% 
paraformaldehyde (PFA) for 2 minutes, dehydrated through 70%, 95% and 
100% ethanol and air-dried. A 1:1 mixture of Cy3-labelied Y chromosome 
and FITC labelled X-chromosome probes (Star-FISH) was added to the 
sections and sealed under a glass coverslip with rubber cement. This was 
followed by hybridisation at 60° C or 80° C for 10 minutes for human and 
mouse tissue, respectively. Sections were then incubated overnight at 37° 
C in a sealed humid chamber. Slides were washed in O.SxSSC in distilled 
water for 5 min and mounted in VECTASHIELD® Hard Set™ mounting 
medium containing DAPI (Vector Laboratories).
2.6.5 Immunohistochemistry combined with Y-FISH
Sections were dewaxed, subjected to antigen retrieval as needed and 
stained using primary antibodies against either pan-cytokeratin, a-SMA, 
CD34, CD31 or HPV. Stainings were performed using the alkaline 
phosphatase technique and visualised with Vector Red. After 
immunocytochemical staining, the Y-FISH protocol was followed, with 
adjusted digestion times depending on the method used for antigen 
retrieval.
2.6.6 Microscopy
Fluorescent immmunohistochemical staining and FISH were detected with 
a fluorescent Olympus BX41 microscope with Smart Capture software. 
Immuohistochemistry was visualised under conventional or reflected light
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(dark-field) conditions (Nikon ME600 with epi-illumination dark-field 
microscopy) and images were captured using Qimaging software and a 
micropublisher 5.0 (GO-5-CLR-12) RTV digital camera from Qimaging.
2.7 ENZYME HISTOCHEMISTRY
Enzyme activity of cytochrome c oxidase was tested in experiments 
outlined in chapter VII. Cytochrome c oxidase consists of several subunits, 
of which 3 are encoded in the mitochondrial DNA and 4 are encoded in the 
genomic DNA. Dual enzyme histochemistry for cytochrome c oxidase and 
succinate dhydrogenase (SDH) was successively used to detect deficiency 
in cytochrome c oxidase and simultaneously the activity of the nuclear 
encoded SDH, the presence of which indicates absence of cytochrome c 
oxidase activity.
2.7.1 Slide preparation
Human skin tissue was snap frozen in liquid nitrogen-cooled isopentane 
and kept at -80° C. To cut sections, the tissue was mounted in OCT (Bayer 
Diagnostics) and cut at 20 pm onto membrane-coated P.A.L.M slides 
(Zeiss) for subsequent laser capture microdissection.
2.7.2 Histochemical assay for cytochrome c oxidase and succinate 
dehydrogenase
First, sections were incubated in cytochrome c oxidase medium (100 pM 
cytochrome c oxidase) (Sigma), 4 pM DAB (Sigma) and 20 pg/ml catalase 
in 0.2 M phosphate buffer, pH 7.0) until enzyme activity was optically 
detectable by brown staining (approximately 40 min). After three washes in 
PBS for 5 min each, sections were incubated in SDH incubation medium 
(130 mM sodium succinate) (Sigma), 200 pM phneazine methosulphate 
(Sigma), 1 mM sodium azide (Sigma), 1.5 M nitroblue tetrazolium (Sigma) 
in 0.2 M phosphate buffer, pH 7.0) until a blue colour was detectable
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(approximately 45 min). Sections were washed in PBS three times for 5 min 
and dehydrated in a graded alcohol series of 70%, 95%, and 100%. They 
were then left to air dry for 1 hr before laser capture microdissection or 
storage at >20° C.
2.8 MOLECULAR METHODS
2.8.1 DNA extraction
Sections with paraffin-embedded skin tumours from kidney transplant 
recipients used for experiments outlined in chapter V were dewaxed and 
scraped off the slides with a sterile needle. Total RNA was extracted with 
an RNeasy kit (Qiagen) following the manufacturer’s protocol. MRNA 
content was measured with a NanoDrop ND-1000 (Wilmington) 
spectrophotometer and stored at -20° C. Proteinase K was deactivated by 
10 min incubation at 95° C
Frozen sections from skin tumours used in experiments for chapter VII 
were, after dual histochemistry, subjected to laser capture microdissection 
using the PALM® laser capture system (Zeiss). DNA from laser-captured 
areas was extracted using the Picopure™ DNA extraction kit containing 
proteinase K (Molecular Devices) by overnight incubation at 65°C. 
Proteinase K was deactivated by 10 min incubation at 95° C.
2.8.2 Quantitative real-time PCR
50ng aliquots of DNA were subjected to qPCR using the Y-quantifiler kit 
(Quiagen) containing primers specific to a sequence on the sex- 
determining gene SRY on the Y chromosome. The manufacturer’s protocol 
was followed. Thermocycling was carried out on the ABI 7700 Real-Time 
PCR system (Applied Biosystems), results were analysed using the 
standard curve method.
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2.8.3 Mitochondrial DNA sequencing
To sequence the mitochondrial (mt) genome of microdissected cells, DNA 
extraction was followed by a two-round amplification, whereby the first 
round consisted of amplifying 9 fragments spanning the entire mt genome, 
and the second round consisted of 36 M13-tailed primer pairs to amplify 
overlapping segments of the first-round products. Individual mutations were 
confirmed by repeating the 2nd round PCR and re-sequencing the product.
2.8.3.1 Primary PCR reactions
Primer pairs were designed to amplify 9 overlapping segments of the 
mitochondrial genome, each of approximately 2 kb in size. PCR reactions 
were carried out in 1x PCR buffer (10mM Tris-HCI (Sigma) pH 8.3, 1.5 mM 
MgCb. 50 mM KCI, 0.001 %wt/vol gelatine), 0.2 mM dNTPs, 0.6 pM 
primers, 1 U AmpliTaq Gold DNA Polymerase (Applied Biosystems) and 
1 pi cell lysate from microdissected cells. Primers used for the reactions are 
listed in Table 2.10 (pg.116). Reaction conditions were as follows:
Initial denaturation 95°C 12 min
Denaturation 95°C 45 sec
Primer Annealing 58 °C 45 sec
Extension 72°C 2 min
Final Extension 72 °C 8 min
1 cycle 
38 cycles 
1 cycle
2.8.3.2 Secondary PCR reaction
Primary PCR products were amplified with 36 overlapping primer pairs that 
span the entire human mt genome, generating fragments between 600-700 
bp. Each first round PCR product was amplified by 4 second-round primer 
pairs, which generated a total of 36 overlapping fragments. Primer pairs 
used for the reactions were M 13-tailed, which resulted in the incorporation 
of the M13-sequence in the final PCR product. Primers are listed in Table 
2.10. PCR reactions were carried out in 1x PCR buffer, using 2 j j i I  of the
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previous PCR product as template. The thermocycling procedure was as 
follows:
Initial denaturation 95 °C 12 min 1 cycle
Denaturation 95 °C 45 sec ^
Primer Annealing 58° C 45 sec y 38 cycles
Extension 72° C 1 min
Final Extension 72° C
j
8 min 1 cycle
2.8.3.3 Agarose gel electrophoresis
To test whether PCR amplification was successful, 5 1^ of PCR products 
were mixed with 1 ^l loading dye (0.25% (w/v) bromophenol blue, 0.25% 
(w/v) xylene cyanol, 30% (v/v) glycerol) and loaded onto a 1.5% agarose 
gel in TBE containing ethidium bromide (Merck). A 100 bp ladder (Quiagen) 
was used as molecular marker. Electrophoresis was carried out for 30 min 
at 120 V in 1xTBE (0.8 mM Tris acetate, Boric acid, 80 mM, 0.02 mM 
EDTA). Gels were subjected to UV illumination using a UV transilluminator 
(UVP Ltd).
2.8.3A PCR sequencing
PCR products from successful amplifications were sequenced, if control 
reactions were negative. PCR products were stripped of any unconsumed 
dNTPs and primers remaining in the PCR product mixture by incubation of 
5 11\ PCR product with 2 ^l of ExoSAP-IT (USB Corporation) for 15 min at 
37°C, followed by inactivation at 80°C for 15 min. Four i^l of the resulting 
PCR product was cycle sequenced using the BigDye® v3.1 terminator 
cycle sequencing chemistries (Applied Biosystems) and M13 primer. The 
PCR programme was as follows:
105
Initial denaturation 96 °C 1 min 1 cycle
Denaturation 
Primer Annealing 
Extension
96 °C 20 sec -s
50°C 20 sec 25 cycles
60°C 4 min
DNA was purified using the DyeEx 2.0 Spin Kit Purification Columns 
(Quiagen) and the products were analysed on the ABI 3100 sequencer 
(Applied Biosystems). Sequences were compared to the revised 
Cambridge reference sequence using sequence alignment software of the 
European Molecular Biology Open Software Suite (2000) (EMBOSS).
2.9 STATISTICAL ANALYSES
All data in tables, graphs or text represent the mean values ± SEM. Tests of 
significance (Prism) were conducted using Mann-Whitney or Kruskal-Wailis 
analyses with Dunn’s post-test for non-parametric data and the Student’s 
two-tailed t-test for parametric data where appropriate. Binomial data were 
analysed using the Chi-square test. Probability (P) values of <;0.05 were 
taken as appropriate levels of significance.
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Table 2.1
Tumorigenicity of sorted SP and Non-SP cells upon s.c. injection into nude
mice
HT29
SP cells 3/5 3/3 1/1 — I
Non-SP cells 2/5 3/3 1/1 0/1 1/1
I Caco2 I
SPcells 1/5 1/3 1/1 — —
Non-SP cells 3/5 2/3 1/1 1/1 0/1
HRA19
SP 2/5 0/3 0/1 — —
Non-SP 3/5 0/3 0/1 1/1 0/1
HGT101
SP 0/5 0/3 0/1 — -
I Non-SP 0/5 0/3 0/1 0/1 0/1 I
Mice culled after 16 weeks or when tumour burden reached a 
threshold diameter of 15 mm.
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Table 2.2
Injection of sorted cell populations from fresh human colonic 
adenocarcinoma (groups 1-6) and normal epithelium (groups 7-12) s.c. into
nude mice
Sorted cell populations
(+cells were injected on the left flank, -cells were injected on the right 
flank)
CD44+ CD44- CD133+ CD133- CD44/133+ CD44/133-
Group 1/7 
Group 2/8 
Group 3/9 
Group 4/10 
Group 5/11 
Group 6/12
100
1000
100
1000
100
1000
100
1000
100
1000
100
1000
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Table 2.3
BM transplantation of HPV 8 mice
HPV group 1 group2 group3 group4
wt group5 group6 group7 group8
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Table 2.4
Lesions developed after kidney transplants included in the study
described in chapter V
Number of Total number of
Type of lesion patients lesions
affected
Malignant Basal Cell Carcinoma (BCC) 17 48
Squamous Cell Carcinoma (SCC) 23 47
Porocarcinoma 3 3
Carcinoma in situ (CIS) 17 43
Pre-
malignant Actinic/Bowenoid Keratosis (AK/BK) 16 26
Lentigo Maligna 1 1
Dysplastic Warts 3 3
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Table 2.5
Optimal staining conditions as determined for each tested 
gastrointestinal tumour cell line
Ceil line Hoechst 33342 (^g/ml) Incubation time (min)
Caco2 6 60
HT29 7.5 60
HGT101 5 60
HRA19b1.1 7.5 90
Col29 7.5 60
CoM 7.5 60
SW480 9 45
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Table 2.6
Fluorescent antibodies used throughout the project
Antibody Fluorescent label Wavelength of Amount Supplier
fluorescent
signal
CD44 APC (Allophycocyanin) 660/20 10^1/10® cells BD
Biosciences
CD133 PE (Phycoerythrin) 575/26 10pl/106 cells Miltenyi Biotec
CD34 PE/Cy7 (Cyanine) 780/60 5pl/10® cells BD
Biosciences
CD117 PerCP
(Peridinin-chlorophyli- 
protein Complex)/Cy5.5
695/40 20^1/10® cells BD
Biosciences
BCRP1 PE/Cy5 660/20 10^/10® cells Chemicon
Ki-67 FITC 530/30 20^1(1:100)/ 
10® cells
BD
Bioscences
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Table 2.7
Primary antibodies used on cell lines
p-eaten in human mouse 1:100 N/A Santa Cruz
CD117 human mouse 1:40 N/A Novocastra
CD34 human mouse 1:25 N/A DAKO
Chromogranin A human mouse 1:50 N/A DAKO
Hes-1 human rabbit 1:200 N/A US Biological
Mdr1 human mouse 1:200 N/A Chemicon
Muc2 human rabbit 1:100 N/A Santa Cruz
Mucin PR4D4 human mouse N/A N/A Cancer 
Research UK
Musashi-1 human mouse 1:20 N/A R&D systems
Oct-4 human mouse 1:100 N/A Santa Cruz
Villin human mouse 1:100 N/A Serotec
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Table 2.8
Primary antibodies used on paraffin-embedded tissue
Antibody Specificity Species Dilution Antigen Retrieval Supplier
a-SMA human/mouse mouse 1:4000 N/A Sigma
Chromogranin A human mouse 1:50 N/A DAKO
CD10 human mouse 1:100 mwv 10’ Abeam
CD133 human rabbit 1:500 pressure cooking 
2’, overnight 
incubation at 4°C
Abeam
CD31 mouse rat 1:20 mwv in EDTA 10’ Pharmingen
CD34 human mouse 1:25 mwv 10’ DAKO
CD 44 human mouse 1:100 mwv/pressure 
cooking 2'
Abeam
CD45 human mouse 1:200 mwv 10' DAKO
CD45
...
mouse rat 1:20 mwv in EDTA Pharmingen
Cytochrome c 
oxidase subunit 1
human mouse 1:250 mwv 10’ Invitrogen
Cytochrome c 
oxidase subunit 2
human mouse 1:250 mwv 10’ Invitrogen
HPV human rabbit 1:40 none/overnight 
incubation at 4°C
Abeam
Ki-67 human/mouse rabbit 1:200 mwv 20’ Novacastra
Muc2 human rabbit 1:100 mwv 10’ Santa Cruz
Pan-cytoke rati n human/mouse mouse 1:25 trypsin 15’ DAKO
Villin human mouse 1:100 mwv 10’ Serotec
(mwv = microwaving in boiling sodium citrate buffer, pH 6.0)
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Table 2.9
Details of secondary antibodies and species-specific sera used throughout
the project
Rabbit anti-mouse IgG 
conjugate
biotin mouse rabbit biotin 1:300 DAKO
Swine anti-rabbit 
conjugate
biotin rabbit swine biotin 1:500 DAKO
Goat anti-rabbit 
conjugate
biotin goat rabbit biotin 1:100 Sigma
Goat anti-mouse IgG 
(FITC) conjugate
af555 mouse goat FITC 1:200 Invitrogen
Goat anti-rabbit IgG 
(Cy3)
af488 rabbit goat Cy3 1:1000 Invitrogen
Swine serum 1:25 DAKO
Rabbit Serum 1:25 DAKO
Goat Serum 1:25 DAKO
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Table 2.10
1st and 2nd round primers for amplification of the mitochondrial genome
AF GCTCACATCACCCCATAAAC 
AR GATTACTCCGGTCTGAACTC
627-646
3087-3068
BF ACCAACAAGTCATTATTACCC 
BR TGAGGAAATACTTGATGGCAG
2395-2415
4653-4633
CF CCGTCATCTACTCTACCATC 
CR GGACGGATCAGACGAAGAG
4489-4508
6468-6450
DF AATACCCATCATAATCGGAGG 
DR GGTGATGAGGAATAGTGTAAG
6113-6133
8437-8417
EF AACCACTTTCACCGCTACAC 
ER AGTG AG AT GGT AAAT GC TAG
8128-8147
10516-10487
FF ACTT C ACGT C ATT ATT GGCT C 
FR AT AGGAGGAGAAT GGGGG AT AG
9821-9841
12101-12080
GF ACCCCCCACTATTAACCTACTG 
GR GGTAGAATCCGAGTATGTTGG
11866-11887
13924-13904
HF TATT C GC AGG ATTT CT C ATT AC 
HR AGCTTTGGGTGCTAATGGTG
13721-13742
15997-15978
IF CCCATCCTCCATATATCCAAAC 
IR GGTTAGTATAGCTTAGTTAAAC
15659-15680
868-847
1F TGTAAAACGACGGCCAGTTCACCCTCTAAATCACCAG 
1R CAGGAAACAGCTATGACCGATGGCGGTATATAGGCTGAG
721-740
1268-1248
2F TGTAAAACGACGGCCAGTTTAAAACTCAAAGGACCTGGC 
2R CAGGAAACAGCTATGACCCTGGTAGTAAGGTGGAGTGGG
1157-1177
1709-1689
3F TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG 
3R TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG
1650-1671
2193-2175
4F TGTAAAACGACGGCCAGTACTGTTAGTCCAAAGAGGAAC 
4R CAGGAAACAGCTATGACCTCGTGGAGCCATTCATACAG
2091-2111
2644-2625
5F TGTAAAACGACGGCCAGTCAGTGACACATGTTTAACGGC 
5R CAGGAAACAGCTATGACCGATTACTCCGGTCTGAACTC
2549-2569
3087-3068
6F TGTAAAACGACGGCCAGTCAGCCGCTATTAAAGGTTCG 
6R CAGGAAACAGCTATGACCGGAGGGGGGTTCATAGTAG
3017-3036 
3374-3356
7F TGTAAAACGACGGCCAGTCCTTAGCTCTCACCATCGC 
7R CAGGAAACAGCTATGACCAGAGTGCGTCATATGTTGTTC
3533-3351
4057-4037
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8F TGTAAAACGACGGCCAGTAATAAACACCCTCACCACTAC 
8R CAGGAAACAGCTATGACCGTTTATTTCTAGGCCTACTCAG
4005-4025
4577-4556
9F TGTAAAACGACGGCCAGTACACTCATCACAGCGCTAAG 
9R CAGGAAACAGCTATGACCGATTTTGCGTAGCTGGGTTTG
4518-4537
5003-4983
10F TGTAAAACGACGGCCAGTTCCATCATAGCAGGCAGTTG 
10R C AG G AAAC AGCT AT G ACCT GT AGG AGT AGC GT GGT AAG G
4950-4969
5481-5462
11F TGTAAAACGACGGCCAGTACCTCAATCACACTACTCCC 
11R CAGGAAACAGCTATGACCTAGTCAACGGTCGGCGAAC
5367-5386
5924-5906
12F TGTAAAACGACGGCCAGTCACTCAGCCATTTTACCTCAC 
12R C AGGAAACAGCT AT G ACCAT GGCAGGGGGTTTT AT ATT G
5875-5895
6430-6410
13F TGTAAAACGACGGCCAGTTTAGGGGCCATCAATTTCATC 
13R C AG G AAAC AGC T AT G ACC AAG AAAGAT G AAT CCTAGGGC
6378-6398
6944-6924
14F TGTAAAACGACGGCCAGTATTTAGCTGACTCGCCACAC 
14R CAGGAAACAGCTATGACCCATCCATATAGTCACTCCAGG
6863-6882
7396-7376
15F TGTAAAACGACGGCCAGTGGCTCATTCATTTCTCTAACAG 
15R CAGGAAACAGCTATGACCGGCAGGATAGTTCAGACGG
7272-7293
7791-7773
16F TGTAAAACGACGGCCAGTTAACATCTCAGACGCTCAGG 
16R C AGGAAACAGCT AT GACCT AC AGT GGGCTCT AGAGGG
7744-7763
8301-8283
17F TGTAAAACGACGGCCAGTACAGTTTCATGCCCATCGTC 
17R C AG G AAAC AGC T ATG AC C GT ATAAGAGAT C AG GTT CGTC
8196-8215
8740-8720
18F TGTAAAACGACGGCCAGTACCACCCAACAATGACTAATC 
18R C AGGAAACAGCT AT GACCGTT GT CGT GC AGGT AG AGG
8656-8676
9201-9183
19F TGTAAAACGACGGCCAGTATCCTAGAAATCGCTGTCGC 
19R C AGGAAAC AGCTAT G ACC ATTAGACTAT G GT G AGCTC AG
9127-9146
9661-9641
20F TGTAAAACGACGGCCAGTCATCCGTATTACTCGCATCAG 
20R C AG GAAAC AGCT AT GACCT AGCCGTT G AGTT GT GGT AG
9607-9627
10147-10128
21F TGTAAAACGACGGCCAGTCAACACCCTCCTAGCCTTAC 
21R CAGGAAACAGCTATGACCAGGCACAATATTGGCTAAGAG
10085-10104
10649-10629
22F TGTAAAACGACGGCCAGTATCGCT C AC ACCT CATATCC 
22R CAGGAAAC AGCT AT GACCAT GATT AGTTCT GT GGCT GT G
10534-10553
11109-11089
23F TGTAAAACGACGGCCAGTCTAATCTCCCTACAAATCTCC 
23R CAGGAAACAGCTATGACCTAGGTCTGTTTGTCGTAGGC
11054-11074
11605-11586
24F TGTAAAACGACGGCCAGTTCCTTGTACTATCCCTATGAG 
24R CAGGAAAC AGCT AT G ACCCGT GT G AAT GAGGGTTTT AT G
11541-11561
12054-12034
25F TGTAAAACGACGGCCAGTACAATGGGGCTCACTCACC 
25R CAGGAAACAGCTATGACCGTGGCTCAGTGTCAGTTCG
12001-12019
12545-12527
26F TGTAAAACGACGGCCAGTCATGTGCCTAGACCAAGAAG 
26R CAGGAAAC AGCT ATGACCCT G ATTT GCCT GCT GCT GC
12498-12517
13009-12991
27F TGTAAAACGACGGCCAGTGCCCTTCTAAACGCTAATCC 
27R CAGGAAACAGCTATGACCGGGAGGTTGAAGTGAGAGG
12940-12959
13453-13435
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28F TGTAAAACGACGGCCAGTCGGGTCCATCATCCACAAC 
28R CAGGAAAC AGCT AT G ACC GTTAGGT AGTT G AGGT CT AGG
13365-13383
13859-13839
29F TGTAAAACGACGGCCAGTACCTAAAACTCACAGCCCTC 
29R CAGGAAACAGCTATGACCAGGATTGGTGCTGTGGGTG
13790-13809
14374-14356
30 F T GTAAAACG AC GGCC AGT C AACC AC CAC C C CAT CAT AC 
30R CAGGAAACAGCTATGACCAAGGAGTGAGCCGAAGTTTC
14331-14350
14857-14838
31F TGTAAAACGACGGCCAGTATTCATCGACCTCCCCACC 
31R CAGGAAACAGCTATGACCGGTTGTTTGATCCCGTTTCG
14797-14815
15368-15349
32F TGTAAAACGACGGCCAGTAGCCCTAGCAACACTCCAC 
32R CAGGAAACAGCTATGACCTACAAGGACAGGCCCATTTG
15316-15334
15896-15877
D1F T GT AAAAC G ACG GCC AGT AT CG G AGG AC AACC AGT AAG 
D1R C AG GAAAC AGCTAT GACC GT GGGT AGGTTT GTT GGTAT C
15758-15777
16294-16274
D2F TG TAAAACG ACG GC C AG TCT C AACT AT CAC AC AT C AACT G 
D2R CAGGAAAC AGC T AT G ACC AGAT ACT GCG AC AT AGGGT G
16223-16244
129-110
D3F TGTAAAACGACGGCCAGTCACCCTATTAACCACTCACG 
D3R CAGGAAACAGCTATGACCCTGGTTAGGCTGGTGTTAGG
15-34
389-370
D4F TGTAAAACGACGGCCAGTGCCACAGCACTTAAACACATC 
D4R CAGGAAACAGCTATGACCTGCTGCGTGCTTGATGCTTG
323-343
771-752
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BUFFERS AND SOLUTIONS
Unless otherwise stated, distilled water refers to ‘Milli-Q Plus’ water 
produced by the reverse osmosis ‘ultra pure water system’ (Millipore).
TISSUE CULTURE
Dulbecco’s modified Eagle’s medium (CRUK), was supplemented with 100 
IU/L penicillin (Gibco BRL) and 100 pg/L streptomycin (Gibco BRL) and 
10% FCS. Medium was stored at4°C until use
TISSUE FIXATION
Neutral buffered formalin (pH 7.0) (NBF, CRUK)
Formalin, full strength (37-40% formaldehyde) 100 ml
Na2HP04 (BDH) 6.5 g
NaH2P04 (BDH) 4 g
Distilled water 900 ml
4% Paraformaldehyde
Paraformaldehyde (Sigma) 16 g
PBS (CRUK) 400 ml
Paraformaldehyde dissolved in PBS at 70°C, cooled to room temperature 
before use.
IMMUNOHISTOCHEMISTRY 
Phosphate buffered saline (PBS, CRUK)
NaCI (Sigma) 8.0 g
KCI (BDH) 0.35 g
Na2HP04 (BDH) 1.43 g
KH2P04(BDH) 0.25 g
Distilled water 1 L
Adjusted to pH 7.2 and autoclaved.
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Bovine trypsin (pH 7.8)
Bovine pancreas trypsin (BDH) 100 mg
CaCl2 (Sigma) 100 mg
Distilled water 100 ml
Heated to 37°C.
Diaminobenzidine (DAB)
DAB (Sigma) 0.05%
Hydrogen peroxide (BDH) 0.001%
PBS 9 ml
IN SITU HYBRIDISATION 
10x salt solution
NaCI (Sigma) 176.2 g
Na2HP04 (BDH) 14.2 g
1M Tris-HCI (Sigma) 100 ml
0.2M EDTA (Sigma) 250 ml
The di-sodiumhydrogenphosphate was dissolved in water and adjusted to 
pH 6.8. The sodium chloride, Tris-HCI and EDTA were then added in order,
and the volume was made up to 1 L with water and stored at room
temperature.
20 X SSC (pH 7.5) (CRUK)
NaCI (Sigma) 175.5 g
Na citrate (Sigma) 88 g
Distilled water to 1 L total volume.
Sodium citrate buffer (pH 6.0)
Tri-sodium citrate (Sigma) 2.94 g
Distilled water 1 L
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POLYMERASE CHAIN REACTION 
Tris/EDTA (TE) Buffer
1 M Tris (pH 7.5, Sigma) 1 ml
0.5 M EDTA (CRUK) 200 pi
Distilled water 98.8 ml
DNA gel loading buffer (6x)
Bromophenol blue (Sigma) 0.25%
Xylene cyano (Sigma) 0.25%
Ficcol (Sigma) in distilled water 15%
TBE Buffer (10x)
NaOH 1g
Tris Base 108g
Boric Acid 55g
EDTA 7.4g
Distilled H20  1L
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CHAPTER III
SIDE POPULATIONS OF HUMAN GASTROINTESTINAL 
CANCER CELL LINES ARE NOT ENRICHED IN STEM CELLS
3.1 INTRODUCTION
It is well known that stem cells are involved in disease processes. Particular 
attention has been paid to their involvement in cancer origin and 
development and the research community focuses with substantial effort on 
the search for potential markers that could distinguish stem cells and 
cancer stem cells.
The Side Population (SP) phenotype has been suggested as a universal 
stem cell marker. It is defined by the ability to efflux the nucleic acid dye 
Hoechst 33342; attributed to the activity of ABC-membrane transporter 
proteins, which are also thought to equip cancer stem cells with a 
resistance to lipophilic drugs and are blockable by efflux pump inhibitors 
and chemosensitising agents such as verapamil (Goodell et a/. 1997), 
reserpine (Zhou et al. 2001) and fumitremorgen C (Budak et al. 2005). SPs 
have been found in several human tissues (Alvi et al. 2003, Asakura et al. 
2002, Bhattacharya et al. 2003, Poliakova et al. 2004, Tabatabai et al.
2005), cancers (Grichnik 2006, Hirschmann-Jax et al. 2004, Szotek et al.
2006), and cancer cell lines (Chiba et al. 2006, Dekaney etal. 2005), and in 
some reports have been shown to display stem cell activity.
However, few studies have directly compared SP and non-SP cells, the 
results obtained have been varied and contradictory and recently, several 
groups have not been able to confirm the stem cell-enrichment of SPs in 
various tissues (Mitsutake et al. 2007, Morita et al. 2006). In the
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gastrointestinal system, SPs have not yet been examined for stem cell 
enrichment.
Here, we examine various human gastrointestinal cancer cell lines for the 
presence of the SP phenotype and directly compare phenotypic and 
behavioural characteristics of Non-SP and SP cell fractions with regard to 
stem cell-typical features. We assess clonogenic ability in vitro, drug 
resistance in vitro, tumourigenity in vivo and differentiation potential both, in 
vitro and in vivo. Additionally, we assess both cell fractions phenotypically 
before and after culture in vitro, and after xenograft tumour formation for the 
expression of putative stem cell markers and the presence of the SP 
phenotype. Moreover, we test for differences in proliferation capacity, 
measured by the expression of Ki-67 and also compare the expression of 
the BCRP1 (ABCG2) transmembrane transporter protein, which is thought 
to be responsible for the SP phenotype (Patrawala et al. 2005, Zhou et al. 
2001); (Zhou etai. 2002)'.
3.2 AIMS
To date, the origin and mechanism of disease development in 
gastrointestinal cancers is not entirely clear. Although a cell hierarchy is 
known to exist in these cancers, no markers for cancer stem cells in 
gastrointestinal cancers has been identified. This project aimed to identify 
and characterise SPs in gastrointestinal cancer cell lines and to elucidate 
whether the SP phenotype can serve as a cancer stem cell marker. We 
sought to directly compare sorted side population and non-side population 
cells with respect to phenotypical and behavioural stem cell-typical 
characteristics such as expression of surface markers, the capabilities to 
self-renew and proliferate and for multipotential lineage differentiation.
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3.3 METHODS
All methods are described in full in Chapter II.
3.3.1 Cell culture
The human gastrointestinal cancer cell lines used for our experiments were 
of colorectal (HT29, HRA19a1.1 [doubly cloned from HRA19 (Kirkland et al. 
1994)], CoM, CoI29 [sublines of HCA7 (Marsh et al. 1993)], SW480, 
SW1222) and gastric (HGT101 (Laboisse et al. 1982)) origin. The cell lines 
were incubated and maintained at 37°C in a humidified atmosphere 
containing 8% CO2.
3.3.2 Side population analysis
To identify the presence of SPs, the protocol developed by Goodell et al., 
(Goodell et al. 1997) was largely followed. Reserpine (100 ^mol/L) was 
used to verify the SP phenotype as described by Zhou et al. (Zhou et al. 
2001). De&d cells were excluded by labelling with propidium iodide (PI). 
The stained cells were analysed using a LSR II Flow cytometer (BD 
Biosciences, San Jose, USA).
Three cell lines (HT29, Caco2, HGT101) were selected for further 
experiments based on their origin and growth characteristics. In vivo 
experiments were carried out with 4 cell lines, using HRA19a1.1 cells in 
addition to the three above mentioned cell lines.
3.3.3 Fluorescence-activated cell sorting
For sorting of SPs, non-SPs and whole populations, cells were stained 
according to the optimal conditions determined above for each of the 
selected cell lines. The SP was defined as the Hoechst 33342-low tail 
population, blockable by the addition of reserpine. Cells retaining Hoechst 
33342 fluorescence were determined as the non-SP population. Cell 
sorting was carried out on a M0 FI0 ™ High Performance Cell Sorter
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(Dakocytomation, Glostrup, Denmark) with excitation and emission 
wavelengths as stated in chapter II.
Doublets and Pl-stained dead cells were electronically gated out. Inhibition 
of the SP phenotype by reserpine was used as guidance for drawing of 
appropriate sorting gates.
3.3.4 Multicolour immunofluorescence flow cytometric analysis
To determine whether SP cells differ from non-SP cells in surface marker 
expression, we analysed the selected cell lines (HGT101, HT29 and 
Caco2) for expression of the putative stem cell markers CD34, CD44, 
CD117 (c-KIT), CD133 (promininl) and BCRP1 (ABCG2). Cells were first 
stained with Hoechst 33342 under previously determined optimal conditions 
and then stained with directly labelled fluorescent antibodies against CD34, 
CD44, CD117, CD133, and BCRP1.
The stained cells were analysed using a LSR II Flow cytometer. Data were 
analyzed using FloJo computer software (Treestar, San Carlos, CA).
3.3.5 Clonogenic assays
To analyse clonogenic and morphological properties of SP and non-SP 
cells of HGT101, HT29 and Caco2 cell lines, single cells of both fractions 
were sorted into 96-well plates and cultured. After 3 weeks, cells were fixed 
in 4% PFA and cloning efficiency was measured to indicate the percentage 
of cells that initiated a clone. Size and morphology of the clones was 
assessed, whereby the different morphological behaviour displayed by 
Caco2 clones was taken into account by a classification system separate 
from HT29 and HGT101 cells. Experiments were performed in triplicate, 
and repeated twice.
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3.3.6 Re-analysis of cultured cell fractions
To examine long-term behaviour of sorted SP and non-SP cells, cells were 
seeded at clonal density in T25 culture flasks (Becton Dickinson, Franklin 
Lakes, USA) and maintained in the culture conditions described above.
3.3.7 Differentiation assays
Purified SP and non-SP cells were plated at 1x103 cells/chamber in plastic
8-chamber slides (LabTek™’ Brendale, Australia). After reaching 
confluency, differentiation was triggered by sodium butyrate. Cells were 
maintained and fixed as described before.
3.3.8 Immunohistochemistry
The fixed colonies derived from the clonogenic assay described above 
were stained with antibodies against putative stem cell markers, namely (3- 
catenin, Oct-4, Hes-1, Musashi-1, CD117, CD34, Muc2, Villin,
Chromogranin A and Mucin PR4D4.
3.3.9 Proliferation capacity measured by expression of Ki-67
To test the proliferating ability of SP and non-SPs, the sorted cell 
populations were fixed in suspension in icecold 70% methanol, washed and 
incubated with a directly conjugated fluorescent antibody against Ki-67. 
Subsequently, emitted fluorescence signals of the stained cells were 
analysed on the LSR II Flow cytometer. The percentage distribution of cells 
among the different cell stages was determined by Watson Pragmatic 
analysis.
3.3.10 Resistance to 5-fluorouracil (5-FU)
Drug resistance of the different cell fractions was analysed by subjecting 
cells to the chemotherapeutic agent 5-FU. Cells were incubated in medium 
supplemented with 5-FU for 3 weeks. To test whether any cell population
128
was more susceptible to the toxic effects of 5-FU, the cells were analysed 
previous to and following the incubation period for the SP phenotype and 
expression of CD133, CD44, CD117 and BCRP1 by multicolour 
fluorescence analysis as outlined in 3.3.4.
3.3.11 Tumour-forming ability in vivo (xenografts)
Xenograft experiments were performed using 4 selected cell lines (HT29, 
HGT101, Caco2, HRA19a1.1). Sorted SP or non-SP population cells were 
injected s.c. into 4-8 week-old nude mice (Table 3.3, pg.152). Tumour 
development was monitored starting from the second week, and then 
measured weekly. All animals were culled 16 weeks after injection or when 
tumour size passed the limit of 15 mm in diameter. Tumours were 
harvested and processed as explained in section 2.4.2.
3.3.12 Statistical analysis
All data in fables, graphs or text represent the mean values ± SEM. Tests of 
significance (Prism, GraphPad, San Diego) were conducted using the 
Kruskal-Wallis analysis with Dunn’s post-test for non-parametric data and 
the Student’s two-tailed t-test for parametric data where appropriate. A 
probability (P) value of ^0.05 was taken as an appropriate level of 
significance.
3.4 RESULTS
3.4.1 Prevalence of SP phenotype in human gastrointestinal cancer 
cell lines
The SP phenotype as defined by low Hoechst 33342 blue and red 
fluorescence intensity was detected in all tested human gastrointestinal 
carcinoma cell lines, ranging between 1.3-17% of cells (Figure 3.1, pg.140). 
Maximal inhibition of the SP-phenotype in reserpine control samples 
verified the SPs and indicated optimal staining conditions for each cell line 
(Table 3.1, pg.150).
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3.4.2 Cell surface phenotype
To elucidate potential phenotypic differences between SP cells and non-SP 
cells, we analysed both populations of cultured Caco2, HT29 and HGT101 
cell lines for the presence of putative stem cell-specific surface markers by 
flow-cytometric analysis. The overall staining patterns were similar between 
cell lines (Table 3.2, left column, pg.151). The vast majority of cells from all 
cell lines expressed CD44 and CD133, with expression levels ranging 
between 87-100% and 76-98%, respectively. Expression of CD117 (cKit), a 
marker of progenitor cells in several human tissues (reviewed in (Miettinen 
et al. 2005)) was barely detectable in Caco2 cells, whereas its expression 
levels in HT29 and HGT101 reached 1.2±0.3% and 4.1+1.6%, respectively. 
CD34 expression showed the largest variation, and interestingly, was the 
only stem cell marker that was significantly different in its levels of 
expression between SP and non-SP fractions. At the time of sorting, the 
SPs were virtually devoid of CD34 expression in HGT101 and HT29, 
whereas their non-SP counterparts reached expression levels of 2.5% and 
0.6%. Interestingly, between SP and non-SP fractions, we could not detect 
a significant difference in expression of BCRP1, the ABC-transporter 
allegedly responsible for the SP phenotype, which ranged between 1.6- 
4.1% depending on the cell line.
3.4.3 In vitro characteristics of SP and non-SP cells
The clonogenic efficiencies of SP and non-SP cells from HT29, HGT101 
and Caco2 were similar (Figure 3.2a,A, pg.141), all differences were not 
statistically significant. This was somewhat surprising, considering that the 
predicted behaviour of precursor cells would include a higher capacity for 
self-renewal. HT29 cells displayed the highest clonogenic potential of 
66±3.7% and 70±3.3% for SP and non-SP cells, respectively. HGT101 SP 
cells and non-SP cells displayed colony-forming efficiencies of 31 ±3.2% 
and 40±4.7% respectively, whereas Caco2 cells were least efficient with 
9±3.7% for SP cells and 15±3.6% for non-SP cells. The clone sizes were
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similar in SP and non-SP derived colonies, indicating that there are no 
differences in doubling time.
Within each cell line, we could not detect significant differences in the 
morphologies of the clones generated by SP and non-SP cells. The 
colonies formed by Caco2 cells were morphologically distinct from those 
originating from HGT101 and HT29 cells and thus categorised 
independently (Figure 3.2a, pg.141). HGT101 and HT29 cells formed 
colonies of 4 different morphologies and were categorised into very small 
(<50 cells) (Figure 3.2a,B), tight colonies displaying clear borders 
(holoclones) (Figure 3.2a,C), dispersed (meroclones) (Figure 3.2a,D) and 
intermediate containing areas of tightly packed and dispersed cells with 
indefinite borders (paraclones) (Figure 3.2a,E). Caco2 cells typically formed 
holoclones, which were categorised by size as small (<50 cells) (Figure 
3.2a,F), intermediate (Figure 3.2a,G), and large (Figure 3.2a,H). After 3 
weeks in culture, HGT101 cells predominantly formed paraclones with no 
significant difference between SPs and non-SPs (Figure 3.2a,I), whereas 
HT29 cells mainly formed meroclones with a frequency of 43±2.7% in SP 
colonies and 37±3.1% in non-SP colonies (Figure 3.2a,J). Only 16±4.5% of 
HT29 SP colonies and 22±4.8% of HT29 non-SP colonies were 
meroclones. Both populations of HT29 and HGT101 colonies displayed 
similar percentages of very small colonies and holoclones, ranging between
9-13% and 24-30%, respectively. The majority of colonies derived from 
Caco2 cells were classified as large; 50±11% of SP-derived colonies and 
52±9.6% of non-SP derived colonies were large, whereas only a few 
remained very small (Figure 3.2a,K). The differences in morphology type- 
distribution and colony sizes between SP and non-SP colonies were not 
significant for any of the cell lines.
Immunophenotypic analysis of the clones generated by SP and non-SP 
cells did not show differences in the expression of putative stem cell 
markers in any of the cell lines. Figure 3.2b displays examples of the 
staining profile of Caco2 cells. After 3-weeks in culture, all clones were
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strongly positive for CD133, p-catenin, HES-1, and the putative intestinal 
stem cell marker Musashi-1, whereas expression of CD117 and OCT4 
were not detected on either SP-originated or non-SP-originated colonies. 
CD34-expression, as well as sporadic MDR-1-expressing cells were 
detected on clones generated from either cell fraction.
3.4.4 Re-analysis of SP phenotype
Re-analysis of Caco2, HT29 and HGT101 SP and non-SP cells grown for 3 
weeks showed the presence of the SP phenotype in both SP and non-SP 
derived cultures, indicating that both cell fractions have the ability to give 
rise to the other (Figure 3.3, pg. 143). However, after 3-weeks of culture, 
the SP fractions observed in the SP-derived culture were larger than the 
original SP-percentage in any given cell line, and similarly, the SP fraction 
appearing in the non-SP derived cells was smaller than the original SP 
phenotype. These results suggest that the cultures, starting from a pure SP 
and non-SP population, have not had enough time to reach equilibrium 
between SP and non-SP populations. This is also supported by the fact that 
cell lines with faster doubling times (HGT101,HT29) were closer to reaching 
equilibrium after 3-weeks culture than slower growing cell lines (Caco2).
3.4.5 Differentiation potential in vitro and in vivo
Subjecting both SP and non-SP cells to differentiation-promoting culture 
conditions using sodium butyrate for 72 hours resulted in successful 
mucous cell (Figure 3.4A,D, pg.144), enterocyte cell (Figure 3.4B,E) and 
endocrine cell (Figure 3.4C.F) differentiation by Caco2 cells. In accordance 
with the known profiles of HT29 and HGT101 cell lines, these cells were 
capable of enterocytic and mucous cell differentiation, but endocrine cells 
were only seen in Caco2 and HRA19 non-SP and SP cells. These results 
confirm the multilineage potential in vitro for both cell fractions.
The capability for multipotential differentiation of both SP and non-SP cells 
was also confirmed in vivo by immunocytochemistry on xenograft tumours
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removed after reaching the threshold diameter of 1.5 cm. Tumours 
generated from both cell fractions of Caco2 and HRA19 cells were capable 
of differentiation into all intestinal epithelial cell types. As shown in Figure
3.4 G-L, xenograft tumours derived from Caco2 SP and non-SP cells show 
differentiation into mucous cells (Figure 3.4G,J) enterocytes (Figure 
3.4H,K) and endocrine cells (Figure 3.4I,L). HT29 cells displayed their 
typical differentiation profile in tumours generated from non-SP and SP 
cells, forming enterocytes and mucous cells, but not endocrine cells.
3.4.6 Proliferation capacity measured by expression of Ki-67
Ki-67 is expressed by proliferative cells and used as a marker for cells from 
late G-phase to mitosis. We failed to detect a significant difference in 
expression levels of Ki-67 by FAC analysis of fluorescently labelled sorted 
SP and non-SP cells (Figure 3.5, pg.145). The percentages of positive cells 
were 3.88% and 4.2% for non-SP and SP cells, respectively. Thus, both 
cell populations show similar proportions of proliferating and quiescent 
cells, attributes that are often used to differentiate stem cells from transit 
amplifying and more mature somatic cells.
3.4.7 Drug resistance to 5-fluorouracil (5-FU)
Subjecting cells to the chemotherapeutic agent 5-FU did not selectively 
compromise any of the cell populations we tested, including cell 
populations expressing CD133, CD44, CD117, BCRP, as well as the SP 
and non-SP (Figure 3.6, pg.146). The population fractions before and after 
culturing of the cell lines in the presence of 5-FU were not different with 
statistical significance. Fractions of BCRP1-positive and CD117-positive 
cells were below 2% before and after treatment with 5-FU, whereas the 
CD133 and CD44-expressing cell populations displayed constant fractions 
of over 80%. None of these populations, including the SP showed an 
elevated drug resistance, which would be typical for a stem cell-enriched 
population. This indicates that compared to each other, none of these 
populations is particularly enriched in stem cells.
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3.4.8 in vivo characteristics of SP and non-SP cells
Subcutaneous injection of varying numbers of freshly-sorted SP and non- 
SP cells into nude mice showed that both SP and non-SP cell fractions of 
Caco2( HRA19 and HT29 cells have an equal tumorigenic potential when 
analysed at 16 weeks after injection or when tumour burden reached a 
threshold diameter of 1.5 cm. Non-SP cells formed tumours of the same 
size and latency as SP cells (Table 3.3, pg.152). HGT101 cells however, 
did not display tumorigenicity in vivo, even at the maximum cell dose of
150,000 cells per injection.
As few as 100 sorted cells from HT29, Caco2, and HRA19a1.1 cell lines 
were capable of tumour formation (Table 3.3, pg.152). There was no 
significant difference between SP and non-SP cells in the number of 
tumours generated, nor in tumour size or the latency of tumour 
appearance. Consistent with their high in vitro proliferative activity, HT29 
cells were most tumorigenic. The first signs of tumour growth appeared as 
early as 4 weeks after injection, and tumour growth was rapid with some 
HT29 SP and non-SP derived tumours reaching the threshold diameter of 
15mm by week 10. All tumorigenic cell lines (Caco2, HRA19a1.1, HT29) 
gave rise to adenocarcinomas resembling the original tumours. There were 
no morphological or histological differences between SP and non-SP 
generated tumours (Figure 3.7, pg.147).
Fluorescence-activated cell analysis of the cells extracted from xenograft 
tumours revealed SPs and non-SPs in all tumours, regardless of whether 
they originated from SP or non-SP cells, again indicating that both cell 
fractions are capable of giving rise to the other (Figure 3.8, pg.148). 
Fluorescent immunophenotyping of the harvested tumour cells by 
multicolour analysis showed expression profiles similar to the 
immunophenotypes of the cell fractions prior to FAC-sorting (Table 3.2, 
right column; Figure 3.8). As before xenografting, the vast majority of both 
SP and non-SP cells from both cell lines expressed CD44. Moreover, in the 
Caco2 populations, the CD44-expressing fraction of cells increased with
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xenografting, approaching levels of 100%. Similar to the initial profile, a 
substantial proportion of both HT29 and Caco2 cells also expressed CD133 
after xenografting; however, the CD133-expressing population of both SP 
and non-SP derived HT29 populations was significantly smaller than its 
original expression prior to grafting. Numbers of CD117 and BCRP1- 
expressing cells increased slightly on Caco2 populations, although they 
were reduced on the HT29 cells extracted from the xenograft tumours. The 
most striking difference between pre-and post-xenograft phenotypes of SP 
and non-SP cells was the large increase in CD34-expressing cells. 
Whereas, CD34-expression was barely detectable in the SP fractions at the 
time of sorting, a substantial fraction, 22.6±3.9% and 47.0+3.7% of Caco2 
and HT29 cells respectively, expressed CD34 after tumour formation in 
vivo. Importantly, as we observed an increase in CD34-positive cells in vitro 
as well as in vivo, any chance that this may simply be an increase in 
endothelial cells within the tumours can be ruled out. All other differences in 
surface marker expression between SP and non-SP fractions after 
xenografting were not significant for both cell lines (Table 3.2, pg.151).
3.5 DISCUSSION
3.5.1 Stem cells in normal and cancerous gastrointestinal epithelia
it has been reported that the SP phenotype comprises a cell population 
highly enriched in stem cells in several adult tissues and human cancers 
(Srour etal. 1993, Asakura et al. 2002, Alvi et al. 2003, Bhattacharya et al. 
2003, Chiba et al. 2006, Dekaney et al. 2005, Morita et al. 2006, Szotek et 
al. 2006). However, many of these studies have neglected to directly 
compare the behavioural characteristics of the SPs and non-SPs derived 
from the same founding cell population. Moreover, as a large proportion of 
this research was performed on murine tissues, evidence about the human 
counterparts is limited. Taken together, these issues raise some doubts 
about the hypothesis of the SP as a universal stem cell marker. In addition, 
recent accounts have challenged the notion of SPs as a useful method to 
identify stem cells (Morita etal. 2006, Mitsutake et al. 2007).
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It is known unequivocally that the gastrointestinal epithelium contains stem 
cells (reviewed in (Leedham et al. 2005)) and it has been proposed that 
stem cells exist in tumour populations, which may sustain their aggressive 
biology in vivo. However, attempts to isolate normal or tumour stem cells 
have to date only yielded limited success. Recently, two groups have found 
that a CD 133-positive population to be stem cell-enriched in the human 
colon, but additional markers still need to be identified to obtain a stem cell 
population with higher purity. It was our aim to investigate whether the SP 
phenotype could prove useful for the identification of gastrointestinal cancer 
stem cells. To accomplish this, we not only sought to determine typical 
stem-cell behaviour, but also to elucidate whether SP cells can be identified 
by differential expression of potential stem cell markers.
3.5.2 Side Populations in gastrointestinal cancer cell lines
In the present study, we show that the SP phenotype exists in all of the 7 
human gastrointestinal cancer cell lines tested. Six cell lines were derived 
from colorectal carcinomas and adenocarcinomas. One gastric 
adenocarcinoma-derived cell line (HGT101) was also found to contain 
reserpine-sensitive SP cells. Although the SP sizes in our study were 
significantly higher than SP fractions reported in bone marrow and other 
primary tissues (Goodell et al. 1996, Alvi et al. 2003, Bhattacharya et al. 
2003, Grichnik 2006), they were comparable to the somewhat higher SP- 
fractions reported in the literature of cells maintained in culture, including 
cancer cell lines (Hirschmann-Jax et al. 2004, Chiba et al. 2006, Haraguchi 
et al. 2006). It has to be noted that SP sizes are not correlated to doubling 
times of the cell lines studied. For example, HGT101 and HT29, the cell 
lines with shortest doubling time had comparable SP fraction sizes to that 
of Caco2, a cell line with considerably slower doubling time.
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3.5.3 Stem cell-typical characteristics of SP and non-SP cells
We tested for stem cell-typical behaviour, such as the capability for 
proliferation and self-renewal by single-cell clonogenic assays in vitro and 
tumorigenicity of cells injected into nude mice at progressive dilutions in 
vivo. We also examined the output phenotypes in differentiation-promoting 
culture conditions in vitro and by histological and immunohistochemical 
examination of xenograft tumours. Additionally, we examined the 
expression of putative stem cell markers before and after culturing the 
sorted cell fractions.
Interestingly, non-SP cells displayed not only a similar clonogenic potential 
in vitro as SP cells, but they were also able to form xenograft tumours at 
limiting dilution with the same size and latency as those derived from SP 
cells. The possibility of these results representing an artefact due to the 
effect of Hoechst staining on cell viability was excluded, since single-cell 
sorted control cells that were not stained with Hoechst 33342 showed the 
same clonogenicity as Hoechst-stained cells (Figure 3.9, pg.149). If 
clonogenic potential and tumorigenicity are valid tests for self-renewal and 
proliferation, these results indicate that non-SP cells contain a similar 
number of cells with stem cell characteristics as SP cells. Another feature 
typical for stem cells is their non-cycling, quiescent state. However, we 
could not detect any difference in the cell cycle status of the populations by 
measuring the expression of Ki-67, a marker of proliferating cells.
None of our experiments demonstrated any behavioural differences 
between SP and non-SP cells. Sorted single cells from both populations 
gave rise to clones of heterogeneous morphologies, as would be expected 
if multipotent stem cells are contained in each population. Both cell 
fractions showed the capability for multipotential differentiation in vitro and 
in vivo, since enterocytes and mucous cells were detected in SP and non- 
SP-derived cultures and xenograft tumours of all tested cell lines. The 
similar histopathological findings of adenocarcinomas formed from both cell
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fractions serves as additional evidence for the similar behavioural potential 
of SP and non-SP cells.
When cultures derived from non-SP and SP cells were re-analysed 3 
weeks later, a reserpine-sensitive SP phenotype, as well as a non-SP 
fraction was observed in cultures originating from both populations. The 
capability to give rise to the other cell fraction suggests that the populations 
are interchangeable and provides additional evidence for the presence of 
immature cells in both populations. Cancer stem cells are discriminated by 
their heightened resistance to drugs, attributable to the elevated expression 
of lipophilic multidrug efflux pumps. We reasoned that the exposure to 5- 
FU, a lipophilic chemotherapeutic agent would selectively compromise the 
population containing the fewest stem cells. However, after 3-week culture, 
both the SP and the non-SP appeared in fractions resembling the original 
SP profile, indicating that no population is enriched for drug-resistant stem 
cells. Moreover, we showed that 5-FU also did not have an adverse effect 
on the fractions expressing the putative stem cell surface markers CD 133, 
CD44, CD117, BCRP1. This confirms that these markers are legitimate 
candidate markers for stem cells since any change in expression profile 
would indicate a population’s vulnerability to the toxic effects of the 
chemotherapeutic agent.
The only difference we could detect between non-SP and SP cells in our 
experiments was of a phenotypical nature. Quantifying the expression of 
CD34, a surface marker whose presence (Srour et al. 1993, Krause et al. 
1994, Morel etal. 1996), as well as absence (Cheng et al. 1996, Goodell et 
al. 1997), has been associated with stem cells in various tissues, we 
noticed that non-SP cells expressed CD34, whereas the SP population was 
CD34-negative. However, after xenografting of sorted SP and non-SP cell 
fractions, a significant CD34-expression was shown in a subset of SP and 
non-SPs derived from HT29 and Caco2 cells. This indicates that the CD34- 
negative population may give rise to CD34 expressing cells. Expression of 
all other tested putative stem cell markers did not differ between the non- 
SP and SPs before or after culture or xenografting.
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Controversy exists about the relationship between ABCG2 expression and 
the SP phenotype. In accordance with recent reports (Patrawala et al. 
2005, Morita et al. 2006), we could not support a correlation between the 
SP phenotype and expression of BCRP1. Expression was identical in non- 
SP and SP cells before and after culture, indicating that other membrane 
transporters must play a role in conferring the ability to efflux Hoechst dye.
3.6 CONCLUSION
Our results show that non-SP cells derived from multiple human 
gastrointestinal cell lines display both progenitor and stem cell 
characteristics, such as self-renewal, extensive proliferation and 
differentiation potential, to a similar extent as the SP population. Although 
the SP fraction clearly contains stem cells, our data indicate that it does not 
exclusively contain stem cells. Clearly, a substantial portion of stem and 
progenitor cells, as defined operationally by our experiments, is also 
contained in the non-SP population. Further research is necessary to 
isolate stem cells from either population and to elucidate potential 
behavioural differences that are conferred by the explicit CD34-negativity in 
the SP population. CD34-negativity has been repeatedly reported to be a 
marker of immature cells (Krause et al. 1994, Morel et al. 1996, Osawa et 
al. 1996, Huss 2000). However, although this could indicate that the SP 
population is enriched in immature cells, we found that the non-SP fraction 
was proportionately enriched in cells with stem cell-behaviour. Thus, the SP 
phenotype does not seem to be useful for isolation, purification or 
characterisation of stem or progenitor cells in gastrointestinal cell lines as 
defined by clonogenicity, tumorigenity and multilineage differentiation 
potential.
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Figure 3.1. Identification of SP (lower gate) and non-SP cells (upper gate) 
in gastrointestinal cancer cell lines (A-D, l-K). Cell suspensions were incu­
bated with Hoechst 33342 and analysed by flow cytometry measuring 
Hoechst blue vs Hoechst red fluorescence (E-H, L-N). Reserpine sensitivity 
was used to verify SP cells and to determine optimal staining conditions.
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Figure 3.2a. (A) Clonogenic behaviour of SP, non-SP and whole popula­
tion (WP) fractions of HT29, HGT101 and Caco2 cell lines, expressed as 
percentage of sorted single cells giving rise to clones after 3-week culture. 
(B-H) HT29, HGT101 and Caco2 clone morphologies as seen by phase- 
contrast microscopy (magnification x40). HT29 (shown here) and HGT101 
colonies are categorised as (B) Very small (<50 cells); (C) Holoclones; (D) 
Meroclones; (E) Paraclones. (F-H) Caco2 colonies were categorised as (F) 
Imall (<50 cells); (G) Intermediate. (I-K) Statistical comparison of colony 
morphologies did not reveal a statistically significant difference between 
the SP and non-SP populations.
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Figure 3.2b. (A) Expression of putative stem cell markers on clones gen­
erated from SP cells (A-D.l-L) and non-SP cells (E-H, M-P). Antibody stain­
ing is visualised by DAB (brown) and counterstained with haematoxylin 
(blue). (A,E) Weak expression of CD34. (B,F) Scattered CD 133-positive 
cells. (C,G) Hes-1 positivity. (D,H) Sporadic Mdr1 -positive cells. (I,M) No 
detectable CD117 expression. (J,N) Ubiquitous p-catenin positivity. (K.O) 
Oct-4 negativity. (L,P) Strong expression of Musashi-1.
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Figure 3.3. Re-analysis of sorted Caco2, HT29 and HGT101 SP and 
non-SP cells for the presence of the SP phenotype after 3-week culture. 
(A,C,E) SP cells give rise to non-SP cells; (B.D.F) Non-SP cells are capable 
of generating SP-cells.
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in vitro  muc 2 villin chromogranin
in vivo muc2 CD10 chromogranin
Figure 3.4. Immunohistochemistry showing potential for multilineage dif­
ferentiation of SP and non-SP cells in vitro and in vivo. Antibody staining is 
visualised by DAB (brown), and cells are counterstained with haematoxylin 
(blue). (A-F) Multilineage differentiation of Caco2 SP (top row) and non-SP 
(bottom row) cells in vitro after 72-hour incubation with 2 mM sodium butyr- 
ate. (G-L) Multilineage differentiation of Caco2 SP (top row), and non-SP 
cells (bottom row) in vivo as seen in xenograft tumours. (A,D,G,J) Muc2 ex 
pression visualising mucous cells. (B,E) Strong anti-villin staining display­
ing enterocytic differentiation. (H,K) CD10 expression, an alternative 
marker for enterocytes. (C.F.I.L) Expression of chromogranin Ain endocrine 
cells.
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Figure 3.5. FAC analysis measuring the expression of proliferation marker 
Ki-67 in non-SP (left column) and SP fractions (right column). (A,B) Dot plot 
graphs visualising the fraction of Ki-67 expressing cells in each population. 
(C,D) Histogram showing fractions of cells in various cell cycle stages.
145
Before treatment with 5-FU After treatment with 5-FU
CD44 CD44
I02 103 104 10s
CD117
0 1000 2000 3000 4000
52WCUAAA
SP Profile
0 1000 2000 3000 4000
925tifrUV-A
SP Profile
BCRP
10' 101 10s to4 10s
BCRP1
CD117
Figure 3.6. Multicolour FACS analysis showing the effects of treatment 
with 5-Fluorouracil (5-FU) on various colorectal cell line populations. Cell 
populations displayed similar fluorescent profiles before (A,C,E,G) and 
after (B,D,F,H) 5-FU treatment, including the SP profile (A.B), and popula­
tions positive for BCRP1 (C.D), CD117 (E.F), CD44 (G,H), and CD133 
(C-H, horizontal axis).
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Figure 3.7. Xenograft tumours developed in nude mice originating from 
s.c. injection of SP (A,C,E) and non-SP cells (B.D.F). (A-F) Well-differenti­
ated adenocarcinomas seen in Haematoxylin and Eosin stained paraffin- 
embedded sections of tumours originating from (A) Caco2 100 SP; (B) 
Caco2 100 non-SP; (C) HRA19a1.1 100 SP; (D) HRA19a1.1 100 non-SP; 
(E) HT29 100 SP; (F) HT29 100 non-SP cells.
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Figure 3.8. Multicolour FACS analysis of tumours generated by 100 HT29 
SP cells and 100 HT29 non-SP. (A,B) Reserpine-sensitive SPs appear in tu­
mours originating from non-SP (right column) and SP (left column) cells; 
(C-J) Surface marker expression of tumours generated from SP (left 
column) and non-SP cells (right column). (C,D) Expression of CD34; (E,F) 
Positivity for BCRP1; (G,H) No expression of CD117; (l,J) Expression of 
CD133. Strong CD44 expression on all tumours is displayed on all y-axes.
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Figure 3.9. Percentage of viable colony-forming Caco2 and HGT101 cells 
when single-cell sorted into 96-well plates with or without incubation with 
Hoechst 33342.
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Table 3.1
Optimal staining conditions for each tested 
gastrointestinal tumour cell line
Caco2 6 60
HT29 7.5 60
HGT101 5 60
HRA19b1.1 7.5 90
Col29 7.5 60
Coll 7.5 60
SW480 9 45
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Table 3.2
Expression of putative stem cell surface markers before and after 
xenografting of sorted cell fractions as determined by multicolour
fluorescence analysis
Caco2 CD44 87.5 ± 4.8 91.0 ±2.9 No 94.8 ±4.7 94.0 ±3.2 No
CD133 96.4 ±3.2 92.0 ±0.4 No 91.3 ±7.2 92.0 ±0.9 No
CD117 0.03 ± 0.0 0.02 ± 0.0 No 0.8 ±0.7 1.5 ±0.6 No
BCRP 1.6 ±0.3 2.1 ±0.1 No 4.8 ±1.9 6.4 ±3.0 No
CD34 0.01 ±0.0 2.5 ±0.1 Yes 47.0 ±3.7 52.1 ±3.2 No
HT29 CD44 100.0 ±0.0 99.9 ±0.1 No 100.0 ±0.0 100.0 ±0.0 No
CD1331 93.9 ± 3.8 98.3 ±2.3 No 61.8 ±3.9 55.3 ±4.2 No
CD117 1.2 ±0.3 1.0 ±0.2 No 0.1 ±0.1 0.2 ±0.1 No
BCRP 3.8 ± 0.8 4.3 ±0.6 No 1.1 ±0.2 0.8 ±0.6 No
CD34 0.1 ±0.0 0.6 ±0.1 Yes 22.6 ± 3.9 17.4 ±6.9 No
HGT101 CD44 99.9 ±0.1 99.9 ±0.0 No
CD133 76.9 ±2.6 82.9 ±5.7 No
CD117 3.0 ±0.8 5.5 ±2.9 No N/A
BCRP 3.7 ±0.5 4.1 ±1.6 No
CD34 30.6 ±2.7 53.5 ±5.4 Yes
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Table 3.3
Tumorigenicity of sorted SP and non-SP cells upon s.c. injection into nude
mice
I HT29 1
SP cells 3/5 3/3 1/1 — —
Non-SP cells 2/5 3/3 1/1 0/1 1/1
Caco2 I
S Peel Is 1/5 1/3 1/1 — —
Non-SP cells 3/5 2/3 1/1 1/1 0/1
HRA19
SP 2/5 0/3 0/1 — —
Non-SP 3/5 0/3 0/1 1/1 0/1
HGT101
SP 0/5 0/3 0/1 — —
| Non-SP 0/5 0/3 0/1 0/1 0/1
Mice harvested after 16 weeks or when tumour burden reached a threshold 
diameter of 15 mm.
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CHAPTER IV
CHARACTERISATION OF CELLS EXPRESSING THE 
PUTATIVE STEM CELL MARKERS CD44 AND CD133 FROM 
HUMAN ADENOCARCINOMA AND NORMAL EPITHELIUM 
OF THE COLON
4.1 INTRODUCTION
To date, it has not been possible to isolate and characterise the stem cells 
residing in the normal or diseased gastrointestinal epithelium. Partly due to 
the fact that there is no culture method robust enough to allow primary 
culture of the intestinal epithelium to test proliferative and differentiation 
potential of intestinal cellular subtypes, there is an ongoing debate 
regarding the exact number and location of intestinal stem cells. Several 
proteins have been implied as potential stem cell markers in the normal and 
neoplastic intestinal epithelium.
Most gastrointestinal cell lines contain a small SP fraction (Haraguchi et al.
2006). However, we have recently found in gastrointestinal cancer cell 
lines, that the SP phenotype does not enrich for cells with stem cell 
characteristics and is thus not a useful stem cell marker in these 
malignancies (Burkert et al. in Press). Two surface proteins have in the 
literature repeatedly been suggested as promising markers for stem cell- 
enriched populations.
CD44, explained in detail in section 1.4.3.2, is an adhesion molecule 
involved in cell adhesion, lymphocyte homing and haematopoiesis. A stem 
cell connection is implicated by the fact that CD44 is involved in the Wnt 
signalling cascade, as its expression is activated by p-catenin (Wielenga et 
al. 1999). It also appears to play a role in tumour progression and the
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metastatic cascade, where it is thought to confer metastatic potential 
through changes in adhesion to extracellular ligands. Differential 
expression and gradual changes in expression of CD44 isoforms can be 
observed between normal, neoplastic, and metastatic tissues (Heider et al. 
1993, Kawahara et al. 1996, Matzku et al. 1989, Yamaguchi et al. 1998). In 
breast and pancreatic adenocarcinomas, prostate carcinoma cell lines, and 
head and neck squamous cell carcinomas, CD44~expressing cell 
populations display phenotypic and functional characteristics typical for 
stem celi-enrichment (Al-Hajj et al. 2003, Ponti et al. 2005, Li et al. 2007, 
Patrawala et al. 2006, 2007, Prince et al. 2007). During the course of our 
experiment, a report emerged identifying the CD44+/EpCAMh,gh population 
as a tumorigenic cell population in colorectal cancers when subcutaneously 
injected into NOD/SCID mice (Dalerba etal. 2007).
CD133, described in detail in section 1.4.3.1, has been claimed to be 
preferentially expressed on stem cells in normal and cancerous tissues. 
Stem cell-pharacteristic behaviour has been reported in CD133-expressing 
populations in the normal haematopoietic system (Yin et al. 1997), 
leukaemia (Vercauteren et al. 2001), neural cells (Uchida et al. 2000), 
normal brain and brain tumours (Singh et al. 2003, 2004, Hemmati et al. 
2003, Galli et al. 2004, Kuhnert et al. 2004, Shmelkov et al. 2005), kidney 
cancer (Bussolati et al. 2005, Florek et al. 2005), normal prostate and 
prostate cancer (Richardson et al. 2004, Collins et al. 2006), and recently, 
colon cancer (O'Brien et al. 2007, Ricci-Vitiani et al. 2007). However, a 
controversial report has recently emerged, indicating that the CD133+ 
population in C6 glioma cells is not more tumorigenic or clonogenic than its 
negative counterpart, and thus not enriched in stem cells (Zheng et al.
2007).
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4.2 AIMS
CD44 and CD133 have both recently been reported as potential cancer 
stem cell markers in human tumours. We aimed to examine and compare 
the expression of CD44 and CD133 in normal human colonic mucosa and 
adenocarcinomas and to explore the possibility of combining both surface 
markers to obtain a purer population of stem cells. We attempted to test 
sorted fractions of cells expressing the markers to be tested for stem cell- 
typical behaviour such as sphere-formation in vitro and serially 
transplantable xenograft formation in vivo.
4.3 METHODS
All methods are described in full in Chapter II.
4.3.1 Patients and Materials
For this study, five patients that underwent surgical resection for colonic 
adenocarcinomas were selected. Specimens were fixed in 4% PFA and 
embedded in paraffin or processed to obtain single cell suspensions for 
FAC analysis and sorting. Ethical approval was sought and obtained as per 
the requirements of the United Kingdom Human Tissue Act (2006), REC 
reference number 07/Q1604/17.
4.3.2 Fresh tissue dissociation
Tissue from normal colon and adenocarcinomas was washed repeatedly. 
Normal colonic mucosa was incubated in E4 medium lacking Ca2+ and Mg, 
supplemented with 30mM EDTA at 37°C for 15 min, after which crypts were 
dislodged by vigorous shaking. Tumour tissue was minced. Both, normal 
and tumour tissue were then incubated in a collagenase/dispase solution in 
a shaking waterbath at 37°C to obtain single cell suspensions. Subsequent 
incubation in ammonium chloride on ice for 10 min was performed to lyse 
red blood cells. Finally, the cell suspensions were filtered through 70p, cell 
strainers.
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4.3.3 Multicolour fluorescence activated cell (FAC) analysis and 
sorting
Single cell suspensions were incubated with directly labelled fluorescent 
antibodies against CD45, CD44, and CD133 on ice for 20 min. Control 
staining was performed with each antibody individually and all-minus-one 
antibodies to guide appropriate drawing of gates. DAPI was used to label 
and electronically gate out dead cells.
The stained cells were analysed using the LSR II Flow cytometer. Data 
were analyzed using FloJo computer software (Treestar, San Carlos, CA). 
Cell Sorting was carried out on a MoFlo™ High Performance Cell Sorter 
(Dakocytomation, Glostrup, Denmark) with excitation and emission 
wavelengths as stated in chapter II.
4.3.4 in vitro culture
For sphere-formation experiments, sorted cell fractions were incubated in 
serum-free medium at 37° C in humidified atmosphere containing 8% CO2.
4.3.5 Xenograft experiments
Appropriate numbers of sorted cells (Tables 1 and 2) were injected s.c. into 
flanks of nude mice in a 1:2 mixture of PBS and matrigel. Fractions 
expressing the surface marker to be tested and the control population 
devoid of antigen expression were injected into opposite flanks.
4.3.6 in situ hybridisation
Sections were dewaxed, permeabilised in 1 M sodium thiocyanate, and 
digested in 0.4% pepsin at 37°C for 15 min. They were then fixed in PFA 
and dehydrated through graded alcohols. A mixture of mouse and human 
pan-centromeric fluorescent probes, directly conjugated to Cy-3 and FITC 
respectively was applied, sections were hybridised at 60°C, incubated 
overnight at 37°C and mounted in medium containing DAPI.
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4.4 RESULTS
4.4.1 Increased expression of CD133 in colon adenocarcinomas
Expression of CD 133 was compared between colon adenocarcinomas and 
adjacent normal colonic tissue of the same patients by 
immunohistochemistry. In normal colonic epithelium, the expression of 
CD133 was extremely sporadic, and restricted to the bottom third of colonic 
crypts (Figure 4.1, pg.164). In adenocarcinomas however, the expression 
of CD133 was highly increased. CD133 was primarily expressed on the 
apical surface of the cells facing the lumen of the duct-like structures that 
are typical in colonic adenocarcinomas. Statistical comparisons based on 
the immunohistochemical results were not possible due to the extreme 
rarity of CD 133-expressing cells in normal colonic epithelium.
Double-fluorescent immunohistochemical staining for CD133 and CD44 
showed CD44 on the cell-cell membranes, whereas CD 133 was again 
restricted to the apical surface of the epithelial cells comprising the tumour. 
CD44 generally displayed a higher expression than CD133 and was more 
ubiquitously expressed throughout the entire tumours. Double expression 
of CD133 and CD44 was rarely seen and only on mutually exclusive sides 
of the cell membrane (Figure 4.2, pg.165). Due to the rare occurrence of 
CD133 on normal colonic tissue, we could not detect any double 
expression of CD44 and CD133 by fluorescent immunohistochemistry on 
normal colonic mucosa.
4.4.2 FAC analysis and sorting
Multicolour FAC analysis and cell sorting was performed on single cells 
derived from normal colonic mucosa and adenocarcinomas. Generally, 
both surface proteins were significantly more expressed on the cells from 
cancer tissues than from the normal colonic epithelium. Consequently, the 
fraction of double-positive cells, expressing both markers was also 
upregulated in the adenocarcinoma cells as opposed to the normal 
epithelial cells (Figure 4.3A, pg.166). CD44 showed the largest difference in
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expression when comparing normal and tumour samples with average 
expression percentages of 0.2% ±0.009 and 2.1% ±0.470, respectively. 
However, when looking at the groups of tumour and normal specimens 
separately, CD133 showed a larger range of expression within those 
groups (Figure 4.3B). One of the adenocarcinomas and its adjacent normal 
colonic mucosa proved to be entirely devoid of CD133 expression.
The possibility of contaminating leukocytes in these experiments was ruled 
out by gating out CD45-expressing cells.
4.4.3 in vitro cultures
Cells from normal and cancer samples were sorted for single expression of 
CD133 and CD44, double expression of both markers, as well as the 
negative counterparts of each fraction. Attempts to establish in vitro 
cultures from the sorted cells in serum-free medium did not result in any 
surviving epithelial cells after 1 week of culture. Initial cell viability was 
tested before cell culture incubation to be 89%. Attempts to establish cell 
cultures were undertaken 5x with an identical outcome. This negative 
finding was not attributable to fungal or bacterial infection.
4.4.4 Lack of xenograft formation
Sorted cell fractions derived from 3 different adenocarcinomas expressing 
each marker separately, as well as doubly expressing ceils did not result in 
xenograft formation up to the maximum injected cell dose of 1000 sorted 
cells. Injection of the negative counterparts also did not show any xenograft 
tumour growth. Tumour growth was monitored weekly for the entire length 
of the experiment of 4 months.
Injections of sorted cells derived from normal colonic epithelium were also 
injected in matrigel to monitor possible stem cell function resulting in crypt 
formation in vivo. H&E staining of serial sections of the injected matrigel
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pellets did not reveal any crypt formation, or formation of any other 
recognisable structures or clusters of cells.
4.4.5 Survival of human-derived cells in vivo
Matrigel pellets that contained the various injected cell fractions were 
examined for surviving human-derived cells 4 months post-injection by 
mouse-human pan-centromeric in situ hybridisation. We could not detect 
human-derived cells in any of the matrigel pellets that had received cell 
fractions from normal colonic mucosa, as well as surface-marker negative 
control populations from adenocarcinomas. However, matrigel pellets that 
originally contained 1000 CD44+ adenocarcinoma cells showed single 
dispersed human-derived cells 4 months post-injection, albeit at very low 
numbers. Where 1000 CD133+ adenocarcinoma cells had been injected, 
we could detect small clusters of 2-11 surviving human-derived cells in the 
matrigel pellets. The most human-derived cells (66) were detected in one 
sample that had received 1000 double-positive CD44/133 adenocarcinoma 
cells.
4.5 DISCUSSION
4.5.1 Differences in surface marker expression between normal and 
tumour tissue
In this study, we showed that expression of putative stem cell surface 
markers CD 133 and CD44 vary between tumour tissue of colonic 
adenocarcinomas and the adjacent normal colonic epithelium. Consistent 
with the view that cancers might possess an elevated number of stem cell­
like cells, an upregulation of both surface markers appeared in the tumours 
vs. the normal tissues, whereby CD44 showed the largest difference 
between the normal and tumour counterparts. FAC analysis revealed the 
exact percentages of cells expressing CD133 and CD44, the location of 
which was visualised by immunohistochemistry. Cells expressing CD44 
were widely distributed throughout the tumour masses, suggesting that its
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sole expression is not indicative of stem cell status. CD133 expression was 
more specific, restricted to the apical surface of cells lining the duct-like 
structures in the adenocarcinomas. However, it has to be noted that its 
expression appeared uniform throughout the entire luminal epithelial sheet, 
or at least big stretches of it with all neighbouring cells expressing the 
marker, which also is not indicative of stem cells. When both surface 
markers were combined, only a few cells were detected expressing both 
markers simultaneously, on different sides of the cell membrane. These 
cells were sporadically distributed throughout the tumours.
4.5.2 Lack of sphere formation in vitro
Despite recent reports in the literature that CD133+ cells are capable of 
sphere formation in proliferation medium for undifferentiated cells, we could 
not replicate these results. After 1-week culture, no viable cells were 
detected, even with repeated attempts of the experiment.
4.5.3 Lack of xenograft tumour formation
Injection of various sorted cell fractions expressing combinations of cell 
surface markers did not result in xenograft tumour formation in any 
instance. Viability of the cells was tested before injection, and thus, it is 
conceivable that the injected cells did not represent tumorigenic 
populations. This indicates that neither CD44 nor CD 133 are suitable 
candidate markers to isolate and purify cancer stem cells. However, our 
results stand in contrast to several reports in the literature, showing 
xenograft tumorigenicity of CD44+ and CD133+ cells (Al-Hajj et al. 
2003,Singh et al. 2003, Hemmati et al. 2003, Galli et al. 2004, Kuhnert et 
al. 2004, Richardson et al. 2004, Singh et al. 2004, Ponti et al. 2005, 
Collins et al. 2006, Patrawala et al. 2006, Li et al. 2007, O'Brien et al. 2007, 
Ricci-Vitiani et al. 2007, Patrawala et al. 2007).
In retrospect, the failure to establish xenograft tumours in our experiments 
could be due to several reasons, mostly reflecting differences in technique.
160
The choice of xenograft host in the literature varies between 
immu nosuppressed NOD/SCI D mice and the slightly more 
immunocompetent nude mice. Although xenografts have been established 
in nude mice on many occasions including our own experiments with 
cultured cancer cells (chapter III), for several experiments with primary 
colonic tissue, the mouse of choice was the NOD/SCID variant. It is 
conceivable that the host immune response of nude mice might be too 
strong for the sensitive primary adenocarcinoma cells, causing their failure 
to produce tumours. Another difference in technique was the route of 
injection. In our experiments, we injected the sorted cells s.c., as this was a 
well-known technique for xenograft tumour formation. However, recent 
successful xenografts with primary colonic tissue formed upon injection of 
the cells into the renal capsule, where the injected cells are less likely to be 
dispersed throughout the body post injection (O'Brien etal. 2007).
One of our hypotheses was that identification of a true stem cell enriched 
population from normal colonic tissue would result in crypt formation and 
differentiation into all epithelial cell lineages of the colon in vivo. We based 
our experiments on findings by Del Buono and colleagues in our laboratory, 
who showed that the grafting of single crypts embedded in collagen pellets 
s.c. into nude mice resulted in maintenance of crypt morphology and the de 
novo formation of crypts and villi (Del Buono et al. 2005). It appeared as 
though the embedded crypts were capable of recruiting host-derived 
stromal cells, which provided the right microenvironment for the cryptal 
stem cells to proliferate. However, in our experiments, fractions of single 
cells did not appear to result in the recruitment of host stromal cells and in 
matrigel pellets that contained cell fractions from normal colonic mucosa, 
no surviving human cells were detected 4 months post injection. Two 
conclusions could be drawn from these findings: (1) CD44 and CD133 may 
not be useful as stem cell markers in the human colonic epithelium, or (2) 
Our experimental set-up did not provide the appropriate microenvironment 
for stem cell behaviour, rendering the results inconclusive.
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4.5.4 Human-derived cells four months post-injection
Matrigel pellets extracted 4 months after injection of cells showed varying 
numbers of surviving human cells through detection by mouse-human pan- 
centromeric FISH. Interestingly, the amounts of human-derived cells in the 
pellets correlated to the reported stem-cell enrichment of the different cell 
fractions. CD44 was arguably the weakest candidate stem cell marker, and 
consequently, we detected only sporadic single human-derived cells in the 
pellets from CD44-expressing adenocarcinoma cells. Matrigel pellets from 
CD 133+ cells showed small clusters of human-derived cells, which is 
consistent with claims in the literature that CD 133 represents an enriched 
stem cell population. In one pellet that had received double-positive cells 
however, we observed a much larger cluster of human cells (Figure 4.4). 
The normal survival of epithelial cells in the human colon is shorter than the 
4 months after which these cells were detected in the murine host. 
Consequently, it is likely that the human cells are derived from the originally 
injected cells, rather than representing surviving injected cells. Although 
this result .could indicate that the CD133/44 double-positive cell fractions 
are able to form the largest clones, which is most consistent with stem-cell 
typical behaviour, such conclusions can only be drawn if the experiment 
was expanded to larger numbers of representative samples.
4.6 CONCLUSION
In this study, we showed that epithelial cells from adenocarcinomas of the 
human colon show a higher expression of putative stem cell markers CD44 
and CD133. In addition, the location and expression characteristics of both 
surface markers was visualised within the adenocarcinoma sections. By 
combining the two cell surface markers, we sought to find a population of 
cells more highly enriched in cells with stem-cell characteristics than the 
reported enrichment of each population separately. Stem cell-typical 
behaviour such as self-renewal and multipotential differentiation has been 
experimentally demonstrated by sphere formation in vitro and serial 
transplantable formation of xenograft tumours. In our experiments, we 
could not observe sphere formation or the ability to generate xenograft
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tumours in any of the cell fractions tested, which might reflect the absence 
of stem cell-like cells in the CD44, CD133 and CD133/44 populations, but 
could also be due to differences in technique. However, human-derived 
cells were detected 4 months post-injection in matrigel pellets from CD44, 
CD133, CD133/44 fractions in quantities reflecting the presumed stem cell 
enrichment of these fractions. Under-representative numbers and lack of 
stem cell characteristics do not allow for conclusions to be drawn from 
these findings.
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Figure 4.1. Immunohistochemistry to show expression of CD133 on (A,B) 
normal colonic epithelium and (C,D) colonic adenocarcinoma. Sporadic 
CD133-expressing cells are detected in normal colonic sections (arrows), 
whereas its expression is upregulated in adenocarcinoma of the colon, 
mostly seen on the apical surface of gland-like structures.
164
Figure 4.2. Expression of CD44 (green) and CD133 (red) shown by fluo­
rescent double immunohistochemistry on a human colonic adenocarci­
noma. CD133 expression is mainly seen on the apical surface, whereas 
CD44 is expressed on the entire cell membrane. (B,C) Higer magnification 
images of cells expressing both surface markers.
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Figure 4.3. Expression of surface markers on single cell suspensions de­
rived from colonic adenocarcinomas and adjacent normal tissue. (A) Mul­
ticolour FAC-analysis showing the expression of CD45 on the dissociated 
cells and the expression of CD45 and CD133 on the gated CD45-negative 
cell population. (B) Statistical analysis of surface marker expression on 
normal and cancer epithelial cells, tested in triplicates.
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Figure 4.4. FISH with a mixture of mouse-human pan-centromeric probes 
to visualise cells derived from the human injected cell populations (green) 
and mouse host cells (red) within matrigel pellets. (A) Injection with sorted 
cells from normal colonic epithelium did not show any surviving human 
cells. (B) Single human cells in mice injected with tumour-derived CD44+ 
cells. (C, D) Small clusters of human cells in mice injected with CD133+ 
cells. (E) Larger cluster of human cells derived from CD133/44 double posi­
tive cells.
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Table 4.1
Tumour development in mice injected with sorted cell populations derived 
from adenocarcinomas of the colon.
100 0/6 0/6 0/6 0/60/6 0/6
1000 0/60/6 0/6 0/6 0/6 0/6
CD133 CD44 CD133/44Number of 
injected cells
Table 4.2
Crypt development in mice injected with sorted cell populations derived
from normal colonic epithelium
100 0/6 0/6 0/6 0/6 0/6 0/6
1000 0/6 0/6 0/6 0/6 0/6 0/6
CD44CD133 CD133/44Number of 
injected cells
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CHAPTER V
DONOR-DERIVED CELLS IN SKIN TUMOURS AFTER RENAL 
TRANSPLANTATION
5.1 INTRODUCTION
The capability of bone marrow (BM)-derived cells to engraft into multiple 
organs is well documented and has in recent years attracted substantial 
attention from the research community. Plasticity of transplanted BM cells 
has been shown in mouse models, as well as in humans, and has been 
observed in many tissues. The extent of BM engraftment varies in different 
epithelial tissues. In general, it reflects the rate of turnover of the tissue in 
question and is enhanced by injury, suggesting that haematopoietic stem 
cell-derived inflammatory cells contribute to epithelial repair.
5.1.1 Engraftment of transplanted cells into the skin
In the normal murine skin, the engraftment of donor-derived cells is 
sporadic and amounts to 1-14% of the total cell population (Krause et al. 
2001, Badiavas et al. 2003, Kataoka et al. 2003, Harris et al. 2004, Brittan 
et al. 2005). The contribution of BM cells to dermal fibroblasts is larger, 
reaching up to 15-20% of the total fibroblast poulation (Fathke et al. 2004). 
In the human skin, engraftment of BM cells into the normal epidermis is 
rare and reports vary between complete absence (Cogle et al. 2007, 
Murata et al. 2007), and 0.07% (Avital et al. 2007), 2-7% (Korbling et al. 
2002) and even as high as 14.8% (Hemmati et al. 2003). It has been 
suggested that epidermal engraftment only occurs in patients with graft- 
versus-host disease (GvHD), specifically in areas of heightened tissue 
damage (Murata et al. 2007).
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importantly, in mice, but not in humans, BM-derived cells in the skin have 
been found in small clusters in known stem cell areas, such as the CD34- 
positive bulge region of the hair follicle and the epidermal proliferative unit 
(EPU) in the interfollicular epidermis, and thus can presumably contribute to 
epithelial homeostasis. They were also shown to actively proliferate by 
incorporation of BrDU and to be capable of colony formation in vitro (Brittan 
et al. 2005). Contrasting observations have been made in humans. Clusters 
of BM-derived epidermal cells have not been shown to date, and when 
Hemmati and colleagues (2003) attempted to culture keratinocytes of bone 
marrow recipients in conditions favourable for keratinocyte stem cells, no 
colonies of BM-derived cells were seen, even though the observed BM- 
contribution to epidermal cells reached up to 14%. This indicates that, while 
BM-derived cells may engraft in stem cell niches in the mouse epidermis, 
this phenomenon may not apply to humans.
In disease scenarios, BM engraftment appears to underlie different 
principles fhan in normal tissues. Acute injury enhances the engraftment of 
BM-derived cells significantly, however, in a transient manner. Fathke et al.
(2004) noted that the majority of BM-derived cells in areas of acute tissue 
damage or acute inflammation express the haematopoietic stem cell 
marker CD34: with time, this expression decreases and most BM-derived 
cells express keratinocyte and fibrocyte markers. Thus, they propose a 
logical mechanism whereby inflammatory cells are recruited from the BM to 
the site of injury, where they aid in tissue regeneration by transdifferention 
into keratinocytes. Subsequently, the tissue follows its normal migratory 
pattern of tissue homeostasis and the BM-derived cells gradually diminish 
in number.
In areas of chronic inflammation, engraftment is not only profoundly 
enhanced in quantity, but donor-derived cells are seen in patterns that are 
typical for cells derived from a common ancestor (Houghton et al. 2004). 
This is different from normal tissues, where BM cells are mostly 
incorporated as sporadic cells, not as clones, suggesting that there they do 
not proliferate or act as stem cells. It appears as though in most cases, an
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environment of continual damage such as chronic inflammation is required 
for BM-derived cells to engraft as stem cells into epithelia. Notably, this is 
different from acute tissue damage or transient infections, where BM- 
derived cells to not appear to engraft as stem cells. A possible explanation 
for this scenario may be that permanent tissue damage eventually results in 
failure of the resident tissue stem cells, whereupon BM cells are recruited 
to fill the free stem cell niche and permanently act as the new resident 
tissue stem cells. This paradigm can be extended to the development of 
epithelial cancers. Acting as tissue stem cells, the BM-derived cells have 
the longevity to acquire the changes required to transform into cancer stem 
cells.
5.1.2 Donor-derived cells in post-transplant cancers
The development of cancerous lesions is a well-known after-effect of tissue 
and cell transplantations, attributable to risk factors such as 
immunosuppression, UV-irradiation and Human papillomavirus (HPV)- 
infection.
Cells of donor-origin have been demonstrated to contribute to post­
transplant cancers to a variable extent. In most cases, the engraftment of 
BM cells in tumours appears to be similar to the engraftment in normal 
tissues; merely as a sporadic contribution. In a recent study, Cogle et al. 
(2007) observed a 1-4% contribution of BM-derived cells to human colonic 
adenomas and a 20% engraftment in lung cancers of BMT recipients, 
similar to the cell fractions found in normal tissues. This led the group to the 
conclusion that epithelial engraftment into post-transplant cancers occurs in 
a similar fashion to normal tissues, merely as a form of cell mimicry. BM- 
derived cells have been found in various tumour-associated structures. 
Both, Duda et al. (2006) and Nolan et al. (2007) found a BM cell 
contribution to the neovascularisation of tumours. In our laboratory, it was 
shown that up to 25 % of stromal myofibroblasts in a mouse model of 
pancreatic insulinoma can be donor-derived (Direkze et al. 2004).
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However, it has also been shown that post-transplant lesions can be 
completely composed of BM-derived cells. For example, Papadopoulos et 
al. (1994) have found a leukaemic clone entirely consisting of donor- 
derived cells in a BM transplant-recipient. In an important study, Houghton 
et al. (2004) proved the BM origin of entire solid tumours in a mouse model 
of gastric cancer after chronic inflammation. Since then, BM cells have 
been shown in vitro as a potential source of malignancy in several different 
tumour types, including epithelial, neural, muscular tumours, tumours of 
fibroblasts and tumours of endothelial origin (Uu et al. 2006).
Engraftment of donor cells has also been observed after solid organ 
transplantations. In a kidney transplant recipient, a promyelocytic leukaemic 
clone completely derived from the donor has been found (Bodo et al. 1999). 
Barozzi et al. (2003) dixcovered neoplastic donor-derived endothelial cells 
in Kaposi sarcomas in recipients of liver allografts. Notably, these are 
tumours of haematopoietic origins and the engrafted cells could be derived 
from haematopoietic progenitors carried over with the graft. One example 
exists of a basal cell carcinoma in a female renal transplant recipient of a 
male kidney that appears to be mostly composed of male cells. However, 
due to unavailability of donor-specific information, it was not possible to 
determine whether the male cells were derived from the grafted organ or 
from peripheral blood microchjmerism (Aractingj et al. 2005).
These few observations suggest that transplanted cells may act as cancer 
stem cells in the host. These could either be neoplastic progenitors 
transmitted with the transplanted organ, or cells from the grafted organ, 
capable to transform into cancer stem cells within the host. Whether these 
cells are haematopoietic stem cells carried over with the transplanted 
organ, or another population of cells residing within the organ, capable of 
plasticity, is not clear.
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5.2 AIMS
This project was undertaken to elucidate the engraftment of donor cells in 
solid tumours of solid organ recipients.
In a study involving 35 female recipients of sex-mismatched kidney 
allografts with a total of 176 skin tumours, we aimed to investigate the 
incorporation of donor cells within post-transplant secondary lesions in 
more detail.
By using various types of skin tumours we aimed to test the extent, location 
and potential cell type preferences of donor cell engraftment on a large 
scale. Additionally, we aimed to investigate whether donor-derived cells 
from solid organ transplants can engraft into the skin as cancer stem cells, 
giving rise to entire clonal post-transplant skin lesions and thus represent 
an additional risk and side-effect of solid organ allografts.
5.3 METHODS
All Methods are described in full in Chapter II.
5.3.1 Patients
35 female recipients of male kidney allografts that had developed skin 
lesions following the transplant were identified. From these patients, 
archival paraffin-embedded biopsies from 176 skin lesions with varying 
histopathological diagnoses were used for this study (Table 5.1, pg.197). 
Ethical approval was sought and obtained as per the requirements of the 
United Kingdom Human Tissue Act (2006), REC reference number 
06/Q0603/1.
5.3.2 Quantitative PCR (qPCR)
Serial sections of every lesion were dewaxed and scraped off with a sterile 
needle into proteinase K solution (Picopure) for overnight digestion. Known 
amounts of the extracted DNA were subjected to qPCR using the Y-
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quantifier kit (Qiagen) with primers specific to a sequence on the sex- 
determining gene SRY on the Y chromosome. Results were analysed using 
the standard curve method.
5.3.3 Fluorescent in situ  hybridisation (FISH)
Sections were de-waxed and then subjected to the FISH-protocol as 
described in chapter II. For XY-FISH, a probe mixture was used consisting 
of Cy3-labelled Y chromosome-specific probes and FITC-labelled X 
chromosome-specific probes. For Y-FISH, a FITC-labelled probe specific to 
the Y chromosome was utilised. The temperature used for hybridisation 
was 80°C. Probes were visualised under the fluorescent microscope.
5.3.4 Immunohistochemistry combined with Y-FISH
Sections were dewaxed, subjected to antigen retrieval as needed and 
stained as described in Chapter II, using primary antibodies against pan- 
cytokeratin, a-SMA, CD34, or HPV. Staining was performed using the 
alkaline phosphatase technique and visualised with Vector Red. After 
immunocytochemical staining, the Y-FISH protocol was followed, with 
adjusted digestion times depending on the method used for antigen 
retrieval.
5.3.5 Statistical analyses
All statistical analyses were conducted using Mann-Whitney and Kruskal- 
Wallis analyses with Dunn’s post-test for non-parametric data and the 
Student’s two-tailed t-test for parametric data where appropriate (Prism, 
GraphPad, San Diego). Binomial data was analysed using the chi-square 
test of statistical signficance. A probability (P) value of <;0.05 was taken as 
an appropriate level of significance.
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5.4 RESULTS
5.4.1 Post-transplant skin tumours containing Y-chromosomal 
genetic material
Quantitative PCR for the sex-determining gene SRY in the Y chromosome 
was sensitive enough to detect as few as 4 Y chromosome copies among 
15,000 cells (equating to 50 ng DNA). Of the 176 tested skin biopsies, 
18.75% contained Y-chromosomal genetic material. These were distributed 
amongst 46% (16/35) of the female transplant recipients. Most patients 
displayed multiple lesions and on average 27% of an individual’s skin 
tumours contained male chromosomal material (Figure 5.1a, pg.186).
We detected Y chromosome-positive cells in squamous cell carcinoma 
(SCC), basal cell carcinoma (BCC), carcinoma in situ (CIS) and 
actinic/bowenoid keratosis (AK) samples with distinct engraftment 
percentages across the different lesion types (Table 5.1, Figure 5.1b). The 
percentage of Y-positive tumour samples ranged between 15-27%, 
whereby there was a higher percentage of Y-positive cells amongst BCCs 
(23%) and AK/BK (27%) tumours than amongst SCCs (15%) and CIS 
(19%). We could not find any tumours containing Y-positive cells in 
sections from porocarcinoma, dysplastic warts and lentigo maligna samples 
(Figure 5.1b,A, pg.187).
When the tumour types were grouped into malignant and premalignant 
categories, the percentage of Y-containing samples in the premalignant 
category was 20%, compared to 18% in the malignant category (Figure 
5.1b,B, pg.187). Statistical analyses using the chi-square test revealed no 
statistically significant difference between the different tumour types or 
malignant and premalignant categories.
5.4.2 Quantities of Y-positive cells determined by qPCR
By qPCR, the contribution of Y-positive cells to the entire tumour was found 
to be on average 1.6%, ranging between 0.02%-10.68% per 50 ng of DNA 
tested, which equates to 4-1626 Y chromosome copies/15,000 cells. The
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percentage engraftment of Y-positive cells showed a distinct pattern when 
the different tumour types were compared (Table 5.1, Figure 5.2A, pg.188). 
BCCs, for example, contained significantly higher amounts of Y-positive 
cells than CIS samples (P=0.032) and when the categories of malignant 
and premalignant tumours were compared, there was a statistically 
significant difference regarding the amount of Y-positive cells in the 
tumours (P=0.009) (Figure 5.2B, pg.188).
5.4.3 Sporadic distribution of Y-chromosome-positive celts with no 
evidence for cell fusion
Exact quantities of Y-chromosomal copies within the entire lesions were 
determined by qPCR. Since these purely quantitative data do not reveal 
information regarding the location and identity of the donor-derived cells, 
we used XY-FISH to visualise Y-positive cells. Location and morphology of 
the Y-positive ceils allowed us to determine cell type and location 
preferences for engraftment. XY-FISH on male control samples of BCC and 
SCC tumours revealed that due to unaccessability of nuclei due to tissue 
sectioning and orientation, only 71% of all nuclei could be successfully 
labelled. No difference was seen in labelling-efficiency between different 
tumour compartments, such as tumour epithelium, normal epithelium and 
tumour stroma. We thus applied a correction factor of 1.4 to all counted cell 
numbers to adjust for the expected underestimation.
Of the post-transplant tumours that upon qPCR showed >1% engraftment, 
5-7 samples of each tumour type were selected for further examination by 
XY-FISH and combined immunohistochemistry and Y-FISH. For each 
analysis, no less than 130 (130-300) cells were counted per sample.
XY-FISH samples showed sporadic incorporation of donor-derived cells 
within the tumours, irrespective of tumour-type and latency of tumour 
development. We reliably detected sporadic donor-derived cells in the 
epithelial sections as well as in stromal sections of the samples, determined 
by morphology (Figure 5.4, pg.190). We could not detect any clusters or
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clones of donor-derived cells in the analysed sections. In every tested 
section, we also checked for events of cell fusion, which would be evident 
by an increased number of sex chromosomes in any given cell. Having 
evaluated more than 3000 cells, we could not find any evidence for cell 
fusion.
5.4.4 Engraftment of Y-positive cells into various cell types
5.4.4.1 Engraftment in CD45-expressing celis
To identify preferential location of potential infiltrating donor-derived CD45- 
expressing lymphocytes and to identify possible peripheral blood 
microchimerism in the transplant patients, immunohistochemistry for the 
pan-leukocyte antigen CD45 and combined CD45-immunohistochemistry 
and Y-FISH were performed on selected tumour sections.
CD45-positive cells were rarely detected dispersed within the tumours, but 
mostly surrounding the tumours and infrequently in separate small pockets 
within the tumours (Figure 5.5). When 1880 cells from 10 separate tumours 
were examined, no peripheral blood microchimerism was found as only 2 
double-positive cells were detected overall.
5.4.4.2 Engraftment in epitheiial cells
The epithelial nature of donor-derived cells was indicated by the large, 
round morphological phenotype typical for epithelial cells. By combined 
immunohistochemistry for pan-cytokeratin antigen expression, combined 
with Y-FISH, we were able to confirm that Y-positive cells can be of 
epithelial nature (Figure 5.6, pg.192). Epithelial Y-positive cells were seen 
sporadically distributed both, in the normal epithelium, and in epithelial 
tumour cells with AK/BK sampled harbouring a particularly low percentage 
of Y-positive cells. No significant difference was seen between the 
percentage of incorporated cells in BCCs (4.2±0.9%), SCCs (5.7±1.7%), 
CIS (4.0±1.7%) and normal epithelium samples (6.5±1.2%). AK/BK 
samples showed an average Y-positive percentage of 0.6±0.5% of all 
epithelial cells. This fraction differed significantly from BCCs (P=0.015),
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SCCs (P=0.031) and normal epithelium (P=0.0054). Again, no clusters of 
Y-positive cells were observed.
5.4.4.3 Engraftment in stromal myofibroblasts
Immunohistochemistry for a-SMA combined with Y-FISH showed that 
male-derived cells contribute to stromal myofibroblasts in a sporadic 
fashion (Figure 5.7, pg.193). Percentages of Y-positive cells among a- 
SMA-expressing cells were found in the range of 13.5-15%. There was no 
significant difference between the different tumour types, and thus, the 
average engraftment could be determined as 14.1 ±1.1% The identity of the 
engrafted cells could also be confirmed by their elongated, flat morphology.
5.4.4.4 Engraftment in endothelial cells
Using the same technique, Y-positive cells were found in cells expressing 
the endothelial marker CD34. However, this was an extremely infrequent 
event, only seen in 2 of 300 counted cells. CD34-positive cells can be 
observed as blood-vessel forming tissue components, but also as single 
cells distributed throughout the tissues. These could represent infiltrating 
haematopoietic stem cells or stem cells within the skin, since CD34 has 
also been implicated as a putative marker for keratinocyte stem cells. In our 
observations, we only detected Y-positive cells within the vessel-associated 
CD34-cells, but never amongst the single CD34-positive cells (Figure 5.8, 
pg.194).
5.4.4.5 Susceptibility o f engrafted cells to HPV infection
The proneness of transplanted patients to HPV-infections was confirmed by 
immunohistochemistry. Y chromosome-positive cells were seen amidst 
HPV-infected areas and the combined staining technique confirmed that 
the engrafted cells are as susceptible to HPV-infection as their surrounding 
recipient-microenvironment (Figure 5.9 A,B, pg.195).
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5.4.4.6 Engrafted cells are not proliferative
The proliferation marker Ki-67 was used to identify actively dividing cells 
within the sections (Figure 5.9, pg.195). Immunohistochemistry clearly 
showed proliferating cells in all tested sections. Although Y chromosome- 
positive cells were observed in the tested sections, they were never found 
to express Ki-67 and thus appeared not to be proliferative.
5.4.5 The engraftment in different tumour components
An overall comparison between the contributions of donor-derived cells to 
different tumour components and the normal epithelium revealed that the 
average percentage of contributing cells is similar within the tumour 
epithelium and normal epithelial cells, amounting to averages of 4.7±0.8% 
and 6.5+1.2% respectively. However the contribution of Y-positive cells to 
stromal myofibroblasts was 14% and thus, significantly different to the 
tumour (P<0.0001) and normal epithelium (P=0.001) (Figure 5.10, pg.196).
5.5 DISCUSSION
5.5.1 Donor cell engraftment in different types of post-transplant skin 
tumours
In this study, we have shown that donor-derived cells stemming from solid 
organ transplants can engraft into post-transplant skin tumours to varying 
degrees. Of 176 post-transplant examined skin tumours, 18.75% showed 
evidence of Y-chromosomal genetic material, distributed among 46% of the 
tested renal transplant recipients. If Y chromosomal DNA was detected in 
one lesion, typically, other tumours of the same patient also showed donor 
cell-incorporation. We showed that presence of donor-derived cells is not 
dependent on tumour type or degree of malignancy, which is consistent 
with observations from a previous smaller-scale study by Aractingi et a i
(2005), who found Y-chromosomal DNA in approximately 50% of examined 
tumours with no significant difference between different tumour types.
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5.5.2 The percentage contribution of Y-positive cells to entire
tumour sections
Through highly sensitive qPCR, it was possible to detect as little as 
4/15,000 Y-chromosome positive cells. The resulting average frequency of 
Y-positive cells in the total cell mass of the examined tumour sections 
ranged between 0.024% - 10.68%, which is in accordance with previous 
studies investigating donor cell engraftment in the healthy epidermis after 
BM transplantation in mice (Brittan et al. 2005). When the contributing 
percentages of Y-positive cells were compared among the different tumour 
types, a significantly higher quantity of Y-positive cells could be detected in 
malignant compared to non-malignant tumour types. These results stand in 
contrast to findings from the previously mentioned study by Aractingi et al., 
which could not detect a difference in engraftment between the different 
tumour types. The signifantly higher number of tumours studied in our 
project likely represents a more accurate reflection and statistical relevance 
of this issue.
Notably, our results were obtained by performing PCR on extracted DNA 
from entire tumour sections, which includes several different cells types, 
including stromal, inflammatory, dermal and adipose layers, as well as 
healthy epidermis. Thus, to more accurately examine the engraftment of Y- 
positive cells with respect to preferential location and tumour components, 
histology-based examination methods were used, such as 
immunohistochemistry and FISH.
5.5.3 Location and cell-type specificity of engrafted Y-positive cells
All tumours that upon qPCR presented with a percentage of Y 
chromosome-containing cells of >1% were examined by XY-FISH and 
invariably showed Y-chromosome-containing cells incorporated as single 
cells, interspersed throughout the sections. In no instance could we find 
evidence for cell fusion by cells containing more than one Y chromosome. 
Cell fusion has been implicated as a mechanism for BM cell-engraftment in 
the liver, but has not been observed in most other epithelia. Even, if fusion 
events were followed by reduction divisions, this would likely not be
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completed in all cells and traces of such a mechanism, such as incomplete 
resolution should be apparent in some of the examined cells. Thus, we 
conclude that fusion is not the mechanism by which Y-positive cells engraft 
into post-transplant skin tumours of female recipients of male kidney 
allografts.
The dynamics of tissue hierarchy imply that clone sizes of donor-derived 
cells reflect the hierarchical position of the original engrafted cell. That is, if 
a cell engrafts and acts as a stem cell, it is capable to give rise to larger 
and more diverse clones of descendant cells than more committed transit 
amplifying cells, and logically, if it incorporates as a terminally-differentiated 
cell, it will remain a single cell of donor-origin in the tissue. Thus, according 
to our observations, donor-derived cells contribute as terminally 
differentiated cells to the tumour mass and tumour stroma of post­
transplant skin tumour patients.
5.5.4 The donor-origin of engrafted cells
The infrequent and dispersed nature of the Y-positive cells rendered it a 
difficult task to confirm whether the origin of the engrafted cells lies within 
the transplanted organ. Previous blood transfusions from male donors 
could have resulted in haematopoietic chimerism in the patients and be the 
source of Y-positive cells within the tumours. It has also been argued that 
foetal microchimerism from previous male pregnancies could result in the 
systemic distribution of Y-positive cells in the transplant patient and thus 
result in the engraftment in multiple tissues. In fact, male cells originating 
from male pregnancies as long as 20 years earlier have been detected in 
the liver and other tissues of females (Johnson et al. 2002, O’Donoghue et 
al. 2004). Previous studies have only marginally dealt with this issue. Bodo 
et al. (2005), proved the donor-derived nature of an entire leukemic clone in 
a liver-patient by immunohistochemistry for a donor-specific HLA-antigen, 
but other studies claiming the donor-derived nature of entire post-transplant 
tumours were unable to prove this, due to unavailability of donor 
information.
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However, several studies used the epidermal engraftment of Y-positive 
cells in transplanted female/female transplant patients with a known history 
of previous male pregnancies as a control and could not detect any Y- 
positive cells (Jiang et al. 2004). Additionally, several recent studies have 
shown that haematopoietic microchimerism is not a frequent event after 
peripheral blood transfusions and mostly transient and restricted to patients 
with graft-versus-host-disease (GvHD) (Collins etal. 1993).
To test for the occurrence of microchimerism and additionally to exclude 
infiltrating leukocytes from the cell counts of incorporated cells, we 
examined CD45-expressing cells for Y-positive cells. The number of Y- 
positive cells within this population was extremely low, indicating that 
microchimerism from previous obstetric history or blood transfusions was 
not present in the tested samples and thus, any Y-positive cells in the 
tumours are likely from the transplanted organ.
These findings are also supported by our observations on CD34-expressing 
cells. However, CD 34-expression is associated with endothelial cells, as 
well as with stem cells. In the haematopoietic system, it has been known for 
many years that CD34 is a stem cell marker (Berenson et al. 1988). It also 
marks dermal stem cells residing in the bulge of the hair follicle in canine 
and murine skin (Tumbar et al. 2004, Pascucci et al. 2006). Moreover, 
recently it was shown that CD34- expression by hair follicles is required for 
skin tumour development in mice (Trempus etal. 2007).
The fact that we could not detect Y-positive cells among the single CD34- 
expressing cells -  possibly representing haematopoietic stem cells -  may 
indicate an absence of haematopoietic chimerism in these patients and 
also suggests that engraftment does not occur in CD34-positive stem cell 
niches in the skin.
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5.5.3 Cell type-specific engraftment
Previous research has examined the engraftment in epithelial or stromal 
tumour compartments, but rates of engraftment were never directly 
compared and differences between cell lineages have never been 
established. Combined immunohistochemistry and Y-FISH, together with 
morphological examination helped us to determine that donor-derived cells 
incorporate into epithelial cells in skin tumours and the normal epidermis, 
as well as into stromal myofibroblasts. Infrequently, donor-derived cells 
were seen incorporated into blood vessels. However, no evidence has 
been found for the incorporated cells to proliferate and thus to contribute to 
tissue homeostasis on an active and permanent basis.
According to our results, there is a preference for donor-derived cells to 
engraft into the tumour stroma compared with epithelial cells. This could 
either reflect a differential affinity resulting in the migration of donor-cells to 
stromal cells as a response to biochemical cues, or it could represent an 
effect of different rates of cellular turnover.
We also observed a significant difference in the amount of donor-derived 
cells between malignant and premalignant tumour epithelial cells, and 
interestingly, the higher engraftment seen in malignant skin tumours is also 
observed in the normal skin. The reason for this phenomenon is unclear, 
but may also lie in different biochemical cues triggering engraftment or 
cellular turnover.
5.5.4 Mechanisms for donor cell-engraftment in post-transplant skin 
tumours
Several pieces of evidence exist in the literature reporting on post- 
transplant tumours that appear to be completely donor-derived. There are 
several possible mechanisms for the development of these donor-derived 
cancers. 1) Donor-derived cells transform to become cancer progenitors 
prior to entering the host; 2) donor cells undergo neoplastic transformation
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in the host and then engraft in the skin as cancer-originating cells; 3) donor- 
derived cells transform after their engraftment into stem cell niches in the 
skin and adopt cancer stem cell characteristics influenced by their new 
immediate environment, including HPV infections.
An important study by Houghton et al. (2004) provides evidence for the 
latter scenario. In mice, chronic infection with Helicobacter felis resulted in 
a completely BM-derived gastric cancer, which suggested to the authors 
that chronic inflammation caused ablation of tissue-resident stem cells, 
whereupon they are replaced by BM-derived cells, which then, acting as 
the new tissue-resident stem cells, have the sufficient lifespan to be 
transformed into CSCs. This indicates that chronic inflammation and the 
loss of tissue stem cells is a prerequisite for the occurrence of donor- 
derived tumours. Indeed, acute inflammation and transient injury did not 
result in donor-derived tumours in this mouse model. Although HPV- 
infection was a common occurrence among the post-transplant tumours in 
our study, this viral infection does not result in inflammation and detrimental 
tissue degradation resulting in stem cell loss.
In humans, although the engraftment of donor-derived cells has been 
repeatedly reported, very few convincing examples exist of donor-derived 
tumours. Most donor-derived malignancies were of haematopoietic nature. 
In the haematopoietic system, stem cells do not home to a locally restricted 
niche which may facilitate the engraftment of donor cells as stem cells and 
thus as potential long-lived transformation-prone cancer stem cells. 
Aractingi et al. provided the first and only observation of a Y-positive solid 
tumour in a kidney transplant patient (Aractingi et al. 2005). However, no 
donor-information or information regarding potential blood microchimerism 
in the patient was available.
It is difficult to determine the cell type of origin of the engrafted cells. Most 
studies reporting donor-derived cells in post-transplant tumours report of 
BM-transplant recipients. The ability of haematopoietic cells to move freely 
systemically makes them likely candidates for transdifferentiation and
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engraftment. Engrafted cells after solid-organ transplants could either stem 
from cell populations within the grafted organs capable of plasticity, or -  
more likely- from haematopoietic cells carried over with the grafted organ.
We thus propose a mechanism, whereby haematopoietic cells can be 
carried over with the grafted organ where they may transiently circulate 
within the blood stream and thoughout tissues as infiltrating leukocytes, 
thereby achieving a systemic distribution. Microenvironmental cues can 
trigger these cells to explore their plastic potential and to transdifferentiate 
into the cell type with which they are surrounded. In this fashion, donor- 
derived cells are capable of sporadically engrafting into various tissues of 
the transplant recipient and contributing to tissue reconstitution by 
responding to environmental cues and mimicking the cell types that are 
needed at that particular moment. Cogle and colleagues recently made a 
similar observation, also reaching the conclusion that the engrafted cells 
may behave in the form of cell mimickry, rather than playing an active and 
dynamic p^rt in the tissues they engraft in (Cogle et al. 2007).
5.6 CONCLUSION
In summary, our comprehensive study to investigate donor cell-engraftment 
into skin tumours of kidney transplant recipients revealed that donor- 
derived cells engraft into tumour and normal epithelial cells and the tumour 
stroma, whereby the stromal contribution is markedly enhanced. We could 
not detect peripheral blood microchimerism as evidence for previous blood 
transfusions or male pregnancies and thus inferred the donor-derived 
identity of the engrafted Y-positive cells. Donor-derived cells were only 
seen as sporadically-distributed cells, never seen in clusters or as 
proliferating cells, and thus we conclude that in a normal setting, in the 
absence of chronic inflammation, donor-derived cells from kidney 
transplants are not likely to engraft as stem cells when triggered to engraft 
into the skin or skin tumours of the recipients.
185
|  60 
I 50
■ s 40
"  20 
|  10
I  0
Percentage of Y chromosome-containing tumours
from each transplant patient
2 2
842 2 7 7 7
-  ---
e—
—
18 c
6 r 11 '— —
9
t H
9
TT
O' O' O &  V* N* 0  a> 'V*/  /  /  /  /  yyyyy yyyyyy<r <r <r <r <r  ^ y y y y y y y <y <y y
Figure 5.1a. The percentage of post-transplant skin tumour samples in 
which Y-chromosomal material was detected for each patient who displayed 
Y-containing tumours. Y chromosomal DNA was determined by qPCR for 
SRY-specific sequences. Number of samples is indicated above bars.
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Figure 5.1b. (A) Percentage of tumours containing Y-chromosomal 
material in different post-transplant tumour types. Red segments indi­
cate Y-positive percentage, yellow segments indicate Y-negative per­
centage. (B) Percentage of tumours containing Y-poitive cells accord­
ing to stage of of tumour development. Number of samples are indi­
cated above bars.
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Figure 5.2. (A) Percentage of cells containing Y chromosomal 
DNA in different types of post-transplant skin tumours. (B) Per­
centage of cells with Y-chromosomal DNA in malignant and pre­
malignant tumours. Amount of Y chromosome-positive cells de­
termined per 50 ng of DNA. Asterisks indicate statistical signifi­
cance.
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Figure 5.3. (A,B) SCC of a male patient. (C,D) BCC of a male patient.
(A,C) H&E staining confirming histology. (B,D) Sections showing DAPI- 
stained nuclei. (i,ii,iii,iv) Tumour areas marked by white squares in (B), mor­
phologically representing (i.iii) tumour stroma and (ii.iv) epithelial tumour 
components shown in higher magnification to visualise sex chromosomes 
detected by XY-FISH. Y-chromosomes visualised by red probe, X-chromo- 
somes visualised by green probe.
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Figure 5.4. (A,C,E,G) H&E stained sections of different tumour types contain­
ing Y-positive cells. (B,D,F,H) XY-FISH on corresponding serial sections to visu­
alise cells containing Y chromosomes. Y-chromosome visualised by red probe, 
X chromosome visualised by green probe. No cell fusion is observed.
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Figure 5.5. (A, B) Immunohistochemistry for CD45 to show location of in­
filtrating leukocytes. CD45-positive cells, labelled by vector red, appear in 
distinct compartments (A) within and (B) outside the lesions and are of dif­
ferent morphology than the large epithelial cells comprising the lesions. (C) 
Combined immunhistochemistry and Y-FISH shows Y-chromosome positiv- 
ity among some of the CD45-positive cells (arrows), in an area distinct from 
the Y-positive CD45-negative cells of different morphology. Y chromosome 
probes are FITC-labelled, CD45 is detected by vector red (red). (D) Per­
centage of Y-positive cells amongst CD45-expressing cells. A correction 
factor of 1.4 was applied to the counted cell numbers to reach final percent­
age.
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Figure 5.6. Combined fluorescent immunohistochemistry for cytokeratin (red) 
and Y-FISH (green) to show donor cell engraftment in epithelial cells in (A) squa­
mous cell carcinoma (SCC); (B) normal epithelium; (C) basal cell carcinoma 
(BCC). Double-positive cells are marked with white arrows. Note the donor- 
derived cell of elongated morphology in the adjacent cytokeratin-negative tissue 
component in (C) (yellow arrow). (D) Percentage of engrafted donor cells among 
cytokeratin-positive cells in different types of post-transplant skin tumours and 
normal epithelium. Differences in engraftment between BCC, SCC, and carci­
noma in situ (CIS) are not significant, but are statistically significant compared to 
actinic and bowenoid Keratoses (AK/BK). P values are indicated where statistical 
significant differences apply
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Figure 5.7. Combined immunohistochemistry for a-SMA (red) and Y-FISH 
(green) to show donor-derived stromal myofibroblasts. (A) Percentages of Y- 
positive myofibroblasts amongst different types of post-transplant skin tumours. 
Differences are not statistically significant. (B) Fluorescent immunohistochemis­
try showing a-SMA-positive myofibroblasts and DAPI-stained nuclei. (C) Magni­
fication of area indicated by white square in (B) showing Y-positive myofibroblast. 
(D) Double-positive cell from a different post-transplant skin tumou
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Figure 5.8. Combined immunohistochemistry for CD34 (red) and Y-FISH 
(green). (A) Typical staining profile. Y-positive cells are seen in the surrounding 
structures (indicated by white arrows), but very rarely amongst CD34-expressing 
cells. (B) Double-positive cell within vessel-like structure (indicated by white 
arrow). (C) Double-positive sporadic cell in male control, not appearing to be part 
of a blood vessel.
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Figure 5.9. (A,B) Two representative sections of combined immunohistochem­
istry for HPV (red) and Y-FISH (green) to show donor-derived HPV infected cells. 
Y-positive cells are observed sporadically in HPV-infected areas, double-positive 
cells are marked by white arrows. (C,D) Combined immunohistochemistry for 
Ki-67 (red) and Y-FISH (green) to show proliferating donor-derived cells. No 
double positive cells were found. Note the surrounding Ki-67-negative cells.
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Figure 5.10. Percentage of Y positive cells among various tissue compart­
ments. differences between tumour and normal epithelium is not statistically sig­
nificant, wheras the differences between the stroma and the other tissue compo­
nents are statistically significant (statistical significance marked by asterisks and 
p values).
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Table 5.1
Distribution of Y-positive cells among different types of skin tumours in
kidney transplant recipients
■
Malignant Basal Cell Carcinoma 
(BCC)
17 48 11 0.05-
10.68%
2.54±1.21%
Squamous Cell Carcinoma 
(SCC)
23 47 7 0.02- 3.93% 1.48±0.62%
Porocarcinoma 3 3 0 N/A N/A
Pre­
Carcinoma in situ (CIS) 17 43 8 0.06- 2.32% 0.76±0.31%
malignant Actinic/Bowenoid Keratosis 
(AK/BK)
16 26 7 0.09- 3.52% 1.32±0.48%
Lentigo Maligna 1 1 0 N/A N/A
Dysplastic Warts 3 3 0 N/A N/A
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CHAPTER VI
THE EFFECT OF LOCAL MICROENVIRONMENT AND 
GENETIC PREDISPOSITION ON CANCER DEVELOPMENT 
IN A MOUSE MODEL OF SKIN CARCINOGENESIS
6.1 INTRODUCTION
6.1.1 BM transplantation and plasticity
The plasticity of transplanted BM cells and their capability to engraft into 
multiple tissues has been well documented in mice, as well as in humans 
and is described in more detail in section 1.8. The factors, which trigger BM 
cells to transdifferentiate and home to the new microenvironment are 
unknown. Nevertheless, the fact that stem cell plasticity is also observed in 
adult tissues challenges the notion that stem cell pluripotentiality is a 
feature exclusive to embryonic stem cells. This presents a new outlook on 
regenerative medicine as adult stem cells are devoid of the ethical 
difficulties associated with the use of their embryonic counterparts.
The extent of engraftment varies between different studies and tissues, is 
enhanced by injury and appears to reflect the turnover-rate of the tissue of 
destination. Cell fusion has been attributed to the mechanism involving BM 
cell incorporation in some cell lineages, such as hepatocytes, skeletal and 
cardiac muscle, epithelial and Purkinjie cells (Wang et al. 2003, Willenbring 
et al. 2004, Camargo et al. 2003, Nygren et al. 2004, Spees et al. 2003, 
Weimann et al. 2003), but these observations have been subject to debate 
and could not be confirmed in most other tissues.
The BM contribution to the normal mouse skin is 1-7%, appearing as 
sporadic cells without any evidence for cell fusion (Krause et al. 2001, 
Brittan et al. 2005, Korbling et al. 2002, Badiavas et al. 2003, Harris et al.
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2004, Kataoka et al. 2003). In areas of injury, engraftment is enhanced up 
to 13% and has been observed in known stem cell niches such as the 
epidermal proliferative units (EPU) of the skin and in distribution patterns 
that suggest an origin in a common ancestor, i.e. a stem cell (Fathke et al. 
2004, Brittan etal. 2005).
If transplanted cells engraft as stem cells in a tissue, they potentially have 
the longevity and proliferation capacity to form fully donor-derived tumours. 
In accordance with this theory, Houghton et al. (2004) showed BM-derived 
gastric cancer in a mouse model of chronic inflammation. Tumours entirely 
composed of donor-derived cells have also been reported in humans. 
Donor-derived haematological malignancies have been seen after BM and 
solid organ transplantation (Papadopoulos et al. 1994, Bodo et al. 2005, 
Barozzi et al. 2003). One case of a donor-derived solid tumour (BCC) after 
solid organ (kidney) transplantation has been described (Aractingi et al. 
2005). However, unavailability of donor-specific information made it 
impossible to rule out an origin in haematopoietic cells stemming from 
earlier blood transfusions. In contrast with these observations, other 
researchers never found fully donor-derived tumours post-transplant 
neoplastic lesions in either humans or mice, and suggested that the 
sporadic contribution of donor-derived cells represents a form of cell 
mimicry by the donor-derived cells (Cogle et al. 2007).
6.1.2 Effect of local microenvironment on transplanted cells
The incorporation of transplanted cells into various tissues of the recipient 
raises the question to what extent the incorporated cells may be influenced 
by their new immediate environment and vice versa. For example, if the 
incorporated stem cells carry a genetic predisposition to neoplastic 
transformation, are they able to engraft into the tissue of destination as 
cancer stem cells and generate a cancer in the host? Similarly, in a pre­
disposed host, will the engrafted cells merely transform as part of the 
cancerous lesion or are they able to influence the local surroundings as a 
result of the normal genetic information they carry? If genetic predisposition
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in a transplanted cell has an impact on the host, a new risk associated with 
transplantations is presented. On the other hand, an immediate influence of 
incorporated cells might also facilitate new exciting therapeutic approaches.
The immediate cellular environment with its biochemical cues clearly exerts 
a strong influence on an engrafted BM-derived cell. It primes the cell to 
adopt new functions inherent to the new resident tissue and in the case of 
stem cells to give rise to differentiating cells. The impact of the immediate 
cellular environment is highlighted in the event of chronic inflammation, 
where it has been shown that intercellular factors such as adhesion 
molecules or cytokines are ultimately responsible for malignant 
transformation.
Importantly, transplanted cells have also affect their immediate 
surroundings. In a mouse model of colitis, transplanted BM-derived cells 
were able to alleviate the symptoms and contribute to epithelial healing 
(Bamba e{ al. 2006). Similarly, in a rat model of myocardial infarction 
incorporation of BM-derived cells significantly improved cardiac function (de 
Macedo Braga et al. 2007). This suggests that the effects between 
incorporated cells and their local microenvironment are reciprocal, and 
similarly challenges the notion of incorporated cells merely contributing to 
their destination tissue in the form of cell mimicry.
6.2 AIMS
In this study, we aimed to investigate whether genetically predisposed 
transplanted cancer stem cells are influenced by their immediate 
surroundings, and to simultaneously investigate whether transplanted 
normal cells can counteract a genetic predisposition to cancer. Additionally, 
our intention was to monitor the extent of engraftment of BM cells into the 
normal and wounded skin, as well as into cancerous lesions. Finally, this 
study was carried out to test whether there is preferential cell type-specific 
engraftment and whether the engrafted cells are functional or just mimic 
their immediate environment.
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6.3 METHODS
All methods are outlined in detail in chapter II.
6.3.1 Mouse strains
The mouse strains used for BM transplantations were either C57/ Black 6 
wild type (wt) mice or transgenic mice with genomic incorporation of the 
complete early region of the cutaneous human papillomavirus 8 (HPV8) as 
described in chapter II, section 2.3.3.1. HPV8 transgenic mice develop 
single or multifocal epidermal lesions with a median age of tumour 
development of 8.4 weeks. 91% of the developing tumours are benign with 
the potential to proceed to moderate or severe epidermal dysplasia. 
Squamous cell carcinomas (SCC) arise in 6% of HPV8 mice (Schaper et al. 
2005).
6.3.2 BM transplantation
Six week-old female recipient mice were lethally iradiated, followed by tail 
vein injection of variable amounts of whole BM cells from male mice. 
Details of transplanted experimental groups are described in chapter IE, 
Table 2.3. All mice were culled by CO2 inhalation and cervical dislocation 
20 weeks post-transplant or when tumour burden was unbearable 
(exceeding the threshold diameter of 20 mm or multiple tumour foci). 
Epidermal lesions, as well as sections of unwounded and wounded skin 
were fixed in NBF and embedded in paraffin.
6.3.3 Cutaneous wounds
Four weeks post-transplantation, two cutaneous wounds of 3 mm diameter, 
were made to the dorsal skin of the mice in the groups indicated in chapter 
II, Table 2.4. Mice were killed 20 weeks post-transplant or when tumour 
burden was unbearable (exceeding the threshold diameter of 20 mm or 
multiple tumour foci).
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6.3.4 Y-FISH
Sections were dewaxed, permeabilised in 1 M sodium thiocyanate, and 
digested in 0.4% pepsin at 37°C for 20 min. They were then fixed in PFA 
and dehydrated through alcohol gradients. A fluorescent probe against the 
mouse Y-chromosome, directly conjugated to a FITC-label was applied, 
sections were hybridised at 60°C, incubated overnight at 37°C and 
mounted in medium containing DAPI.
6.3.5 Combined immunohistochemistry and FISH
Sections were dewaxed and subjected to a three-step 
immunohistochemistry protocol using the strept-AP detection system. Final 
detection was carried out with the Vector Red Alkaline Substrate Kit 1 
(Vector Laboratories). Primary antibodies used were to detect pan- 
cytokeratin, SMA, CD31, and Ki-67. The immunohistochemistry protocol 
was immediately followed by in situ hybridisation for the Y-chromosome as 
described above. Where antigen retrieval was performed during the 
immunohistochemistry protocol, digestion times were adjusted to 2 min.
6.3.6 Statistical analysis
Statistical analyses were conducted using Mann-Whitney and Kruskal- 
Wallis analyses with Dunn’s post-test for non-parametric data and the 
Student’s two-tailed t-test for parametric data where appropriate (Prism, 
GraphPad, San Diego). A probability (P) value of <:0.05 was taken as an 
appropriate level of significance.
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6.4 RESULTS
6.4.1 Tumour development
We observed development of skin lesions in HPV8 transgenic mice with an 
average latency of 9 weeks. This was in accordance with previous reports 
concerning the HPV8 phenotype. Most lesions developed as multifocal 
papillomas with the tumour burden exceeding the permitted threshold 
before they could progress to further degrees of malignancy (Figure 6.1, 
pg.208).
Tumour development was specific to HPV8 transgenic mice. Wt type mice 
did in no instance develop skin lesions within the experimental period of 5 
months, irrespective of the genotype of BM they received and the post­
transplant treatment (Table 6.1, pg.216). The type of BM administered 
influenced the latency of tumour development significantly (P=0.0411) 
(Figure 6.2A, pg.209). Unexpectedly, recipients of wt BM showed the first 
signs of skin lesions on average 3 weeks earlier than recipients of HPV8 
BM. This indicates, that the type of donor BM may influence the genetically 
pre-determined phenotype.
Post-transplant treatment in the form of epidermal wounding also had an 
impact on the latency of tumour appearance in the tumour-developing 
HPV8-transgenic recipient mice (Figure 6.2B, pg.209). Groups that were 
wounded 3 weeks after BM transplantation developed tumours at around 
7.8±0.8 weeks, which was significantly earlier than the 10.7+0.9 weeks in 
non-wounded groups (P=0.041). In wounded mice, tumours preferentially 
developed in the previously injured area.
6.4.2 Extent and location of engraftment of donor-derived cells
Y-FISH revealed the incorporation of donor-derived cells into the normal 
skin and skin tumours of BM recipient mice. Engraftment was seen in the 
normal epithelium, and both the bulk of the skin tumours and the tumour
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stroma, mostly in small clusters of cells and as sporadically incorporated 
cells with a different rate of incorporation in each part of the tissue (Figure 
6.3, pg.210). Male control samples showed that approximately 25% of all 
nuclei could not be labelled by Y-FISH as a consequence of inaccessibility 
of nuclei due to orientation or cutting. Therefore, a correction factor of 1.3 
was applied to account for the potential underestimation upon counting of 
Y-positive nuclei.
The genetic background of the recipient mice and BM type did not influence 
the degree of engraftment. Mice that were subjected to epithelial injury 
showed a significantly higher incorporation of donor-derived cells in all 
tested tissue components and across all experimental groups (Figure 6.4, 
pg.211). Donor-derived cells engrafted into normal epithelia distributed 
sporadically throughout the epithelial layers, contributing 2.5-11% of all 
epithelial cells. The epithelial components of the skin tumours showed a 
greater fraction of donor-derived cells, amounting to 6-26%. The highest 
percentage of donor-cell incorporation was observed in the tumour stroma, 
with up to 38% of stromal cells showing Y-positivity and thus being of 
donor-origin. Whereas there were no significant differences between the 
experimental groups comprising the wounded and non-wounded fractions, 
wounding had a significant impact on engraftment in all tissue components. 
After wounding, significantly higher amounts of Y-positive cells contributed 
to normal epithelia (P=0.0002), epithelial tumour cells (P=0.0022), and 
tumour stroma (P=0.0006) when compared to the non-wounded 
counterparts.
6.4.3 Identity of engrafted cells
A technique combining Y-FISH with fluorescent immunohistochemistry 
against cell-type specific antigens was employed to reveal the identity of 
the engrafted donor-derived cells, whereby the resulting observations 
confirmed the results obtained upon Y-FISH and morphological analysis. Y- 
positive cells of epithelial nature (expressing cytokeratin) were observed 
sporadically distributed (Figure 6.5, pg.212). Donor-derived cells were also
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capable of engrafting as stromal cells, identified through their expression of 
a-SMA (Figure 6.6, pg.213). Moreover, we observed sporadic donor-cell 
incorporation in the vascular components of the tumour lesions, marked by 
their expression of the endothelial surface antigen CD31 (Figure 6.7, 
pg.214). Ki-67, a protein expressed specifically in actively proliferating cells 
has also been found to be expressed in donor-derived cells, indicating that 
the donor-cells engraft as functional and dividing cells (Figure 6.8, pg.215). 
Notably, all these observations were not dependent on the type of BM 
administered (i.e. HPV8-positive or wt).
6.5 DISCUSSION
6.5.1 Engraftment of BM cells in epidermis
In this study, we confirmed that transplanted BM cells engraft into the 
normal epidermis, skin tumours and their surrounding stroma in a functional 
and proliferating manner in the absence of cell fusion. Expression of cell 
type-specific surface markers confirmed that the cells fully 
transdifferentiated, suggesting that the engraftment did not merely 
represent a form of cell mimicry.
The stromal components showed a higher efficiency of donor cell- 
engraftment than both the tumour and normal epidermal tissue 
components. This is consistent with previously published reports, showing 
preferential BM engraftment into the stroma of pancreatic tumours, but 
rarely in the tumours themselves (Direkze et al. 2004). Although we 
detected a slightly larger percentage of engrafted cells in the skin tumours 
than in the normal epidermis, this was statistically not significant.
It is well known that injury increases the rate of engraftment of BM-derived 
cells. This was confirmed by our results. Epithelial injury also decreased the 
latency of tumour appearance. However, there was no correlation between 
wounding and transplanted BM type.
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6.5.2 Effect of transplanted cells on tumour development
In the literature, it has been proposed that donor-derived cells stemming 
from BM transplantations, and even from solid organ allografts, could give 
rise to entire post-transplant cancers in humans (Barozzi et al. 2003, Bodo 
et al. 2005, Aractingi et al. 2005). In mice, Houghton and colleagues (2004) 
have demonstrated BM-derived gastric cancer upon H.felis infection. Based 
on these studies, two possibilities for tumour development were proposed. 
The transplanted cells could have carried a predisposition for cancer 
development and thus presented an inherent risk of transplantation, or the 
transplanted cells could have engrafted in the tissue as sporadic cells, 
undergoing transformation at the site of engraftment. This raises two 
important issues: 1) does transplantation of genetically pre-disposed cells 
present an increased risk for the recipient to develop cancer? 2) Can 
engrafted healthy cells have a positive effect on their genetically- 
predisposed surroundings and thus be explored for therapeutic purposes?
In this study, we could not detect an effect of engrafted donor-derived cells 
on their surroundings. The expected outcome phenotype of the recipient 
mice was not reversed or decreased by BM transplantation of cells with a 
different genetic predisposition. For example, although donor-derived 
HPV8-positive cells engrafted as functional cytokeratin-expressing and 
actively proliferating cells into the recipients’ epithelia, wt mice did in no 
instance develop skin lesions. It is conceivable that the experimental 
course of 5 months was not sufficient time to allow the recipient cells to 
show the full extent of their influence on their surroundings. But 
interestingly, injection of HPV8 mice with wt BM did not even retard the 
development of the resultant phenotype. On the contrary, the latency of 
tumour formation was decreased compared to the control group recipients 
of HPV8-BM. This might be due to adverse physiological reactions and 
recognition of the genetically different BM.
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We could not detect an adverse effect of engrafted transgenic cells on their 
new surroundings. Similarly, we could not find reason to suggest that a 
genetically predisposed environment stimulates transformation of newly 
engrafted cells to cancer stem cells, giving rise to cancerous clones. In fact, 
no patterns of donor-derived cells were observed that would suggest 
common ancestry, which renders it unlikely that donor-derived cells 
engrafted in stem cell niches or assuming stem cell function. The absence 
of entire tumours or larger clones derived from donor-derived cells 
indicated that genetic predisposition might not present an additional risk 
factor to transplantation medicine. Additionally, this suggests that external 
factors such as UV exposure are responsible for triggering transformation 
after engraftment.
6.6 CONCLUSION
It has been previously suggested that donor-derived cells could be the 
source of tumours in mice and in humans. We could not observe donor- 
derived skin tumours in our present transgenic mouse model of 
spontaneous skin carcinogenesis with or without the effect of acute skin 
injury. Our results suggest that transplanted cells show considerable 
plasticity and can engraft into tissues distant to their site of origin as 
functional members of the target tissue. There they may be capable of 
undergoing neoplastic transformation and act as cancer stem cells, 
particularly if they engrafted into the tissue as stem cells. However, we 
could not find evidence for the hypothesis that the genetic make-up of 
transplanted cells exert an effect on their surroundings and thus present an 
additional risk factor for transplant patients. Further research involving long­
term studies is necessary to confirm these results.
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Figure 6.1. H&E stainings showing epithelial tumours typically developed 
by HPV8-transgenic mice.
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Figure 6.2. Latency of tumour development in HPV8 transgenic mice 
measured in weeks after BM transplantation. (n=6 for each group). (A) Dif­
ferences in tumour latency were significant between HPV8 transgenic mice 
depending on administered BM (P=0.0411). Compared to the control 
groups (HPV mice receiving HPV BM), receiving wt BM decreased tumour 
latency. (B) Wounding significantly decerased the tumour latency in HPV8- 
transgenic mice (P=0.0411). Note that no tumour development occured in 
wt recipient mice, hence these groups are absent from this graph. X axis 
legend indicates ‘BM recipient/BM donor.
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Figure 6.3. Engraftment of donor-derived cells into various tissue compo­
nents. The Y chromosome is detected by green fluorescent FITC-labelled 
probe. Donor-derived cells were found in (A,B) normal epithelia, (C,D) 
tumour bulk, (E,F) stromal components. Nuclei were counterstained with 
DAPI (blue).
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Figure 6.4. Engraftment of donor-derived cells into various tissue compo­
nents with and without epithelial injury. Across all groups, wounding in­
creased the percentage of engraftment significantly (significant differences 
marked by asterisks and P values). Within the wounded and non-wounded 
groups, no significant differences were found. Collective assessment of 
wounded and non-wounded groups are shown on right hand graphs, dis­
playing significant differences. (A) Percentage contribution of donor-derived 
cells to the normal epithelium. (B) Percentage contribution of donor-derived 
cells to epithelial tumour cells. (C) Percentage contribution of donor-derived 
cells to the tumour stroma. Overall, more engraftment was seen in the 
tumour stroma than in the other tissue components.
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Figure 6.5. Donor derived cells of epithelial nature as shown by combined 
immunohistochemistry for pan-cytokeratin and Y-FISH. Cells engraft as epi­
thelial cells in a sporadic fashion (A) normal epidermis, (B,C) skin tumours. 
Epithelial donor-derived cells are marked by arrows. Cell indicated by arrow 
in (C) is magnified in inset.
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Figure 6.6. Donor-derived cells engrafted into the tumour stroma as 
shown by expression of a-SMA (red) and presence of the Y-chromosome 
(green). Outlines of cell borders are marked. Arrowheads indicate donor- 
derived myofibroblasts expressing a-SMA.
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Figure 6.7. Donor derived endothelial cells as shown by combined immu­
nohistochemistry for CD31 and Y-FISH. Cells engraft as endothelial cells in 
a sporadic fashion. Endothelial donor-derived cells are indicated by arrows.
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Figure 6.8. Donor derived cells that are actively dividing as shown by 
combined immunohistochemistry for Ki-67 and Y-FISH. Proliferating 
donor-derived cells occur throughout the entire sections and are marked by 
arrows.
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Table 6.1
Tumour development 20 weeks after BM transplantation
Recipient
Wounding No
wounding wounding
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CHAPTER VII
CLONALITY IN SKIN TUMOURS AND IMPLICATIONS FOR 
LINEAGE RELATIONSHIPS IN THE SKIN AND THE ORIGINS 
OF BASAL CELL CARCINOMAS
7.1 INTRODUCTION
7.1.1 The human skin
The skin is the largest organ in the human body. Its multilayered epthelium 
comprises the interfollicular epidermis (IFE), interspersed with hair follicles, 
sebaceous and sweat glands. The cells of the IFE and sebaceous glands 
follow a single terminal differentiation pathway to form the stratified 
cornified epithelial layer and the lipid filled sebocytes, respectively. Hair 
follicles comprise eight different cell lineages. Medullary cells lie in the 
centre, surrounded by cortical and hair cuticle cells, which are in turn 
surrounded by the three cell lineages of the inner root sheath (IRS). This is 
covered by the outer root sheath, which lies upon a companion layer 
separating the IRS and ORS (reviewed in (Watt 2002, Watt et al. 2006).
Cells are continuously shed from the epidermal surface and homeostasis is 
maintained by basally situated self-renewing stem cells (SC). Several 
distinct SC compartments have been proposed to replenish the various 
lineages (Ghazizadeh et al. 2001). However, cells from these different SC 
pools seem to retain multipotential characteristics when exposed to the 
appropriate stimuli and can be triggered to interconvert, as described in 
more detail in chapter I (Watt 1998, Panteleyev et al. 2001, Taylor et al. 
2000, Oshima et at. 2001, Reynolds et al. 1992, Ferraris et al. 1997, Miller 
et al. 1998). It appears as though under normal conditions, SCs follow their 
normal pattern of differentiation, retaining multilineage potential for 
emergency situations, such as injury or stress.
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The IFE SCs are believed to be organised in small clusters of basal 
quiescent cells surrounded by proliferative transit amplifying cells (TAC), 
which after a few cell divisions undergo terminal differentiation (Jones et al. 
1995, Jensen et al. 1999). Controversy exists about the number of SC 
populations in the hair follicle.
A widely accepted SC pool, claimed by some to be the the only one, is 
located in the hair bulge, a specialised region in the ORS (Fuchs et al. 
2001). According to the Unitarian hypothesis, bulge SCs form the ORS and 
additionally move along the ORS to the matrix of the hair bulb, where they 
function as SCs to replenish IRS and hair shaft (Kopan et al. 2002). 
Another theory, backed up by lineage tracing studies, claims that the cells 
generating the IRS lineages reside in a separate stem cell pool in the 
matrix at the base of the hair follicle, whereas the ORS is derived from 
bulge SCs (Kamimura et al. 1997, Blanpain et al. 2004, Legue et al. 2005). 
However, it is unclear whether the matrix progenitor cell represents a SC 
itself, thus separating the developmental origins of IRS and ORS, or 
whether it is merely a progenitor pool, fed from bulge SCs. The evolutionary 
origin of the companion layer and its attribution to either the IRS or the 
ORS is also subject to debate. Analysis of keratin expression patterns 
ascribed it to the IRS as its outermost layer (Gu et al. 2007).
Much research has focused on identifying markers of skin stem cells. 
Putative markers include Wnt-inhibiting factor (Wifi) and Dickkopf (Dkk3) 
(reviewed in (Watt et al. 2006)), the bulge-specific keratin 15, a6 and p1 
integrins, and as recently suggested, CD200 (Terunuma et al. 2007). CD34 
has also been explored as skin SC marker, due to its expression in the 
ORS of anagen follicles just below the ‘bulge’, a known SC zone in the hair 
follicle (Poblet et al. 1994).
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7.1.2 Skin tumours and their origins
Constant exposure to environmental assaults, such as UV radiation, 
chemicals and pollution makes the skin vulnerable to carciogenesis. 
Different types of epidermal tumours show variances in cell lineage 
differentiation, arguably reflecting the SC pool they originated from. For 
example, SCCs have elements of IFE differentiation and are thought to 
originate from the IFE SC pool. Trichofolliculomas and pilomatrichomas 
show differentiation towards the hair shaft and are thus believed to 
originate in the SC pool that gives rise to these lineages.
BCCs are the most common skin tumours in humans. Although they can be 
invasive tumours, they do not metastasise. BCCs display a homogenous 
appearance and it is conceivable that they arise from the same SC pool as 
the similar looking ORS. This relationship is supported by the fact that sonic 
hedgehog (SHH) signalling, the malfunction of which results in BCC 
development, only occurs in hair follicles.
There is evidence for a cellular hierarchy within skin tumours (reviewed in 
(Perez-Losada et al. 2003)). The now classical experiment if chemical 
tumour initiation and promotion showed that the only cells with a sufficient 
lifespan to have been present at the time of initiation are SCs (Van Duuren 
et al. 1975). In fact, SCs seem to be necessary for tumour development, 
since CD34 knockout mice fail to develop papillomas in initiation-promotion 
experiments (Trempus et al. 2007). The stem cells of the hair bulge have 
been shown as a target for UV-induced mutagenesis and the source of 
SCCs, since mice that had their IFE removed, still developed SCCs in 
response to UVB radiation (Faurschou et al. 2007).
Skin tumours are believed to be clonal lesions. Mutation tracing studies 
have shown differences in clonality patterns between different types of skin 
tumours; in particular they have revealed a link between actinic keratoses 
and SCCs, but not with BCCs. Despite a morphologically multifocal 
appearance, genetic analysis, such as X chromosome inactivation and loss
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of heterozygosity (LOH) of chromosome 9 (9q22.3), and three-dimensional 
reconstructions of BCCs have favoured a unicellular origin (Walsh et ai 
1996, Shulman et al. 2006). However, in some tumours, tracing molecular 
markers suggested polyclonality. This could indicate an independent origin 
of two or more tumours, or show subclonality following a late mutation in 
carcinogenesis (Asplund et al. 2005). SCCs are believed to harbour more 
genetic heterogeneity. Comparison of the LOH patterns in oesophageal 
SCCs has suggested that they are clonal neoplasms with a considerable 
degree of divergence and genetic progression (Shima etal. 2006)
Controversy exists regarding the origin of the stroma associated with 
BCCs. Xenograft studies have suggested that BCCs generate their own 
‘specialised stroma', interspersed with cells derived from the host, whereas 
other researchers believe that BCCs are embedded in a connective tissue 
stroma, at least in part of polyclonal origin (Stamp et al. 1988, Hales et al. 
1989, Asplund et al. 2005).
7.2 AIMS
There is much debate concerning the number of SC pools in the human 
skin and the dynamics and origins of skin tumour development. Following 
the spread of mt mutations in a variety of human skin tumours, we aimed to 
provide insight into the origins and dynamics of skin cancer development 
and additionally to shed light on the dispute regarding lineage relationships 
in the skin. To do so, we applied the techniques well established and widely 
used in our laboratory in the study of clonality and spread of mutations in 
the gastrointestinal tract to the study of the epidermis. This may provide a 
better understanding into the development, risk factors and therapy of skin 
cancer.
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7.3 MATERIALS AND METHODS
7.3.1 Patients
For this study, six patients that underwent surgical resection of skin 
tumours were selected. Specimens were snap-frozen in liquid nitrogen- 
cooled isopentane or fixed in 4% PFA and embedded in paraffin. Ethical 
approval was sought and obtained as per the requirements of the United 
Kingdom Human Tissue Act (2006), REC reference number 06/Q0603/1.
7.3.2 Immunohistochemistry
Paraffin-embedded sections were de-waxed and blocked, frozen sections 
were dried and fixed in cold acetone. After appropriate antigen retrieval for 
paraffin-embedded sections, non-specific staining was blocked by 
incubation in rabbit serum for 25 min. Sections were successively 
incubated for 35 min with anti-cytochrome c oxidase subunit 2, rabbit anti­
mouse IgG and Strep-HRP. Antibody staining was detected with DAB and 
sections were counterstained with haematoxylin.
7.3.3 Cytochrome c oxidase enzyme histochemistry
Frozen sections underwent successive histochemical staining at 37°C for 
cytochrome c oxidase and succinate dehydrogenase, the detection of the 
latter indicates absence of cytochrome c oxidase activity. Incubation in 
cytochrome c oxidase was performed until enzyme activity was optically 
detectable by brown staining. This was followed by an incubation in SDH 
incubation medium to detect succinate dehydrogenase until a blue colour 
was detectable.
7.3.4 Laser capture microdissection
Cells from cytochrome c oxidase-positive and negative areas were cut by 
laser microdissection. Cell digestion and DNA extraction was performed by 
overnight incubation in a DNA extraction kit (Picopure™) at 65°C.
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7.3.5 PCR and Sequencing
The extracted DNA was used to sequence the entire mitochondrial genome 
from microdissected areas. A two-round amplification method was followed, 
whereby the first round consisted of amplifying 9 fragments spanning the 
entire genome, and the second round consisted of 36 M13-tailed primer 
pairs to amplify overlapping segments of the first-round products. 
Sequencing was performed using the BigDye terminator cycle sequencing 
method on an ABI Prism Genetic Analyzer and compared to the revised 
Cambridge reference sequence using sequence alignment software of the 
European Molecular Biology Open Software Suite (EMBOSS).
7.4 RESULTS
7.4.1 Different types of skin tumours vary in clonality patterns
Cytochrome c oxidase enzyme activity and immunohistochemistry showed 
distinct patterns of cytochrome-deficient cells in different tumour types. 
SCCs displayed small and frequent patches of cytochrome oxidase- 
deficiency dispersed throughout the lesions. The cytochrome-deficient 
areas mostly comprised the cornified islands, and appeared as though they 
are fed from the immediate surrounding squamous cells that show distinct 
heterogeneity in cytochrome oxidase deficiency (Figure 7.1, og228). In 
BCCs, we observed a more homogeneous distribution of cytochrome 
oxidase deficiency (Figure 7.2A-E, pg.229). In most cases, the cytochrome 
oxidase-deficiency included the entire lesion, which interestingly was also 
observed to include the tumour stroma (Figure 7.3, pg.230). In one case we 
observed a homogeneous cytochrome-deficiency throughout the entire 
lesion that extended to a histologically normal ORS of a hair follicle, 
suggesting a developmental link (Figure 7.2 D,E, pg.229). However, some 
BCC sections also showed patches of cytochrome deficient areas 
dispersed throughout the lesions, albeit they were larger areas than the 
patches observed in SCCs.
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7.4.2 Cytochrome c oxidase-deficient areas share identical mutations
Comparison of the mitochondrial sequences of cells from various tumour 
areas to the revised Cambridge Reference Sequence (rCRS) revealed 
sequence variations throughout the entire mitochondrial genome. Similar to 
the observations in the gastrointestinal tract, we detected on average 
approximately 1-2 mutations per amplified DNA segment (app 400 base 
pairs). The detected sequence divergences included common 
polymorphisms published in the human mitochondrial genome database 
(Mitomap), as well as novel mutations.
Sequence comparison of mt DNA extracted from blue and brown areas of 
the tumours showed a high sequence homology. Most mutations were 
shared by various cytochrome oxidase-deficient and cytochrome oxidase- 
competent areas. However, a few mutations were identified in cytochrome 
oxidase-deficient areas, where neighbouring cytochrome c oxidase-positive 
areas displayed the wt sequence. Notably, in all tested tumours, the 
sequence .divergence was only observed between blue and brown areas, 
but we never detected sequence differences between only the blue or 
brown areas, respectively. Some of the mutations shared by cytochrome- 
deficient areas occurred in the genes coding for cytochrome oxidase 
subunits, such as the synonymous 7415 A>G mutation in cytochrome c 
oxidase subunit I in the squamous tumour (carcinoma in situ) shown in 
Figure 7.4 (pg.231). However, sequence divergences between cytochrome 
oxidase-deficient and cytochrome oxidase-competent areas did not 
necessarily occur in cytochrome c oxidase subunit genes. We also 
observed other synonymous changes, such as 13740 T>C (Figure 7.5A, 
pg.232). Moreover, mutations were also found in other mt genes, such as 
the 3313 A>C and 3363 C>A in the NADH dehydrogenase subunit 1 
(Figure 7.5B, pg.232), or the 4916 A>G transition seen in NADH 
dehydrogenase subunit 2 (Figure 7.4, pg 231). Although these changes 
most probably were not the cause of the deficiency in cytochrome oxidase, 
they show that a single mutation can be shared by various areas of the
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tumours and even persist throughout the entire tumour and possibly 
originate in histologically normal tissue areas.
7.4.3 BCCs originate from normal SCs of the ORS
One of the BCC lesions in our study showed a pattern of cytochrome c 
oxidase deficiency that not only comprised all tumour buds of the lesion, 
but also extended to a histologically normal hair follicle ORS. Mutation 
analysis revealed 2 mutations shared by all examined blue areas of the 
ORS, as well as by tumour buds from spatially distinct locations of the 
tumour, whereas adjacent brown areas showed wt sequence (Figure 7.5, 
pg.232). This indicates a common origin of the normal ORS and the BCC 
lesion.
7.4.4 Companion layer and ORS originate from different SC pools
It is an open debate whether the companion layer separating the IRS from 
the ORS evolutionary belongs to the IRS or the ORS. Here, we observed 
cytochrome oxidase deficiency throughout the outermost layer of the ORS, 
but layers beneath, including the companion layer were cytochrome 
oxidase-competent, providing evidence that the companion layer is not 
rooted in the same SC population as the ORS (Figure 7.2D,E).
7.4.5 Deficiency in cytochrome c oxidase does not affect cell function
To investigate whether the mutations that were traced in order to 
investigate tumour development confer a pathological effect on cell activity, 
cell functionality of the epithelial tumour cells was tested by expression of 
cytokeratin. Using a pan-cytokeratin antibody, we confirmed that all cells 
within the cancer are functional epithelial cells, irrespective of their 
deficiency of cytochrome oxidase. Patches that showed a deficiency in 
cytochome c oxidase activity upon the cytochrome c oxidase enzyme 
reaction, stained for pan-cytokeratin with the same level of intensity as 
observed in the cytochome oxidase-active patches (Figure 7.6, pg.233).
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7.5 DISCUSSION
7.5.1 Clonality and multiple cancer SCs in skin tumours
In this study, we observed distinct patterns of cytochrome c oxidase 
deficiency in different types of skin tumours, indicating that different tumour 
types differ in their developmental dynamics and origins. Dispersed patches 
of cytochrome oxidase-deficiency were observed in all examined SCCs. 
This intratumour heterogeneity could either indicate that SCCs generally 
have a high mutation rate during tumorigenesis, or that SCCs are of 
polyclonal origin and harbour multiple stem cells. However, the limited 
number of mt mutations and consistency thereof in all cytochrome oxidase- 
negative areas suggests that the number of founding cancer stem cells is 
limited and that cytochrome-deficient areas might be related on a three- 
dimensional level. It is also conceivable that the original initiating SC 
harboured a considerable level of heteroplasmy that was passed on in an 
imbalanced way to its progeny, resulting in a falsely perceived polyclonality. 
However, this possibility would not be recreated at such consistency in all
V
SCC samples, as observed in this study.
In BCCs, cytochrome c deficiency showed a much more homogeneous 
pattern. In the majority of tumours, the absence of cytochrome c oxidase 
extended throughout the entire lesions, suggesting a monoclonal origin. 
This uniformity was also confirmed on a molecular level, by detecting the 
same mutations in all areas of the multifocal tumours. A monoclonal origin 
could be challenged by the observation of cytochrome-deficient patches in 
some BCCs. Possible explanations of this phenomenon are the acquisition 
of mutations at later stages of tumour development, creating subclonal 
populations. It was previously suggested, that the perceived polyclonality 
could also reflect the simultaneous presence of more than one distinct 
tumour. The genetic heterogeneity could be based on heteroplasmy within 
the founding CSC. This is more conceivable than in SCC lesions as 
mentioned above, due to bigger patch sizes and the fact that most BCCs 
seem to be of monoclonal origin both, in our studies, as well as in the 
literature. Interestingly, cytochrome oxidase-deficiency in our study
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generally also included the stroma surrounding the BCC lesions. Although 
a common origin has not been molecularly confirmed yet, the consistency 
of the results obtained in all other tumour areas indicate that BCCs and 
their stroma are derived from a common ancestor. This confirms previous 
claims based on xenograft studies that BCCs generate their own 
‘specialised’ tumour stroma (Stamp et al. 1988), rather than recruiting a 
polyclonal stroma from the host as seems to be the case with most 
cancers.
Taken together, these results suggest that BCCs and SCCs follow distinct 
developmental pathways originating in separate SC pools, which is also 
reflected by tumour-specific differences in cell lineage differentiation. 
Accordingly, this suggests that BCCs are monoclonal lesions, whereas 
SCCs seem to be of polyclonal origins, stemming from several SCs with no 
sign of monoclonal conversion.
7.5.2 Mohoclonality of BCC and its origin in hair bulge SCs
The pattern of cytochrome oxidase deficiency with its identical mutation 
profile across various tumour locations suggests that BCCs are typically 
monoclonal, originating from a single pool of CSCs. This has been 
suggested before and, based on histological observations, researchers 
have suggested that the origin of BCCs may lay in the SCs of the hair 
follicle bulge. However, this hypothesis has never been experimentally 
confirmed. In this study, we detected a BCC that showed a distinct pattern 
of cytochrome oxidase-deficiency, displaying a continuity extending from a 
histologically normal ORS of a hair follicle to the entire tumour. The 
common origin of this monoclonal phenomenon was confirmed by mutation 
analysis of various cytochrome oxidase-deficient areas. These findings 
provide evidence for a common origin of BCCs and the ORS in the SCs of 
the hair bulge. Interestingly, the ORS is histologically normal and the 
neoplastic phenotype appears to only affect the interfollicular areas. This 
might be due to a different rate of cell division between the two different
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tissue areas, or local microenvironmental cues that keep the cells in the 
ORS in check.
7.5.3 The origin of the companion layer
Patterns of cytochrome c oxidase activity and molecular analysis confirm 
that the ORS is founded in a SC pool distinct from the IRS and the hair 
shaft. The origin of the companion layer has been a topic of discussion and 
has been attributed to both, the SCs in the hair bulge thus presenting a 
lineage relationship with the ORS, as well as the hair shaft, rendering it 
evolutionary related to the IRS. Our results show that the companion layer 
is part of the cytochrome c oxidase-competent component of the tissue, 
thus attributing it evolutionary to the hair shaft as the outermost layer of the 
IRS.
7.6 CONCLUSION
In this study, we are contributing important information to the ongoing 
debate concerning lineage relationship status in the skin, as well as to the 
origin and development of different types of skin cancer.
We show on a histochemical and molecular level that different SCCs and 
BCCs are evolutionary distinct and develop from different SC pools. This 
study reveals several important aspects of lineage relationship in the skin 
and the development of skin tumours. We show that (1) BCCs are typically 
monoclonal and thus derived from one founding SC, whereas SCCs appear 
to be polyclonal as evidenced by their multiple dispersed patches of 
cytochrome oxidase c deficiency throughout the tumours. (2) BCCs and 
SCCs most probably differ in their SC type of origin, which is also reflected 
in their histological characteristics (3) ORS and BCCs originate from the 
same SC pool, presumably in the bulge of the hair follicle. (4) The SC pool 
generating the ORS and BCCs is distinct from the one generating IRS 
lineages. (5) The companion layer is evolutionary distinct from the ORS 
and thus part of the IRS and can thus be viewed as its outermost layer.
227
Figure 7.1. Typical patterns of cytochrome c oxidase-deficient patches in 
squamous tumours. (A.C.E) H&E staining identifying sections (A,C) as 
squamous cell carcinomas and section (E) as carcinoma in situ. (B) Immu- 
nohistochemistry for cytochorome c oxidase expression on serial section of 
the tumour shown in (A) showing patches lacking cytochrome c oxidase 
(blue) dispersed throughout the lesion. (D,F) Cytochrome c oxidase histo­
chemistry on the biopsy shown in (C,E), displaying patches lacking cyto 
chrome c oxidase enzyme-activity (blue) and patches with active cyto­
chrome c oxidase enzyme (brown) in the same tumour
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Figure 7.2. Cytochrome c oxidase-deficiency in BCCs. (A,C,F) H&E stain­
ing identifies lesions as BCCs. (B) Immunohistochemistry for cytochrome 
oxidase expression shows that the entire tunour is homogenously cyto­
chrome oxidase-negative (blue), whereas normal epithelium and surround­
ing tissue expresses the protein (brown). (D.E) Cytochrome c oxidase 
enzyme activity assay performed on serial sections of lesion shown in (C), 
displaying cytochrome c oxidase deficiency throughout the tumour buds, 
extending to histologically normal ORS of a hair shaft (blue). The inner cell 
lineages of the hair shaft show activity of cytochrome c oxidase (brown). (G) 
Cytochrome c oxidase enzyme activity assay performed on serial section of 
lesion shown in (F) showing patches of cytochrome c deficiency amidst a 
largely cytochrome c oxidase-competent tumour.
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Figure 7.3. A BCCs including its surrounding stroma and theoverlying epi­
dermis are devoid of cytochrome c oxidase expression, whereas adjacent 
tissues express the enzyme, as shown by immunohistochemistry. Dotted 
lines outline approximate boundary of cytochrome c oxidase expression. 
(T=Tumour, S=Stroma).
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Figure 7.4. Sequence analysis of DNA from microdissected cells in cyto­
chrome c oxidase-deficient (blue, indicated by green arrows) and compe­
tent (brown, indicated by red arrows) areas of the squamous tumour shown 
in (A). (C,E) Sequence mutations shared by all blue areas, showing a 4916 
A>G and 7415 A>G mutation (arrows). (D, F) The brown areas show the wt 
sequence (arrows).
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Figure 7.5a. Sequence analysis of DNA from microdissected cells in cyto­
chrome c oxidase-deficient (blue) and competent (brown) areas of the 
BCCshown in (A) and (B). (C) All blue areas share a 13740 T>C mutation, 
whereas (D) the brown areas show the wt sequence.
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Figure 7.5b. Sequence analysis of DNA from microdissected cells in cyto­
chrome c oxidase-deficient (blue, indicated by green arrows) and cyto­
chrome oxidase competent (brown, indicated by red arrows) areas of the 
BCC shown in (A). (B.D) All blue areas show mutations 3313A>C and 
3363C>A. (C,E) The brown areas show the wt sequence in both locations.
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Figure 7.6. The tumours shown in Fig 7.2 (C) and (F) stain uniformly posi­
tive for pan-cytokeratin by immunohistochemitry, indicating that cytochrome 
c oxidase deficiency does not confer a pathologic effect on the cells..
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CHAPTER VIII 
DISCUSSION
8.1 GENERAL SUMMARY
The research carried out in my project was aimed to expand and elaborate 
on the knowledge of cancer stem cells and cancer-originating cells in 
epithelial cancers, including their phenotype, their developmental dynamics 
and the reciprocal relationship between individual cells and their 
microenvironment.
Examination of cancer stem cells first focused on the applicability of the SP 
phenotype for isolation and identification of cancer stem cells in colorectal 
cancer cell lines. Our results showed that non-SP cells were identical in 
phenotypiqal and behavioural stem cell-like characteristics, defined by the 
expression of putative stem cell markers, clonogenicity in vitro, 
tumorigenicity in vivo and multilineage differentiation potential in vitro and in 
vivo. Based on these observations, the SP did not represent a stem cell- 
enriched population in colorectal cancer cell lines. Subseqently, we tested 
whether the combination of two surface markers, CD44 and CD133, that 
recently have been suggested as markers for stem cell-enriched 
populations, might characterise a stem cell-enriched population in primary 
human colonic adenocarcinomas. Tumours showed an upregulation of both 
surface markers and non-random distribution restricted to the columnar 
cells facing the luminal surface of the gland-like structures typically found in 
colonic adenocarcinomas. However, we could not confirm stem cell 
characteristics of isolated double-positive cells in vitro by sphere formation 
assays or in vivo by subcutaneous injections of double-positive cells into 
nude mice.
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Two projects were carried out to investigate the effect of cells originating in 
organ or BM transplantations on the host in particular with respect to their 
potential to act as cancer-originating cells in the skin. First, post-transplant 
skin tumours of human female kidney transplant patients who had received 
a male organ were tested for Y-positive genetic material in a large-scale 
study, involving 35 patients and 176 skin tumours.
Second, a study was carried out involving a mouse model of spontaneous 
skin carcinogenesis to test the applicability of the above-mentioned results 
to mouse models and take advantage of the possibility to control the 
experimental settings. The effects of genetic predisposition of transplanted 
cells and the local microenvironment on each other was tested by 
reciprocal BM transplantations involving wt C57/BI 6 mice and an HPV8 
transgenic mouse model of spontaneous skin carcinogenesis. Our findings 
were similar to the observations made by other researchers, namely, that 
donor-derived cells engraft in the human normal epidermis and skin 
tumours sporadically without evidence for cell fusion or stem-celt typical 
characteristics, such as clone formation or preference for known stem cell 
niches (Hemmatti et al. 2003, Cogle et al. 2007). Monitoring tumour 
development and cellular make-up revealed that the phenotypic outcome 
was largely dependent on the host genetic make-up and was not 
significantly altered by the engraftment of transplanted cells.
We thus reach the conclusion that in the absence of chronic 
injury/inflammation such as described by Houghton et al. (2004), donor- 
derived cells contribute to the tissue by adjusting their phenotype and thus 
mimicking the cells in their surroundings rather than playing a dynamic 
active role in carcinogenesis and tissue homeostasis. We propose a 
scenario, whereby circulating donor-derived leukocytes that were 
transferred with the grafted organ may be capable of transdifferentiating 
into epidermal and stromal cells when exposed to the appropriate 
biochemical stimuli. It appears as though the type of transplantation plays a 
role in the engraftment process. BMT generally results in a higher level of 
engraftment, plasticity and the occurrence of BM-derived tumours. The
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donor-origin of the only donor-derived tumour after a solid organ 
transplantation could not be completely validated, and could be stemming 
from an earlier blood transfusion or an extremely rare phenomenon.
Furthermore, this research contributes new information to the development 
dynamics and origins of BCCs and to the ongoing debate concerning 
lineage relationships in the skin. Using mt DNA mutations as a marker of 
clonality, I show that BCCs and SCCs most probably differ in their SC type 
of origin, which is also reflected in their histological characteristics. 
Whereas I found a polyclonal appearance in SCCs, BCCs were 
histologically and genetically monoclonal and thus derived from one 
founding CSC. Molecular continuity with a histologically normal ORS 
suggests that both the ORS and BCCs originate from the same SC pool, 
presumably in the bulge of the hair follicle. I also provide evidence for an 
evolutionary distinctness between the ORS and IRS lineages and the 
evolutionary relationship of the companion layer with IRS, whereupon it can 
be viewed as its outermost layer.
8.2 PHENOTYPICAL CHARACTERISATION OF CANCER 
STEM CELLS
Following the discovery of the SP phenotype and its initial presentation as a 
stem cell-enriched population, a surge of research has emerged claiming 
stem cell characteristics in SPs from a wide variety of murine and human 
cell lines, normal tissues and tumours (Srour et al. 1993, Asakura et al. 
2002, Alvi et al. 2003, Bhattacharya et al. 2003, Dekaney et al. 2005, 
Morita et al. 2006, Szotek et al. 2006, Chiba et al. 2006). Altogether, the 
evidence suggested that the SP may represent a universal stem cell 
marker. With the intention of finding a stem cell marker for the yet 
undefined stem cell population in normal and malignant gastrointestinal 
tissues, my research was undertaken to test the SP of gastrointestinal 
cancer cell lines for stem cell-typical phenotypes and behaviour. However
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during the course of my experiments, increasing evidence has emerged 
challenging this notion (Mitsutake et al. 2007, Morita et al. 2006). 
Additionally, upon close examination many of the studies supporting the SP 
as a stem cell marker have neglected to directly compare the behavioural 
characteristics of SPs and non-SPs. Moreover, as a large proportion of this 
research was performed on murine tissues, evidence about the human 
counterparts is limited. Our research directly compared the SPs and non- 
SPs from various human gastrointestinal cancer cell lines with regard to 
phenotypical and behavioural stem cell-like characteristics. The two 
populations showed similar clonogenicity in vitro, formed xenografts in vivo 
with no differences in number, size, latency, or histopathology and were 
both multipotential with the ability to generate enterocytes, endocrine and 
mucus cells. Additionally, we showed that SPs and non-SPs are 
interchangeable; able to generate each other and reconstitute the original 
SP profile. Exposure to 5-FU, a lipophilic chemotherapeutic agent, did not 
selectively compromise any population, which would be expected for a 
population with a lower stem cell fraction. Moreover, 5-FU also did not alter 
the fractions expressing the putative stem cell surface markers CD133, 
CD44, CD117, and BCRP1, suggesting that these molecules are legitimate 
candidate markers for stem cells, since any change in expression profile 
would indicate a population’s vulnerability to the toxic effects of the 
chemotherapeutic agent. The validity of our results was confirmed by the 
absence of a detrimental effect of Hoechst 33342 on cell viability.
The only difference we could detect between non-SP and SP cells in our 
experiments was the initial absence of CD34-expression on the SP 
fractions. In the literature, CD34-expression (Krause et al. 1994, Morel et 
al. 1996, Srour et al. 1993) as well as its absence (Cheng et al. 1996, 
Goodell et al. 1997) has been associated with stem cells in a tissue and 
species-specific manner. In our experiments, CD34-negative SP cells were 
able to generate CD34-positive cells in xenograft tumours, but this 
phenotype did not confer any behaviour that would indicate a stem cell- 
enriched population. A behavioural significance for this phenotypical 
phenomenon has yet to be elucidated. In agreement with recent reports
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(Patrawala et al. 2005, Morita et al. 2006), we could not support a 
correlation between the SP phenotype and expression of BCRP1, 
indicating that other membrane transporters must play a role in conferring 
the ability to efflux Hoechst dye.
CD44 and CD133 have both been implicated as markers for stem cell 
enriched populations. In colorectal carcinomas, the CD44+/EpCAMhi9h 
population was shown to be tumorigenic when injected subcutaneously into 
NOD/SCID mice (Dalerba et at. 2007). A recent report indicated that 
CD133+ cells may also represent a stem cell-enriched population in colonic 
carcinomas. The CD133+ fraction of between 2.5-9% of all cells in primary 
human colorectal cancer cells was capable of sphere formation in serum- 
free medium and was 200-fold enriched in serially transplantable 
tumorigenic cells upon renal capsule or subcutaneous injection into 
immunodeficient mice (O'Brien et al. 2007, Ricci-Vitiani et al. 2007). I was 
able to demonstrate a higher expression of putative stem cell markers 
CD44 and CD133 in epithelial cells from adenocarcinomas of the human 
colon than in the normal colonic mucosa. The expression of CD44 was 
widely distributed throughout the tumours, whereas CD133 expression was 
restricted to the apical surface of cells lining the duct-like structures in the 
adenocarcinomas. The abundance of both markers suggests that they 
would not represent a pure stem cell population, but the combination of 
both surface markers only identified a few cells, which were distributed 
throughout the tumours but always occurred in the basal columnar cells 
lining the duct-like structures within the tumours. However, when testing 
stem cell-like behaviour, we were not able to replicate the results from the 
above-mentioned studies and additionally could not find similar stem cell­
like behaviour when combining both surface markers. After one-week in 
culture in serum-free medium, no viable cells or spheres were detected and 
moreover, none of the isolated cell fractions resulted in xenograft formation 
in nude mice. These results may reflect technical difficulties and differences 
such as my choice of immunodeficient mouse model or my route of 
injection. Reduced cell viability after sorting was ruled out by testing viability 
before the in vivo injection and culturing of cells. Thus, the combination of
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CD44 and CD133 may not be a suitable candidate marker combination to 
isolate and purify cancer stem cells in human colorectal adenocarcinomas.
Human cells were found in the matrigel pellets 4 months post-injection in 
small numbers and to varying degrees. Matrigel pellets injected with 
CD133+, CD44+ and double-positive fractions from normal colonic mucosa 
did not show any surviving human cells. Interestingly, in pellets injected 
with tumour cells, the numbers of human cells correlated with the expected 
stem cell enrichment of the cell fractions, with the least human cells in 
CD44-containing pellets and larger human cell clusters in pellets with 
double-positive cells. The detected human cells might well be progeny of 
the original injected cells since their longevity by far exceeds the normal 
lifespan of colonic epithelial cells and could potentially reflect the capability 
for self-renewal of a stem cell-enriched fraction. This could indicate that the 
CD133/44 double-positive cell fraction is most enriched in stem cells. 
However, small numbers did not allow for statistical evaluation of my 
observations, and considering the absence of operationally defined stem 
cell characteristics, such conclusions cannot be drawn. The results 
obtained by these experiments may also highlight the importance of the 
stem cell niche. It has previously been shown in our laboratory that single 
collagen embedded crypts can recruit host-derived stromal cells thereby 
initiating crypt and villus formation (Del Buono et al. 2005). These findings 
could not be extended to single cells. It is conceivable that the single­
injected cells are not able to recruit a stem cell-supporting, host-derived 
matrix and thus cannot act upon their stem cell fate.
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8.3 THE ROLE OF TRANSPLANTED CELLS IN TUMOUR 
DEVELOPMENT
Transplant medicine is faced with various secondary complications such as 
the development of post-transplant cancers due to immunosuppression, 
UV-irradiation and HPV-infection. In recent years, cells originating from the 
transplanted tissues have been repeatedly found in post-transplant 
malignancies, but their role in the development and the potential impact of 
the donor-genotype on the host system has yet to be elucidated.
In this thesis, we tested both, the extent and range of engraftment of donor- 
cells in post-transplant tumours in humans and the effect of genetically pre­
disposed transplanted cells on post-transplant tumour formation in a mouse 
model.
8.3.1 Donor cell-engraftment in human post-transplant skin tumours
Close examination of the literature suggests that the degree of engraftment 
depends on the type of transplanted organ. Cells of haematopoietic origin 
appear to play a more significant role in the phenomenon of donor-cell 
engraftment both, regarding the diversity of plasticity and the amount of 
engraftment, as well as in the development of post-transplant tumours. For 
example, after BMT, 2-7% of cells in the normal skin were found to be 
donor-derived (Korbling et al. 2002, Hemmati et al. 2002), whereas after 
kidney transplantation, no donor-derived epidermal cells were found 
(Barozzi et al. 2003). Furthermore, post-transplant tumours that appear to 
be completely donor-derived are either found after BM transplantation or 
are of haematopoietic origin, such as Kaposi Sarcoma in kidney transplant 
recipients and leukemia in liver transplant recipients. These malignancies 
might stem from haematopoietic cells carried over with the transplanted 
organ. The only observation of solid tumour after solid organ 
transplantation, is a BCC composed mainly of male cells in a sex- 
mismatched female kidney transplant patient (Aractingi et al. 2005). 
Unavailablity of information regarding previous blood transfusions or donor-
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specific information makes it impossible to exclude a haematopoietic origin 
of this neoplasm. It is conceivable that the systemic reach of 
haematopoietic cells enables them access to tissues that they then can 
engraft in upon stimulation by local biochemical cues.
We performed the first large-scale study examining donor-cell contribution 
to skin tumours of kidney transplant patients. The absence of 
microchimerism in CD45-positive cells, as well as the previous observation 
of the lack of epithelial engraftment of male cells in multiparous control 
females in our laboratory (Alison et al. 2000) led us to the conclusion that 
the Y-positive cells in this study are indeed donor-derived and not from 
previous blood transfusions or male pregnancies. The cell type of origin of 
the donor-derived cells could not be determined and might well be 
haematopoietic cells carried over with the grafted kidneys.
Consistent with the findings by Aractingi et al. (2005), approximately 50% of 
the patients in our study showed the presence of Y-positive cells. However 
in contrast to their study, we did not observe tumours that were entirely 
derived from the donor and found engrafted cells only sporadically 
distributed, comprising 0.5-6.5% of all epithelial cells in skin tumours and 
the normal epidermis. Similar levels of engraftment, between 2-8%, have 
been previously reported in the normal skin with no indication of GvHD 
(Korbling et al. 2002, Hemmati et al. 2002). However, other groups could 
not find any epithelial donor cell-engraftment in the human epidermis 
(Cogle et al. 2007, Murata et al. 2007). Like other researchers that studied 
epithelial engraftment, we could not detect any events of cell fusion.
A comparison of the levels of donor-cell engraftment between our HPV 
mouse model and the human transplant patients revealed that engraftment 
of transplanted cells into the tumour and normal epithelia did not differ 
between the two studies. The stroma was the preferred tissue compartment 
for incorporation of donor-derived cells. This could be due to stronger 
stromal cues for the recruitment of donor-derived cells or the higher 
accessibility of the tumour stroma to circulating leukocytes. Stromal
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engraftment also appeared to be significantly higher in human patients than 
in mice. Although the history of GvHD in our patient pool is not known, 
immunosuppression, more pronounced inflammatory responses and 
consequently a larger amount of infiltrating donor-derived leukocytes may 
contribute to this result.
The extent of donor cell-engraftment appeared to correlate with tumour 
status, showing significantly less engraftment in premalignant lesions than 
in lesions that had progressed to the malignant stages. This observation 
can be explained if progressive stages of tumour development are viewed 
as higher degrees of injury, where engraftment of donor-cells is known to 
be enhanced.
Donor-derived cells engrafted as part of the epithelial tumour component 
and as stromal myofibroblasts; they were susceptible to HPV-infection and 
contributed to CD34-expressing cells. CD34 has been known for many 
years as a stem cell marker for haematopoietic stem cells (Berenson et al. 
1988). It is also expressed on endothelial cells (Fina et al. 1990), marks 
dermal stem cells residing in the bulge of the hair follicle in canine and 
murine skin (Tumbar et al. 2004, Pascucci et al. 2006) and recently, it has 
been shown that its expression in hair follicles is required for skin tumour 
development in mice (Trempus et al. 2007). Finding Y-positive CD34- 
expressing cells in the tumour stroma suggests that donor-derived cells 
were able to contribute to tumour-associated blood vessels. The absence 
of single CD34-expressing cells without any apparent association to blood 
vessel-like structures may be an indication that donor-derived cells are not 
likely to engraft in the skin as stem cells.
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8.3.2 The impact of the microenvironment on transplanted cells
One of the goals in this thesis was to shed more light onto the reciprocal 
impact that transplanted cells and host cells exert on each other. This is not 
only an important issue in transplant medicine, associated with harbouring 
potential risk factors and additional side effects for patients, but can also 
help in the development of new treatment strategies. It is well documented 
that the microenvironment provided by the stem cell niche influences the 
function of stem cells to a great extent (section 1.1.1). On the other hand, it 
has also been shown that engrafted BM-derived cells can contribute to 
epithelial and myocardial healing and thus exhibit a healing influence on 
their surroundings (de Macedo Braga et al. 2007) or conversely form entire 
donor-derived tumours (Barozzi et al. 2003). It is not clear what role the 
genetic predisposition of host and donor cells plays in those reciprocal 
effects. For example, is it possible that a genetic predisposition for cancer 
development of the donor cells follows its phenotypic destiny and causes 
cancer development in the host and thus presents an inherent risk of 
transplantations and vice versa, is it possible to reverse an adverse genetic 
predisposition by transplantation of genetically-normat BM cells?
We used a mouse model of skin carcinogenesis and C57/BI 6 wt mice for 
reciprocal BM transplantations after lethal irradiation, and additionally 
applied epithelial wounding in some of the experimental groups to test the 
effect of injury. With respect to the extent of BM engraftment, our results 
confirmed previous findings from our laboratory and others: BM cells 
engrafted into the normal epidermis, skin tumours and their surrounding 
stroma in a functional and proliferating manner in the absence of cell 
fusion. Expression of cell type-specific surface markers together with the 
ability to proliferate (expression of Ki-67) confirmed that the cells fully 
transdifferentiated and are capable of division, suggesting that the 
engraftment did not merely represent a form of cell mimicry. Consistent with 
previously-published reports from a mouse model of pancreatic insulinoma, 
we observed a higher efficiency of donor cell-engraftment in the tumour 
stroma than in the bulk of the tumour or the normal epithelium (Direkze et
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al. 2004). Interestingly, we could not detect a higher engraftment in skin 
tumours than in the normal mouse epidermis, contrasting with our findings 
in the skin tumours of kidney transplant recipients, where the degree of 
malignancy correlated with the percentage of engrafted donor-derived cells. 
However, the HPV8 mouse model is distinguished merely by benign 
papilloma formation, but tumour progression and malignancy is rarely 
observed, preventing a direct comparison to the scenario in human 
carcinogenesis.
Our results did not reveal an influence of the genotype of engrafted BM- 
cells and highlighted the importance of the local microenvironment on 
individual cells. Incorporation of wild type cells did not reverse or decrease 
the expected host phenotype. The cells behaved as a proliferative (Ki-67 
expression) part of the tumour and moreover, the latency of tumour 
formation was even decreased compared to the control group recipients of 
HPV8-BM. This might be due to adverse physiological reactions and 
recognition of the genetically different BM. On the other hand, we could not 
detect formation of larger clones or HPV8+-derived tumours in wt mice, 
This may indicate that donor cells in both, the human study and our mouse 
model did not engraft as stem cells. Future research involving mouse 
models of chronic injury and higher degrees of malignancy may reveal 
different patterns of engraftment.
In summary, our results indicated that genetic predisposition of 
transplanted cells may not present an additional risk factor to 
transplantation medicine and that the effect of the local microenviroment on 
individual cell function is larger than vice versa.
8.3.3 Mechanisms of engraftment and development of donor-derived 
tumours
It has been previously shown that the development of donor-derived 
neoplasms might be dependent on the engraftment of donor cells in the 
stem cell niche as functioning new tissue resident stem cells, for example 
due to ablation of the original tissue stem cells upon chronic inflammation 
(Houghton et al. 2004). This theory is supported by the widespread belief 
that tumours are hierarchically-organised and have their origin in a long- 
lived cell with sufficient lifespan to acquire carcinogenic mutations, such as 
stem cells. However, when no chronic inflammation is present, donor cells 
do not appear to be able to engraft as stem cells in most tissues, and it is 
not known whether humans may have additional barrier functions 
preventing the engraftment of ‘foreign’ stem cells in other tissues. It is 
conceivable however, that the haematopoietic stem cell niche is less 
localised and may permit donor-derived cells to incorporate as stem cells 
and finally act as leukaemia-initating cells. Based on our results, we 
suggest that donor-derived cells capable of plasticity are distributed with 
the blood stream to the skin, where they are stimulated by the cues from 
the local environment to transdifferentiate into various ceil types. The 
newly-engrafted cells contribute to the tissue as differentiated, non­
proliferating cells, imitating the differentiated cells of their surroundings in 
phenotype and function. Thus, while they may contribute to post-transplant 
skin tumours, they are unlikely to play a role in generating or driving 
neoplastic formation or progression even when genetically predisposed for 
tumour development. HPV-infection does not appear to confer sufficient 
damage to the skin to cause ablation of skin stem cells und subsequent 
substitution by donor-derived cells. We cannot determine whether the 
donor-derived cells are haematopoietic cells within the transplanted organ 
or a separate cell population capable of displaying plasticity.
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8.4 LINEAGE RELATIONSHIPS IN THE SKIN AND
DEVELOPMENTAL PATHWAYS IN SKIN TUMOURS
Lineage relationships in the skin and the development of skin cancers are 
much disputed topics. By employing a histochemical assay for activity of 
the mitochondrially encoded cytochrome c oxidase, successfully 
demonstrated in our laboratory as a reliable marker of clonality in intestinal 
crypts, and additional sequencing of the mt genome, we contributed 
information to several concepts of skin tumour biology. In accordance with 
the literature, BCCs were generally found to be monoclonal, whereas SCCs 
were polyclonal. However, in some BCCs, the enzyme assay showed 
clonal heterogeneity, which could indicate genuine polyclonality within the 
same tumour or the perceived polyclonality could reflect the simultaneous 
presence of more than one distinct tumour. Alternatively, the polyclonal 
pattern could represent subclonality following the acquisition of genomic 
mutations at later stages of tumour development (Asplund et al. 2005) or be 
based on heteroplasmy within the founding CSC. The latter three are more 
conceivable scenarios, not only because of bigger patch sizes than the 
ones observed in SCCs, but also due the high sequence homology 
between the cytochrome-deficient and competent patches suggesting that 
the distinguishing mutation must have occurred at a later developmental 
stage. Additionally, BCCs generally seem to be of monoclonal origin both, 
in our studies, as well as in the literature.
Controversy exists regarding the stromal origin of BCCs. Xenograft studies 
suggested that BCC generate their own ‘specialised stroma’, interspersed 
with cells derived from the host (Hales et al. 1989, Stamp et al. 1988), 
whereas other researchers believe that BCCs are embedded in a 
connective tissue stroma at least in part of polyclonal origin (Asplund et al. 
2005). Our results display cytochrome oxidase-deficiency in BCCs, which 
extended to their surrounding stroma. Although the common origin has not 
been molecularly confirmed, the consistency of the results obtained in all 
other tumour areas indicate that BCCs and their stroma are derived from a 
common ancestor. This supports claims that BCCs generate their own
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‘specialised’ tumour stroma, rather than recruiting a polyclonal stroma from 
the host as seems to be the case with most cancers.
Researchers, based on histological observations, have argued before that 
BCCs originate from the same SC pool that gives rise to the ORS located in 
the hair follicle bulge. In this study, we were able to support this hypothesis 
by showing a BCC showing continuous cytochrome c oxidase-deficiency, 
extending throughout a histologically normal ORS of a hair follicle to the 
entire tumour. The common origin of this monoclonal phenomenon was 
confirmed by mutation analysis of various cytochrome oxidase-deficient 
areas.
The observations made during this project not only show that the cell 
lineages of the IRS are developmental^ distinct from the ORS, but also that 
the companion layer is genetically linked to the IRS and can be viewed as 
its outermost layer. This is important evidence in the debate regarding the 
genetic origin of the companion layer and supports previous claims 
ascribing the companion layer to the IRS based on analysis of keratin 
expression patterns (Gu et al. 2007). Taken together, these results suggest 
that BCCs and SCCs follow distinct developmental pathways originating in 
separate SC pools, which is also reflected by tumour-specific differences in 
cell lineage differentiation.
8.5 FUTURE DIRECTIONS
The characterisation of cancer stem cells and the developmental dynamics 
of cancer-originating cells are important and exciting topics not only in the 
search for new therapeutic targets against cancer, but also in the areas of 
regenerative and transplantation medicine. Although it is widely accepted 
that a cellular hierarchy exists in tumours, the markers distinguishing cells 
within this hierarchical system and separating them from normal stem cells 
are still not clearly defined. The vast amount of contrasting evidence 
makes one wonder whether the concept of a ‘cancer stem cell signature’ is 
a realistic idea or whether the variety of cancer mutations and types of 
cancer render every cancer with an individualistic set of characteristics that
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does not allow for a universal cell fingerprint to be found. Our observations 
that SP cells are not enriched in stem cells, despite being negative findings, 
are a step forward in the attempt to understand cancer stem cells. At the 
start of our experiments, the SP phenotype appeared as the most 
promising marker for the identification of stem cells and was regarded as a 
potential universal stem cell marker. Our results, together with other 
recently published reports have shown that this is not the case. However, 
an interesting feature in our SP fraction was the distinct CD34-negativity. 
The behavioural impact of this phenotype has not been elucidated and 
would necessitate further research.
Our results indicated that CD44 and CD133, as well as their combination 
may not be useful cancer stem cell markers in colorectal carcinomas. 
However, other researchers have obtained contrary results. It is 
conceivable that the results reported in those studies apply to individual 
cancers and not universally to colon cancers, but repeating our 
experiments in a different mouse model such as NOD/SCID mice and 
changing the route of cell administration to renal capsule injection might be 
useful to validate our findings and exclude the technique as a potential 
confounding factor for our results.
In this thesis, the first large-scale study is presented, examining donor-cell 
engraftment in posttransplant skin tumours of kidney transplant recipients. 
We conclude that donor cells engraft as fully differentiated cells, through 
biochemical cues triggered to transdifferentiate and imitate the local 
surrounding cells in phenotype and function. Our results suggest that while 
donor-derived cells can contribute to various tumour components, they 
generally do not play a role in tumour development or progression. We 
showed that HPV-infection does nor confer enough tissue damage to cause 
ablation of resident stem cells and donor-derived stem cell recruitment. 
While our results indicate that organ transplantation does not carry an 
inherent risk for tumour development in the recipient in normal transplant 
tissue conditions, further studies should be undertaken to examine 
engraftment of donor cells in circumstances of chronic tissue damage and
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the potential of donor-derived tumours in such circumstances. Additionally, 
while the HPV8 mouse model used in my experiments provides insight into 
the impact that genetic predisposition of cellular environment and 
transplanted cells have on cancer development. However, the experiments 
did not aim to replicate the environmental influences and situations that 
human transplant patients undergo and thus, to model post-transplant 
development, a different experimental set-up including 
immunosuppression, UV-irradiation and HPV infection would be the next 
step.
In this thesis, I provide first experimental evidence that the tumour stroma 
of BCCs is continuous with, and thus generated by, tumour cells. These 
observations were based on immunohistochemistry and histochemical 
enzyme assay results, but should in future be confirmed by molecular 
analysis on a wider variety of samples.
We show on a histochemical and molecular level that different SCCs and 
BCCs are evolutionary distinct and develop from different SC pools and 
reveal several important aspects of lineage relationship in the skin and the 
development of skin tumours. The experimental evidence of a BCC being 
genetically continuous with histologically normal ORS is novel and exciting 
and provides important information to the understanding of BCC 
development -  the most common skin tumour in humans. This finding 
should in future be validated on a larger number of samples. Understanding 
the stem cell pool a tumour originates from is one step on the path to a new 
targeted therapeutic approach.
In summary, I believe that the results presented in this thesis contribute to 
several aspects of understanding cancer stem cells and the dynamics of 
cancer originating cells. The dynamics and interactions between 
transplanted and host cells not only are an important aspect in transplant 
medicine and understanding the impact of cellular chimerism, but they can 
be an important tool in the research into developmental dynamics and 
factors facilitating and influencing cancer development.
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